Академический Документы
Профессиональный Документы
Культура Документы
2010, 4
1997 .
., ., ., ., .
(), , () .....
16
S-- L-
................................................................................................................
26
.., .., ..
................................
32
...........
37
44
.. -
, .............................................
52
..............................................................................
57
.., .., . .
.........................................................................................................
63
, , 2010, 4
.., .. , .., .., ..,
.., .., .. -
, ........................................................
69
CD25+CD4+ -
........................................................
77
..
/ (/ IIIA) ..
83
87
.., .. , -
,
......................................................................................................................
94
. ., . ., .. -
......................................................................................................................
99
.. - ...........
104
.., ..
......................................................................................
110
.., .. -
- , , ..........................................................................................................................................
115
.., ..
.............................................
119
...................................
125
. , .. -
, ..
130
..
...................................
135
142
.., .. -
......................................................................................................................
146
.., ..
...................................................................................
150
.., ..
.........................................................
154
.. - -,
................................................................................................................................
159
.., .., .., ..,
., .
..........................................................................................
.., .., .., ..
N- ...........................
..
- ..............
162
165
168
.. ,
3034 ..........................................................................................................................
172
.., .., ..
................................................................
175
..
..........
179
.., .., .. -
....................................................................................................................
182
............................................................................................
185
..
.................................................
187
..
: ...........................
191
.., .. -
...................................................................................................
194
.......................................
197
.., E.., ..
, ..............................
199
.., ..
............................................................................................................................
203
.., .., ..
IIIII ..............
206
.., ..
.................................................................................................
209
.., .. -
.............................................................
212
.., .., ..
.......
217
220
.. , ......................
223
.. ()
.........................................................................
226
, , 2010, 4
.., ..
...............................................................
..
- .................................................................
.., .., .., .. (Helianthus tuberosus L.) NNP K ..............................................
..
..............................................
.., .., ..
........................................................
229
234
237
241
245
..................................................................................................................
.., .., .. ..........................................................
.., .., ..
1822
..........................................................
247
250
254
.......................................................................
.., .., .., ..
- ()
...................................................................................................................
.., .., .. / ..
.., .., ..
..............................................................
258
260
264
269
............................................................................................................................
.., .., .., ..
...........................................................
273
276
........................................................................................
283
.. - -
...........................................
288
292
, - N- ......................................................................................................
295
.., .. ................................................................................................
298
.., .., .., ..,
.., .., .., .. -
...........................................................................
300
..........................................
.., ..
...............................
.., ..
..........................
.., ..
..........
.., .. ......................................
.., ..
........................................................................................
.., .., .., ..
1- II .....................................................................................................................
.., ..
...................
..
..........................................................................................................................
.., .., ..
-01 .......................
.., .., .., ..
- 5 ( ) ......
.., .., .., ..
, ................
A.., .. .........................................
.., .., .. -
....................................
.., .. .....................................
.., .., .., .. .........................
303
306
309
312
316
320
323
326
330
333
338
342
348
354
357
360
..................................
362
367
, , 2010, 4
.., .. -
..............................................................................................
.., ..
.........................................................................................................................
.. ................................................................................................
.., .., .. ....................................................................
.., .., ..
....................................................................
.., ..
............................................................................................................
.. ...............................................................................................
.., ..
( . ) .............................................................................................................................
.., ..
, ...........
.., .. . .................................................................................................................
372
379
383
386
390
393
398
401
406
410
....................................................
416
............................
.., .., .., ..
....
.., ..
...............................................................................
.., .., .. ...................................
.. ......................................................................................
..
................................................................
.., .., ..
....................................
.. .........................................................................................................
.., .. -
,
...................................................................................
.., .., .., ..
................................................
420
423
426
429
432
436
440
443
447
451
.., ..
, , ................................................................
456
:
...............................................................................................................................
.., .. ...................................................................................
.., ..
.........................................................................................................................
.. ....
.. (
) ........................................................................................................
.., .., .., .. ....................................................................................................
.., ..
.....................................................................
.., .., ..
...............................................
.., .., .., .. -
.....
.., .., .., ..
...............................................................
459
462
466
469
471
475
478
481
486
489
- ....
..
........................................................................
.., .., ..
......................................................................
.., .., .. .................................................................................................
.., .., ..
................
..
.......................................................................
.., ..
............
.. ......
.. () ..
.. .............................................................
.., ..
...........................................................................................................................
493
497
501
503
508
511
516
519
522
526
530
, , 2010, 4
.., .., .. -
..................................................................
533
.., .., .. -
...................
.., .., .. .............................................................................................................................
538
544
..........................................................................................................
549
, , 2010
, 2010
BULLETIN
of Peoples Friendship
University
of Russia
SCIENTIFIC JOURNAL
Founded in 1993
Series
MEDICAL
2010, N 4
Series founded in 1997
Peoples Friendship University of Russia
CONTENTS
Cornlissen G., Frolov V., Chibisov S., Kharlitskaya E., Halberg F. Personalized
chronome (time structure) complements genome detecting vascular variability disorders
(vvds), including mesor-hypertension .................................................................................
16
Siatkin S.P., Fedoronchuk T.V., Gridina N.Ya., Neborakh E.A., Shevkhun N.A.,
Sokueva N.A., Ustinova E.V., Sokuev R.I. The influence of chemical analogs of decar-
boxylated ornithine and S-(adenosil)-methionine on the growth of L-cell tissue culture .......
26
32
Schyogolev A.A., AlSabunchi O.A., Klochneva E.., Azimova J.A. Modern treat-
37
44
Eltyshev N.A. Eltyshev N.A. The modern diagnostics and treatment of patients with
52
Vlasov A.P., Visaitov D.A., Trofimov V.A., Leschankina N.U., Pyanov V.,
Mustaytsa V.F. The lipid structure and functional status of blood cells under endoge-
57
63
, , 2010, 4
Khartchenko V.P., Lutfaliev T.A. , Kunda M.A., Chazova N.L., Bershanskaya A.M.,
Eltyshev N.A., Zapirov G.M., Barushnicov V.L. The terms of restoration of functional
and structural liver changes in jaundice, caused by pancreatic head cancer ........................
69
Agaev N.M., Avdoshin V.P., Moskaleva .YU., Popova .N., Severin S.E.
CD25+CD4+ regulatory lymphocytes in peripheral blood of patients with prostate cancer and prostate adenoma .....................................................................................................
77
83
Kirichenko I.M., Shonia L.I. Popadyuk V.I., Daihes N.A. Meaning of circulatory disturbance in vertebrobasilar system in development sensorineural hearing loss ...................
87
tional activity of the vessel wall in patients with arterial hypertension and metabolic syndrome, who suffered from the occlusion of eye vessels ......................................................
94
Volkova N.I., Rymashevsky A.N., Dimitriadi T.A. Clinical application of method diagnostics hyperandrogenism syndrome on women of reproductive age ..............................
99
104
Polyakova A.G., Drubich T.V. New form of the reducing treatment of patients with the
110
Serebrennikova L.V., Kajdan E.I. The features of collective and personal stressful psy-
115
Goidenko V.S., Fedorova I.L. The complex treatments efficiency of the patients with
119
kimkin .., Goncharov E.N., Rodionov A.V., Tereshchenko G.V., Znamenskiy I.A.
agneti-resonance imaging of damage of the shoulder against presence of the accompanying impingement syndrome ..........................................................................................
125
130
Alekseenko S.P. Complex research of alcohol products consumption and its consequences for health of population of the Rostov region ............................................................
135
Alikova .., Mamsurova I.Ch., Alikova Z.R. Prevalence and the medical and social
importance of the glaucoma in Republic of North OsetiaAlania .....................................
142
Ananev V.N., Anikiev A.V. Influence of inert gases of argon and kripton on oxygen absorption ................................................................................................................................
146
Antropova G.A., Okonenko L.B. Drug assortment formation at the chemist`s shops in
regard of consumers` preferences ........................................................................................
150
154
159
162
Bass S.M., Yarygina T.I., Korkodinova L.M., Kurbatov E.R. Elaboration the meth-
10
165
Contents
Bitsoev V.D. Application of restoration technology of underwater tracture with underwa-
168
172
Bronfman S.A., Kudaeva L.M., Agarkov V.A. Latent depression among women with
175
179
182
185
187
191
194
197
199
203
206
209
212
217
220
223
226
229
234
237
241
11
, , 2010, 4
Kovyazina N.A., Reshetnikov V.I., Funcner E.V. Development of medical films for
bacteriophage treatment of infection ...................................................................................
245
Kozlova O.G., Shirokova L.U., Bashkina A.S., Dolgova L.N., Nagibin R.M., Shi0
rokova T.U., Kuznecov M.M., Smekalova M.V. Effect of weakness muscle corset
247
250
254
258
260
264
269
273
Kuznetsova E.V., Shemonaev V.I., Stolyarchuk A.S., Trudov A.F. Testing of bent
wire denture clasp metals hardness and condition after titanium and zirconium nitride
plasma spraying on its surface .............................................................................................
Kuznetsova E.P., Tetelytina F.K., Serebrennicova K.G., Halilov R.Z. Surgical approach to restoring reproductive function in patients with tumors ovarian ..........................
Kuzmin S.A. Results of military-medical examination among boys pre- and military age,
living in Orenburg region ....................................................................................................
Kunitsyna N.., Perelygin .V., Varavina L.Yu., Speranskij S.L. About quality of
othorynolaringological aid for elders ...................................................................................
Kurbatov E.R., Shakirova A.B., Korkodinova L.M., Bass S.M., Yarygina T.I. Synthesis, physical and chemical propaties and biological activity of amide N-allylanthranylic acid ..............................................................................................................................
Kurushina O.V., Barulin A.E. Influence of pain beliefs on resuts of algetic syndrome
treatment ..............................................................................................................................
276
283
288
292
295
298
Ledyaikina L.V., Balyukova L.A., Razdolkina T.I., Naumenko E.I., Vereshagina V.S.,
Samoshkina E.L., Dzubich L.I., Garina S.V. linical manifestation and phatomorpho-
300
303
12
306
309
312
Contents
Mavlikaeva Y.A., Bronnikov V.A. Evaluation of complex rehabilitation of disabled people
in a specialized centre .........................................................................................................
Maximov M.L., Dralova O.V. Clinical efficiency of medium and high doses of valsartan
in the treatment of patient with arterial hypertension and chronic kidney diseases ............
Starodubtsev A.K., Maximov M.L., Dralova O.V., Ermolaeva A.S. Clinical efficacy of
AT1-receptors of angiotensin II valsartan in the pharmacotherapy of patients with arterial
hypertension and chronic heart failure ................................................................................
Mamalyga M.L., Mamalyga L.M. Dynamics of RNA quantity change in neuroneglia
system of nucleuses monoaminergic of a brain during deadaptive .....................................
Medvedev D.S. The short-wave-therapy in regulation of general vasus resistance in polymorbidity in elders ...........................................................................................................
Merkulova G.A., Pegova E.V., Tulupova M.S. The use of DgKDT-01 computer technology for health state evaluation of medical personnel .....................................................
Mitrofanov A.V., Ovchinnikova T.A., Komarova T.V., Gasilina E.S. Combination subtoxis diphtheria oropharyngeal and acute cytomegalovirus infection persistence in a case
of Epstein-Barr virus in a child 5 years (clinical case) ........................................................
Mikhaylichenko K.Yu., Nazarov V.A., Kondrashova A.S., Chizhov A.Ya. Parameters of
the school environment as a factor that affects the health of pupils ....................................
Mikhaylov A.V., Bunyatyan N.D. Possibilities of application of benchmarking in increasing of competitive advantages of the chemists organizations ............................................
Mishina N.A., Davydkin I.L., Kupaev V.I. Oxidant-antioxidant status of erythrocytes
in chronic obstructive pulmonary disease ...........................................................................
Molohova .I., Grigoryan L.G. The influence of technological parameters of adjuncts
on the quality of powders with bifidobacteria .....................................................................
Motina N.V., Lepilov A.V., Zharicov A.Yu., Motin Yu.G. Renal structure reorganisation
early in the development of experimental nephrolithiasis model ........................................
316
320
323
326
330
333
338
342
348
354
357
360
Mushnikov D.L., Polakov B.., rlova .V., Bajutin .M., Carpov D.., Schultz S.V.
362
367
372
379
383
386
390
393
398
401
406
13
, , 2010, 4
Pronyaeva A.I., Kosyreva T.F. Studying of interrelation of quality of potable water in
the zone of residing of children with noncariouses defeats of enamel of the teeth ..............
410
Prosvetov R.S., Torshin V.I., Alchinova I.B., Arkhipova E.N., Antonova N.P.
Prophylactic dental check-up with additional use of laser correlation spectroscopy ...........
416
Prashchayeu K.I., Medvedev D.S., Gurko G.I., Perelygin .V., Kunitsyna N..
420
423
426
429
432
436
440
443
447
451
456
Sovenko G.N., Prashchayeu K.I., Chizhova M.A., Churnosov M.I., Ilnitski A.N.
The genesis of polymorbidity in elder female & the role of neuronspecific enolase ...........
Sultanaeva Z.M., Sharafutdinova N.Kh. Reqional peculiarity of infantile and perinatal
mortality .....................................................................................................................................
Tarasenko I.V., Lopukhova V.A. Pharmacoepidemiological treatment analysis of the
chronic obstructive pulmonary disease and bronchial asthma at the inpatients department
Tlupova T.G. Influence of counter bright light on visual acuity of healthy faces ..............
Torshina I. Analysis of diagnosis errors of viscerasyphilis (according to the Smolensk
region) ..................................................................................................................................
Turyshev A.Y., Sogrina A.N., Yakovlev A.B., Oleshko G.I. Innovations in the medicinal resource science .............................................................................................................
Fateeva N.M., Posokhova .. Study of formation of speech breathing in preschoolage children with speech irregularities ................................................................................
Chekryshkina L.., Sattarova O.E., Yarygina T.I. The development of electronic
catalogue of identity response of pharmaceutical substance ................................................
Chizhova M.A., Sovenko G.N., Zakharova I.S., Pavlova T.V. The clinical and pathopfysiologic basis of ambulatory medical aid for elder patient with coronary heart disease
and fe-deficite anemia ................................................................................................................
14
459
462
466
469
471
475
478
481
486
Contents
Shabalina J.A., Shurygin A.A., Lvova I.I., Varankina A.A. Pulmonary tuberculosis
489
Shabanov G.A., Lebedev Yu.A., Pegova E.V., Merkulova G.A., Rybchenko A.A.
493
497
501
503
508
511
516
519
522
526
530
533
538
534
549
Introduction
As compared to a genome-based personalized care in the future, self-care based
on monitoring key marker variables, with data analyzed by computer and interpreted
for their time structure (chronome) as-one-goes could involve most people treated for
high blood pressure (BP). Data analyses can be handled by a computer-savvy individual in a circle of family and friends, as well as offered as part of community services, e.g., in schools. The complexity and cost of a chronobiologic system could be
greatly reduced by automating analyses on a secure website that also offers educative
materials. A summary of results could be returned cost-free to participants, while the
data are archived for later interpretation in the light of outcomes as they become
available. This is now ongoing on a small scale in a project on The Biosphere and the
Cosmos, BIOCOS (corne001@umn.edu). Decades-long time series of around-theclock measurements have become available for the BP and heart rate (HR) of clinically healthy subjects, which served to derive reference values, computed as 90%
prediction intervals qualified by gender, age and ethnicity for circadian parameters as
well as for time-specified values along the 24-hour scale. Outcome studies assessed
the relative risk of morbid events associated with deviations from these norms, thus
identifying Vascular Variability Disorders (VVDs). Among them are MESORhypertension, an elevation of the BP-MESOR (M, Midline-Estimating Statistic Of
Rhythm), and CHAT (Circadian Hyper-Amplitude-Tension), a BP overswing. These
chronobiologically-interpreted records are useful for diagnosis and treatment validation and must be rendered affordable as a step toward a chronome-based personalized
health care, experimentally validated in the context of BP and HR.
16
Cornlissen G. et al. Personalized chronome (time structure) complements genome detecting vascular...
, , 2010, 4
U.S. National Institutes of Health and later the head of the institutes clinical center,
checked on his patient whose BP was previously diagnosed differently by spotchecks
made by two physicians who saw him at different times of day (4). Around-the-clock
monitoring at NIH for 17 days provided an explanation for the discordant diagnoses,
as shown in Figure 1. Bartter concluded in print (4).
Figure 1. Blood pressure (BP) measurements taken 6 times each day for 17 days by staff at the Clinical Cen
ter of the U.S. National Institutes of Health on a 61yearold patient show the large withinday variation that
accounts for his diagnosis as normotensive by a physician habitually seen in the morning and as hyperten
sive by another physician regularly seen in the late afternoon. Guidelines of BP assessment can use time
varying rather than fixed limits and can assess daytoday and longerterm variability. The diagnosis of bor
derline hypertension based on casual office measurements assessed by WHO limits resembles flipping
a coin to decide whether to see a physician in the morning or the evening. (Even for patients with a 24hour
mean of SBP/DBP around 149/90 mmHg, hypertension is not detected 22% of the time because of the lack
of consideration of circadian variation in computations based on a circadian amplitude of 20 mmHg [near, but
still below the upper 95% prediction limit in clinically healthy adults] and acrophase of 240 [4 PM].) Limita
tions in dealing with casual measurements or officehour profiles of BP interpreted by fixed limits, irrespec
tive of gender and age, can be replaced by timevarying reference standards (chronodesms) and one must
rely on more than one or a few casual BP measurements. In the absence of a measurement error, the cir
cadian rhythm in BP results in contradictory diagnoses at different clockhours. Halberg.
Cornlissen G. et al. Personalized chronome (time structure) complements genome detecting vascular...
2010, when we still have to explain what the Chronobiology of BP ought to be, we
realize that Agostino was an optimist (4).
Koop et al. (2) advocate a system change from centralized hospitals to focus on
neighborhoods and the home through technology and aim to merge private health
care, public health care, national security and education. In the broad context of their
detailed, scholarly and hardly improvable vision as to communication, we record
what has already been implemented by us since 2000, in terms of BP and HR monitoring, not only toward their goal of modernizing conventional spotcheck-based care
but also with respect to an improved quality of care, based on self-collected time series rather than upon spotchecks at home, if not in the office of a care provider. Such
screening has been implemented on students at the Peoples Friendship University of
Russia in Moscow. The same kind of BP and HR self-surveillance is also under way
in two Japanese towns, a university hospital in Japan, one in Hong Kong and another
in Italy, a university clinic in the Czech Republic, two hospitals in India, a research
facility in Mexico, and in general practice settings in Belgium. With current technology, this approach can be extended further on an international scale as an immediate
answer to the demands of at least one important BP-related aspect of universally
available computer-aided preventive care at affordable cost, with BP chronobiology
being the first step pertinent to a large segment of the population (4).
Internet-aided self-help in monitoring BP and HR constitutes a step toward
changes from a manual spotcheck-based to cyber-collected and automatically-analyzed data, yielding diagnoses and treatment recommendations based on the chronomes
of BP and HR time series. For screening or self-surveillance during treatment, the
chronome-based approach is cheaper since it does not require a care provider, yet it
automatically provides what is already a sine qua non in research, namely inferential
statistical analyses that include both hypothesis testing and point as well as interval
estimates of parameters. Hence, decisions are better than those based on spotchecks
that may depend on the time of day when a patient is seen by a care provider (4). It
seems pertinent that the complexity of these analyses is no problem when they are
provided automatically by a website or currently by BIOCOS.
Why MESOR and other characteristics rather than only the mean?
It is well recognized that BP is highly variable. Since part of this change is
rhythmic, a diagnosis based on single, albeit repeated measurements runs the risk of
being dependent on the time of day when they were taken, affecting the recommendation of treatment, perhaps for a lifetime. The least squares fitting of models consisting
of one or more cosine curves with anticipated periods (of 24 and 12 hours) accounts
for part of the variability, yielding estimates of the circadian amplitude and acrophase, together with a measure of location, the MESOR, that is usually more accurate
and/or more precise than the arithmetic mean. The circadian parameters further allow
the detection of VVDs that today are not screened for in health care. Examples of
VVDs are illustrated in Figure 2, screened for in a summary called sphygmochron
(4). Some of these conditions can be induced by treatment aimed solely at decreasing
the BP-MESOR, whereby iatrogenically, one may trade a bigger risk, such as CHAT
for the lowering of an elevated BP. Taking the chronome into account is now possible
in the context of an improved yet more affordable health care (4).
19
, , 2010, 4
Figure 2. Definitions and illustrations of abstract vascular variability disorders, (a) to (c)
diagnosed by cosinor (parametrically), (d) and (e) diagnosed by thresholds:
(a) MESORhypertension (MH), can be systolic (SMH), diastolic (DMH), mean arterial (MAMH), or a combination of these
conditions, incomplete when demonstrated only parametrically (complete when complemented nonparametrically by an
extent of excess during 24 hours > 50 mm Hg x hour).
(b) Circadian HyperAmplitudeTension (CHAT), which can also be systolic (SCHAT), diastolic (DCHAT), mean arterial (MA
CHAT) or a combination of these conditions.
(c) Odd timing of the circadian rhythm of BP but not of that in HR (BP ecphasia).
(d) Excessive pulse pressure (EPP), when the difference in the MESORs of SBP and DBP for adults exceeds 60 mm Hg, a
threshold that remains to be replaced by reference values from clinically healthy peers (eventually with diseasefree longlife
outcomes) specified further by gender, age, ethnicity and geography.
(e) A deficient HR variability (DHRV), defined as a standard deviation of HR less than 7.5 beats/minute, a threshold that re
mains to be replaced by reference values from clinically healthy peers (eventually with diseasefree longlife outcomes)
specified further by gender, age, ethnicity and geography. Halberg.
Chronomes and genomes are complementary structures in time and space, respectively. The genetic aspect of a personalized medicine has been thoroughly discussed by Richard Gallagher (5). He rightly lists goals: First, everyones genome will
be sequenced cheaply and the sequence will be interpretable, and predictive. Second,
[a persons] medical problems, discerned by analysis of the sequence, will be avoided
by genetic, lifestyle or therapeutic means. And third, where a disease has to be treated, [medicines will be] exquisitely tailored to... patient and ailment. No risk, no mess,
no problem. Specifically, Gallagher anticipates a $1,000 genome assessment and notes that it would not be useful at $10,000 an interpretation. Gallagher also notes that
the genome is a moving and complex target, and refers to a commercial use, Directto-Consumer genotyping, indicating that it isnt a success. A handful of companies
continue to provide information on ancestry (whimsical), findings on traits (trivial),
and a little advice on disease risk. They need time for research to turn them into a ge20
Cornlissen G. et al. Personalized chronome (time structure) complements genome detecting vascular...
Figure 3. A popular drug, if prescribed without personalized surveillance, can induce a vascular variability
disorder, VVD, such as Circadian HyperAmplitudeTension (CHAT). A change in the time when the drug is
taken can make the same dose of the same drug in the same person beneficial or vice versa. At one admini
stration time (before noon), Hyzaar induces CHAT in diastolic BP and exacerbates a preexisting CHAT in sys
tolic BP. At another time of administration, Hyzaar eliminates a preexisting VVD. These opposite effects were
found in tests at six medication times, each administered for about a month, with halfhourly surveillance of
BP during the last week of each span. These differences occur as a function of the timing of the drugs use
along the scale of 24 hours. Original study by Dr Yoshihiko Watanabe. Halberg.
21
, , 2010, 4
Cornlissen G. et al. Personalized chronome (time structure) complements genome detecting vascular...
the cost of a 24-hour/7-day record is already reduced to below $2 per weeklong profile, as compared to thousands of dollars for a personalization via the genome. If an
instrument is to be used to 24-hour/365-day records, the cost is now reduced to $450
a go (within the BIOCOS project) in exchange for the data (corne001@umn.edu) and
with cost-free analyses. The cost can be reduced to below $100 an instrument by currently available instrumentation in a government or other public health plan (4). Introduction into secondary education of the already available why and how of chronobiology can be accompanied by a yet-to-be updated book (4).
Figure 4. The incidence of VVDs is assessed herein in a clinic population of 297 patients. Blood pressure
(BP) and heart rate (HR) of each subject were monitored around the clock for 2 days at 15minute intervals at
the start of study. Each record was analyzed chronobiologically and results interpreted in the light of time
specified reference limits qualified by gender and age. On this basis, MESORhypertension, MH (diagnosed
in 176 patients), excessive pulse pressure (EPP), CHAT (a circadian overswing) and a deficient heart rate
variability (DHRV) were identified and their incidence related to outcomes (cerebral ischemic attack, coronary
artery disease, nephropathy, and/or retinopathy). Outcomes, absent at the start of study in these non
diabetic patients, were checked every 6 months for 6 years, to estimate the relative risk associated with each
VVD alone or in combination with 1, 2, or 3 additional VVDs, shown in columns. Earlier work showed that
CHAT was associated with a risk of cerebral ischemic event and of nephropathy higher than MH, and that the
risks of CHAT, EPP, and DHRV were mostly independent and additive. It thus seemed important to determine
the incidence of each VVD, present alone or in combination with one or more additional VVDs. The 176 pa
tients with MH were broken down into 103 (34.7% of the population of 297 patients) with uncomplicated MH,
55 (18.5%) with MH complicated by one additional VVD, 15 (5.1%) and 3 (1.0%) with MH complicated by two
or three additional VVDs (top left). In the latter group, all 3 patients had a morbid outcome within 6 years of
the BP monitoring. Ambulatory BP monitoring over only 48 hours, used for diagnosis, is much better than a
diagnosis based on casual clinic measurements, yet its results apply only to groups. With this qualification, of
the 176 patients with MH, 73 (42.2%) had additional VVDs that further increase their vascular disease risk,
and that are not considered in the treatment plan of these patients since current practice does not assess
these VVDs. This proportion may be smaller in 7day records. Results related to an excessive pulse pressure,
EPP (bottom left), CHAT (upper right), and a deficient heart rate variability, DHRV (bottom right), illustrate
that these conditions can be present in the absence of MH in as many as 12 (4.0%) of the 297 subjects. Since
they do not have MH, it is unlikely that these subjects would be treated from a conventional viewpoint, even
though their vascular disease risk can be as high as or even higher than MH.
23
, , 2010, 4
Evidence exists to suggest that treatment of these conditions may translate into a
reduction in morbidity and/or mortality from vascular disease. Another lesson from
these results is that around-the-clock monitoring of BP and HR interpreted chronobiologically is needed, even in the absence of MESOR-hypertension, to detect vascular
disease risk associated with VVDs such as CHAT and DHRV, that cannot be assessed
on the basis of casual clinic measurements, so that non-pharmacologic and/or pharmacologic intervention can be instituted in a timely fashion before the occurrence of
adverse outcomes. Once implemented across the board rather than in selected patient
populations, vascular disease could be curbed to a much larger extent at relatively low
cost if the monitoring is offered directly to the public and care providers become involved only after detection of a VVD. A website has to be built to interest many people
and to provide cost-free analyses in exchange for the data, as is now provided worldwide by the BIOCOS project on a small scale (corne001@umn.edu). Halberg.
Dividends as one goes
The merits of chronobiologic monitoring, if the data are saved, as could be done
on a website, could serve for more than stroke and other life-threatening disease prevention. It would reveal the mechanisms underlying more than the circadian component documented thus far (6, 7). Each newly mapped spectral component could greatly increase the merits of sequencing the chronome for translation from research to
clinical practice. More specifically, a dividend from monitoring BP and HR would allow the uses of novel spectral components to the extent that the mechanisms of these
new entities are clarified by 24-hour/365-day or 24-hour/lifetime data on population
outcomes. Already mapped are about 5-month quinmensal rhythms not only in solar
flares and other environmental features, but also in human physiology, including BP,
HR and melatonin, and in pathology, such as sudden cardiac death (7). Quinmensals
and other newly found frequencies such as transyears (10) are reflected in the breakdown products of steroidal hormones in urine and in the melatonin of circulating blood.
Mapping the chronome is the indispensable counterpart to sequencing genomes. The
latter widely heralded endeavor is but a complement to the former. A decrease in circadian amplitude was associated with a reduction by one half of cardiovascular morbidity (8). Systematic tests to find the optimal time of treatment administration for the
individual patient, to be sure that benefits from a hypotensive effect are not curtailed
by inducing or exacerbating another VVD are a challenge for all those receiving antihypertensive therapy. The percentages involved are estimated in Figure 4, involving
very many millions of people currently diagnosed or misdiagnosed as hypertensive.
The further dividends from monitoring the sun by the data collected for stroke prevention are another story (6, 7), also in the spirit of Vasily Vasilyevich Dokuchaev,
Vladimir Ivanovich Vernadsky and Alexander Leonidovich Chizhevsky (9), with special focus upon the frequencies that can be resolved (7, 10). The chronobiologic path
depends on its being learned in education broadly, not only in universities but also in
secondary schools. Eventually, monitoring of BP and HR will be started most effectively in pregnancy and continued for a lifetime, starting at birth (4).
REFERENCES
[1] Chibisov SM, Cornlissen G, Halberg F. Magnetic storm effect on the circulation of rabbits.
Biomed & Pharmacother 2004; 58 (Suppl 1): S15S19.
24
Cornlissen G. et al. Personalized chronome (time structure) complements genome detecting vascular...
[2] Koop CE, Mosher R, Kun L, Geiling J, Grigg E, Long S, Macedonia C, Merrell RC, Satava
R, Rosen JM. Future delivery of health care: cybercare. A distributed network-based healthcare system. IEEE Engineering in Medicine and Biology Mag 2008; 2938. doi
10.1109/MEMB.2008.929888.
[3] Halberg Franz, Cornlissen G, Katinas G, Syutkina EV, Sothern RB, Zaslavskaya R, Halberg Francine, Watanabe Y, Schwartzkopff O, Otsuka K, Tarquini R, Perfetto P, Siegelova J.
Transdisciplinary unifying implications of circadian findings in the 1950s. J Circadian
Rhythms 2003; 1: 2. 61 pp. www.JCircadianRhythms.com/content/pdf/1740-3391-2-3.pdf
[4] Halberg F, Cornlissen G, Otsuka K, Siegelova J, Fiser B, Dusek J, Homolka P, Sanchez de
la Pena S, Singh RB, BIOCOS project. Extended consensus on means and need to detect vascular variability disorders (VVDs) and vascular variability syndromes (VVSs). LeibnizOnline Nr. 5, 2009 (http://www.leibniz-sozietaet.de/journal). 35 pp.
[5] Gallagher R. Stumbling towards Nirvana. The Scientist 2009; 23 (12): 13.
[6] Halberg F, Cornlissen G, Wilson D, Singh RB, De Meester F, Watanabe Y, Otsuka K,
Khalilov E. Chronobiology and chronomics: detecting and applying the cycles of nature. Biologist 2009; 56 (4): 209214.
[7] Halberg F, Cornlissen G, Sothern RB, Katinas GS, Schwartzkopff O, Otsuka K. Cycles tipping the scale between death and survival (=life). Progress of Theoretical Physics 2008;
Suppl. 173: 153181.
[8] Shinagawa M, Kubo Y, Otsuka K, Ohkawa S, Cornlissen G, Halberg F. Impact of circadian
amplitude and chronotherapy: relevance to prevention and treatment of stroke. Biomed &
Pharmacother 2001; 55 (Suppl 1): 125s132s.
[9] Breus TK, Chibisov SM, Baevsky RM, Schebzuhov KV. The chronostructure of heart biorhythms under effects of external environment factors. Moscow: Russian University of Peoples Friendship, Polygraph Service; 2002. 231 pp.
[10] Halberg F, Cornelissen G, Katinas G et al. International BIOCOS Group. Chronobiology
's progress: season's appreciations 20042005. Time-, frequency-, phase-, variable-, individual-, age- and site-specific chronomics. J Applied Biomedicine 2006; 4: 138.
http://www.zsf.jcu.cz/vyzkum/jab/4_1/halberg.pdf
(),
0,
()
. *, . **, . **,
. **, . *
* ,
, ,
**
. -, 8, , , 117198
, , , , -, .
, , , ,
,
, - .
: , , , ().
25
S0 L0
.. , .. , .. ,
.. , .. , .. ,
.. , .. , ..
. -, 8, , , 117198
-
S- L- . ( ) c . 1-3- () S-(5-)-S--- () ,
. L- 5060%. , .
.
: , , , , L-, (), -() ().
.
, () ,
, [1, 2].
, [3, 4].
- S- L- .
. . , N,N-1--5- (-1)
Schuchardt () Koch-Light (),
.
[5].
26
.. . ...
13
S(5)S
()
CHF2
|
H2NCH2CH2CH2CHCOOH
|
NH2
2HCINH2OCH2CH2CH2NH2
2H2SO4NH2OCH2CH2S Ade
|
CH3
NH
||
H3CC=NNHCNH2
|
HC=NNHCNH2
||
NH
+
27
, , 2010, 4
.
-
( ),
- [8].
1--3- () 5--5- () L-
(. ).
. 1 2.
. 1. 13 () 55
()
L :
3
: L (10 1 ),
6
10 ). 1 L, 2 ,
3 , 4 , 5
, . ,
L- 4- 50 60%,
(. 1). 7- , (. 2).
.
- [8] L- 0,87.
L-.
28
.. . ...
. 2. , ,
L :
L (),
(%). 1 , 2 , 3 + ,
4 , 5 , 6 +
, L- .
, , , ,
. ,
.
, , .
. - [8] L- .
. - : 1--3- ()
29
, , 2010, 4
: , - [9] , ,
[10].
L- . , L- .
, , ,
L-, ,
[6].
30
.. . ...
.. 1, .. 2,
.. 3
1
,
3
. , 51, , , 163000
,
- , .
,
.
: , ,
.
: ; 15
16- ( ).
.
91500.11.0004-2003.
lg / [6].
14 1 3 2 .
()
( 1
106 Bifidobacterium bifidum)
( 1 108 Lactobacillus plantarum 8RA-3) ,
,
. 77.99.23.3 12192.10.05 21.10.2005 ( 9383-00701898718-05). 77.99.23.3 12193.10.05 21.10.2005
( 9383-007-01898718-05).
SPSS 13.0, . 0,05.
.
13,9% I , 8,2% II ,
50,0% .
, .
53,9% I, 62,8% II .
- ( < 0,05)
(. 1).
. 1.
, I, II .
:
< 0,05, < 0,01, < 0,001
33
, , 2010, 4
: ( < 0,05);
, .
( < 0,001) ,
( < 0,001).
, .
, 13,9% 17,1% . .
, I- 21,7% , I- 15,1% (p < 0,01),
39,5%; II- 30,7%, II-
21,4% (p < 0,05), 44,4% .
:
I- 26,2% II- 30% (p < 0,05), ,
14,4%; II- 23,2%, II-
28,6% (p < 0,05), 9,5%.
: I-
52,1% I- 55% (p < 0,01) 32,7% ;
II- 46,1% II- 50,0%,
29,6% .
I- - ( < 0,01) ( < 0,01) 1 . (. 2).
. 2.
I () .
: < 0,05,
< 0,01, < 0,001( ); 1 . < 0,05,
< 0,01, < 0,001 ( )
I- - . I- ( < 0,05),
34
( < 0,01) 1 .; 51,12 0,09% 45,10 0,11% ( < 0,001), 32,36 0,46% 7,93 0,16% ( < 0,001), 14,80 0,16% 5,30 0,23% ( < 0,001).
II- (.3) ( < 0,01) 1 ., II-
.
39,56 0,07% 33,50 0,16% ( < 0,001), 32,86
0,21% 7,93 0,16% ( < 0,001),
16,60 0,24% 10,23 0,16% ( < 0,001).
. 3.
II () .
:
< 0,05, < 0,01, < 0,001; 1 .
< 0,05, < 0,01, < 0,001.
. , , , II III , , . ,
, .
,
- , , , , .
, .
, - ,
.
35
, , 2010, 4
Department of Pathophysiology
2
Department of Microbiology
3
Department of Infectious Diseases
Northern State Medical University
Troitsky Ave., 51, Arkhangelsk, Russia, 163000
It has been shown that liver damages of viral genesis were accompanied by disturbances of the
large intestine microbial ecology and a reliable decrease in the number of bifid and lactic acid bacteria,
increased frequency of staphylococcus occurrence and decreased enterococcus number. It has been
grounded that it was necessary to correct the large intestine flora in patients with chronic hepatitis and
chronic hepatitis by using probiotic preparations stimulating growth and rehabilitation of normal flora
functions.
Key words: microbiocenosis, viral hepatitis and , probiotic preparations.
36
.. , .. -
. , 1, , , 105058
..
.
. , . 4, -, , 392524
..
36
. , 1, , , 105058
199
. () 104 ,
, .
() 95 , ;
. 1 ()
45,2% (47 ).
8,5% (4 ).
57 (54,8%) . 12,3% (7 ), , (1,9%). 1
10,5% (11 ).
3 (3,2%).
. 40%
(2 ). 1,1% (1 ). 3,2%
(3 ).
,
, .
: , .
, , 1014% [5]
, 8085% [8, 9], , 3040% [7]
37
, , 2010, 4
, .
, , .. ,
, - ,
, [5].
,
, .
. .
. ( 66,8%) 8,0% 810% [8].
, , , [1, 4], ,
. ,
.
, , , .
2001 2008 199 .
() 104
, ,
. ()
95 ,
; .
1 , ,
( , 12-
12- +
+ ) . 1,
. 2.
38
.. . ...
1
)
)
) ,
,
)
) , ()
) 1,3
) 0,8
1
2
(n = 95)
.
(n = 104)
.
69
72,6
69
66,3
26
27,4
35
33,7
33
34,7
38
36,5
60
63,2
63
60,6
2,1
2,9
: 40
27
28,4
24
23,1
41 60
46
48,4
40
38,5
61 80
22
23,2
40
38,5
() Forrest.
0,001% 5 15 .
13 (12,5%) .
62 (59,6%) , .
; ( , 3
2 12- , 50 /
) : (, ), ( ) (
) . (. . 1).
39
, , 2010, 4
1 . 2 3 , .
,
. (2, 3 ). , , .
1-
.
. 40 , 100
6 2 .
20 2
4 .
(), , 95 .
,
. 2.
. 2. 2 3,
, ,
, .. .
3
(n = 95)
(n = 104)
49
51,6
65
62,5
26
27,4
17
16,3
20
21,1
22
21,2
2- 12 (12,6%) . 65 (68,4%) , .
Forrest . 4.
. 4, Forrest
.
40
.. . ...
4
Forrest
Forrest
Forrest 1a
(n = 77)
(n = 75)
6,5
5,3
Forrest 1b
9,1
Forrest 2a
32
41,6
31
Forrest 2b
12
15,6
Forrest 2c
21
27,3
22
12
41,3
12
29,3
2-
. 0,001%
5 15 ,
() .
, , , 12 24 .
( ).
2- 56 (58,9%).
, 12 (12,6%) 2-
,
44 (46,3%), ,
.
2- , , (
). 40 , 100
6 2 . 20 2 4 .
500 2
7 1000 2 7 .
: c 1- () 45,2% (47 ).
8 (17%),
37 (78,7%), 2 (4,3%) .
8,5% (4 ). .
57 (54,8%) .
12,3% (7 ), 2 - 41
, , 2010, 4
, 5 .
, ,
(1,9%). 1-
10,5% (11 ).
95
3 (3,2%), , 2 . ,
5,3% (5 ). 40% (2 ). 2 .
90 , ,
.
,
1,1% (1 ). 3,2% (3 ).
,
,
.
42
.. . ...
E.. Klochneva
Regional hospital Tambov city
Polevaya str., buil. 4, village Pokrovo-Prigorodnoe, Tambovskaya region, 392524
CRH of Tambovskaya region
J.A. Azimova
Clinic city hospital 36
Fortunatovskaya str., 1, Moscow, Russia, 105058
The problem of acute gastroduodenal hemorrhages remains one of the most urgent and unsolved
tasks of urgent surgery
Our study included 199 patients with hemorrhage from chronic ulcers. The first group (control)
consist 104 patients with hemorrhage of chronic ulcers, in which active tactics was used, based on forecast of rebleeding.
The second group (basic) consist 95 patients with hemorrhage of chronic ulcers, which treated
with endoscopic and drug hemostasis; operation was performed only in the case of rebleeding.
Surgical activity in control group was 45,2% (47 patients). Postoperative death was 8,5% (4 patients). Conservative treatment undergone 57 patients (54,8%). Rebleeding occur in two patients (1,9%).
Common death rate in first group was 10,5% (11 patients).
In basic group rebleeding occur in 3 patients (3,2%), they all were operated. Postoperative rate
death was 40% (2 patients). The Death rate in conservative treatment was 1,1% (1 patient). Common
death was 3,2% (3 patients).
Thus the use of endoscopic hemostasis and conservative treatment in patients with hemorrhage
from the chronic ulcers, reduce quantities of operations, and decrease the percentage of rebleeding with
a reliable decrease in the rate of death.
Key words: ulcer gastroduodenal hemorrhages, endoscopic hemostasis.
.. , .. , ..
. , 42, , , 119415
, ,
.
, ,
.
, ,
.
: , , .
: , ,
, ,
[2]. . ,
, ,
. .
2008 ,
. 2007 () 1199
. :
28%, 28%. ,
44% (!) I dont know... [8].
, . , , , .. .
, , ,
10% [14]. , . ,
, ,
, .
44
.., .., ..
, , , .
, ,
.
.
, , ,
[9, 16]. , P. Thomas et al. 2007 31973 :
13,1%, 2,4%,
1,1% [16]. (..
) ,
[9,15]. , , [16].
.
(1 ) (. 1). .
. 1.
(, )
. [16]. , , .
,
, , . .
( ) .
45
, , 2010, 4
,
, [11, 13].
, ,
(, , -, ,
.). , [5].
(, ,
.) [17]
, , ,
.
, () .
. , ,
. , ,
,
.
.
.
, .
, , , , , . , .
, , [7]. , , ,
, . , (510%).
, (43%),
[14].
: 2500 3000 ; , ,
, .
46
.., .., ..
, , ,
3035%
[12]. , .
, () ( , , , ) [18].
(. 2).
. 2. ., 23 , 3
( )
, , , . , , , .
, , ... . ( )
, , .
. (,
).
47
, , 2010, 4
. ( )
, [19]. , DHS 70% [4, 6, 10]. ,
,
[7].
, , . .
: 2040% [1].
,
, ..
. , ,
, 2 . . 3 DCP ( ).
. 3. ., 61 ., 1 , ,
6
LC LCP ( ); (. 4).
48
.., .., ..
. 4. ., 62 .
. 5. . 24 ., , ,
1
, , ,
49
, , 2010, 4
, .
.
. ,
, .
, , .
. ,
.
[1] Beaupre G.S., Csongradi J.J. Refracture risk after plate removal in the forearm // J. Orthop.
Trauma. 1996. 10(2). P. 8792.
[2] Bostman O., Pihlajamaki H. Routine implant removal after fracture surgery: a potentially
reducible consumer of hospital resources in trauma units // J Trauma. 1996. 41.
P. 846849.
[3] Breederveld R.S., P. Patka, J.C. van Mourik. Refractures of the femoral shaft // Neth. J. Surg.
1985. Aug; 37(4). P. 114116.
[4] Davison B.L. Refracture following plate removal in supracondylar-intercondylar femur fractures // Orthopedics. 2003. 26(2). P. 157159.
[5] Evans N.A., Evans R.O. Playing with metal: fracture implants and contact sport // Br. J.
Sports Med. 1997. 31. P. 319321.
[6] George B., Gaheer R.S., Ratnam A. Spontaneous femoral neck fracture after removal of Dynamic Hip Screw // J. Orthopaedics. 2007. 4(1). e14.
[7] Gsling T., Hfner T., Hankemeier S., Zelle B.A., Mller-Heine A., Krettek C. Femoral nail removal should be restricted in asymptomatic patients // Clin. Orthop. Relat. Res. 2004.
P. 222226.
[8] Hanson B., Chris van der Werken, Dirk Stengel. Surgeons Beliefs and Perceptions About
Removal of Orthopaedic Implants, BMC Musculoskeletal disorders. 2008. 9. P. 73.
[9] Krischak G.D., Gebhard F., Mohr W., Krivan V., Ignatius A., Beck A., Wachter N.J., Reuter P.,
Arand M., Kinzl L., Claes L.E. Difference in metallic wear distribution released from commercially pure titanium compared with stainless steel plates // Arch. Orthop. Trauma Surg.
2004. 124. P. 104113.
[10] Kukla C., Pichl W., Prokesch R., Jacyniak W., Heinze G., Gatterer R. et al. Femoral neck
fracture after removal of the standard gamma interlocking nail: a cadaveric study to determine factors influencing the biomechanical properties of the proximal femur // J. Biomech.
2001. 34(12). P. 15191526.
[11] Lovell M.E., Galasko C.S., Wright N.B. Removal of orthopedic implants in children: morbidity
and postoperative radiologic changes // J. Pediatr. Orthop. B. 1999. 8(2). P. 144
146.
[12] McGarry S., Morgan S.J., Grosskreuz R.M., Williams A.E., Smith W.R. Serum titanium levels
in individuals undergoing intramedullary femoral nailing with a titanium implant // J. Trauma. 2008. 64(2). P. 430433.
[13] Peterson H.A. Metallic implant removal in children // J. Pediatr. Orthop. 2005. 25.
P. 107115.
50
.., .., ..
[14] Sanderson P.L., Ryan W., Turner P.G. Complications of metalwork removal // Injury.
1992. 23(1). P. 2930.
[15] Serhan H., Slivka M., Albert T., Kwak S.D. Is galvanic corrosion between titanium alloy and
stainless steel spinal implants a clinical concern? // Spine J. 2004. 4. P. 379387.
[16] Thomas P., Schuh A., Ring J., Thomsen M. Orthopedisch-chirurgische Implantate und Allergien. Gemeinsame Stellungnahme des Arbeitskreises Implantatallergie (AK 20) der Deutschen Gesellschaft fur Orthopedie und Orthopedische Chirurgie (DGOOC), der Deutschen
Kontaktallergie Gruppe (DKG) und der Deutschen Gesellschaft fur Allergologie und Klinische Immunologie (DGAKI) // Orthopade. 2008. 37(1). P. 7588.
[17] Townend M., Parker P. Metalwork removal in potential army recruits. Evidence based changes
to entry criteria // J P Army Med Corps. 2005. 151. P. 24.
[18] Yang K.H, Byun Y.S., Park H.W., Park S.J. Failure on attempted removal of a Gamma nail in
two young patients // J Orthop Trauma. 2003. 17. P. 379382.
[19] Yang Kyu-Hyun, Yoo-Wang Choi, Jung-Hoon Won, Je-Hyun Yoo. Subcapital femoral neck
fracture after removal of Gamma/Proximal Femoral nails: report of two cases // Injury Extra.
2005. V. 36, iss. 7. P. 245248.
IMPLANTS REMOVAL
N.V. Zagorodny, A.A. Volna,
M.A. Panin
Traumatology and orthopedic department
Peoples Friendship University of Russia
Lobachevskogo str., 42, Moscow, Russia, 119415
In spite of the rapid development of the traumatology in the past few years the elaboration of the
new materials for the metal implants and other new devices for the internal fixation, one question stays
opened whether it is necessary to remove the implant. Quite many complications after the removal of
the metal implants, ambiguous specialists opinions, also insufficient attention of the Russian authors
show that a common attitude is needed towards this problem. This article is based on the grounds of the
most citied foreign authors as well as on our clinical experience.
Key words: implants removal, allergie, refracture.
,
..
. , 86, , , 117997
110 , .
,
. 30 , 54 , 16 10
. 5- 20,0% 10,3.
: , ,
, , ,
, , .
. ,
.
47% , 5- 25%,
69 .
, - , - , .
, , ,
.
110
, 1990 2008 .: 79, 31; 61,6 4,7 .
- .
, , .
52
.. ...
.
110 108 .
99
- , 11
,
,
,
, , .
50 .
52 . 6
.
103, 35
.
41 .
91 . 48 , 12 .
, .
, - ,
.
79
, 30 , 1 .
110 .
, , , .
. 51 , 39 , , 16 53
, , 2010, 4
, 4
.
34 . ,
,
. . 29 . 19 .
.
. 1.
1
I
T2N0M0
II
T3N0M0
III
T2N1M0
T3N1M0
IV
T2N1M1
T3N0M1
:
18
40
22
18
5
7
110
,
I 18, II 40, III 40, IV 12 .
, .
, ,
, , ,
,
.
, -
.
110 (. 2).
54
.. ...
2
I. :
1
2
3
II.
:
66
7
16
41
44
110
.
, , .
, 30 , 54 , 16 , 10
).
. .
30 . 5060 .
20
: 11
, 3 , 4 , 2 . .
6
, 74 .
54 , ; 42
6670 ., 12 4450 .
16 . 5-, , , , , .
35-
40,0% 12,6 20,0% 10,3 .
, 35- 19,9
3,9 ., 9,3% 3,9, 1,8% 1,8 .
55
, , 2010, 4
7,7 0,6 .
(p > 0,05).
, .
56
.. , .. , .. ,
.. , ..
, ,
,
. ..
. , 68, , , 430000
..
. -, 8, , , 117198
. , ,
.
: , , .
, - , [5]. ,
.
, , .
.
[4, 8].
, , , , .
. , ,
(n = 15)
(n = 44). () ()
.
(), = / 1 [3]
(),
, = /.
57
, , 2010, 4
, /
, /
, . .
, . .
52,20 0,77
1
3
5
35,40 1,21*
38,31 1,12*
44,91 2,47*
42,30 1,19
23,60 1,35*
26,90 1,53*
31,14 1,77*
0,81 0,04
0,68 0,03*
0,57 0,03*
0,70 0,03*
0,23 0,01
0,55 0,03*
0,89 0,05*
0,62 0,04*
: * (p < 0,05)
,
(. 2).
() 56,2
63,3%, () ().
() ,
() 40,753,8%,
() 20,938,9%, () 22,719,3% ( < 0,05).
58
.. . ...
2
( %)
(30 )
23, 2 1, 2
20, 8 1, 5
7, 8 0, 9
14, 5 11
,
7, 0 1, 2
11, 4 1, 8
27, 4 3, 6
18, 9 1, 3
16,1 1, 7
16, 8 0, 9
7, 4 0, 7
8, 5 0, 7
5, 7 0, 6
6, 0 0, 7
7,1 1, 4
15, 0 1, 2
7, 8 0, 9
9, 4 0, 7
4, 4 0, 4
4, 8 0, 5
4, 4 0, 6
7, 4 0,2
7, 5 1, 0
9,1 0, 7
19,1 0, 8
21, 2 0, 68
35,2 1, 0
31, 4 0, 9
24, 5 0, 7
32, 3 1, 0
19, 6 1, 2
19, 0 0, 81
33, 6 2, 0
31, 0 1, 9
44, 8 1, 0
40, 4 1, 2
54, 5 2,1
39, 0 11
,
36, 3 4,1
39, 0 1, 7
11, 6 1, 6
16, 3 0, 8
34, 9 1, 6
23, 9 11
,
24,1 1, 7
30,1 11
,
23, 0 2, 0
7, 8 0, 5
4,1 0, 4
1, 98 0, 2
7, 4 0, 6
4, 3 0, 4
2, 3 0, 7
4, 7 0, 6
13, 5 1, 6
5, 0 0, 6
6,2 1, 0
8, 2 0, 8
9, 4 0, 2
4, 9 0, 3
10, 4 11
,
17, 9 0, 8
53,1 1, 7
48, 9 0, 8
37, 7 11
,
35, 8 0, 7
35, 6 1, 2
30, 6 1, 6
42, 7 1, 5
48, 3 11
,
21, 4 1, 0
26,2 0, 5
20, 7 1, 3
27, 8 0, 7
22, 5 2, 4
21, 9 1, 3
21, 6 11
,
21,2 0, 6
3, 2 0, 5
2, 7 0, 4
11
, 0,1
7, 4 0, 7
2, 2 0, 5
: , .
,
, (. 3).
3
(M m)
3,68 0,20
1
3
5
10,56 0,58*
9,12 0,50*
7,05 0,39*
I max
1,23 0,07
2,30 0,13*
2,16 0,12*
1,96 0,11*
ST max
0,94 0,04
1,84 0,08*
1,79 0,08*
1,53 0,07*
tg 1
2,01 0,12
3,44 0,20*
3,36 0,21*
2,90 0,17*
tg 2
0,49 0,03
0,60 0,05*
0,54 0,04
0,52 0,04
59
, , 2010, 4
()
53,284,1%, 6,37,9 ,
27,434,1%, 30,332,7%,
26,231,8% () 66,1
76,5% ( < 0,05).
() 23,131,0%, 44,363,6%,
60,266,3%, 4,56,5 ,
32,542,9%,
39,447,2%, 26,328,8% ( < 0,05).
()
92,3110,2%, 21,236,8%, 8,18,5 , 97,2103,4%, 54,772,5%, 60,8
75,4% ( < 0,05).
, , ,
.
,
( , ), . ,
, . , ,
.
,
,
[2]. , , (. 4).
4
(M m)
,
..
, %
0,77 0,04
1
3
5
0,56 0,03*
0,46 0,02*
0,62 0,03*
38,22 1,91
48,91 2,69*
55,01 2,56*
46,15 2,48*
, [1, 6]
, (. 5).
60
.. . ...
5
0 (20 )
(M m)
, %
, tg a
,
33,30 1,83
1,21 0,07
123,60 5,56
1
3
5
55,30 3,04*
51,16 2,81*
38,90 2,14
2,28 0,13*
2,13 0,12*
1,76 0,19*
105,50 4,97*
117,90 5,31
120,10 5,40
, , , . ,
(0,43 0,028 100 ),
() ( 0,82 0,032 100 ).
. (5 ) (5 ) in vitro .
, , , , , ,
, , .
, . .
, - , , .
61
, , 2010, 4
V.F. Mustaytsa
The pathological physiology chair
Peoples Friendship University of Russia
Miklukho-Maklaya str., 6, Moscow, Russia, 117198
The lipids structure of blood cells and plasma has specific modification under endogenous intoxication. The pathological complex of lipid modification is top-ranked reason of blood cells dysfunction
under endogenous intoxication. It is necessary to correct one opportunely.
Key words: endogenous intoxication, blood cells, lipids.
.. , ..
. , 86, , , 117997
. .
. -, 6, , , 117198
, . , , , , , .
.
, . ,
.
: , , .
, , , . , , ,
.
.
(), , . (
) ,
.
.
: , , .
.
() .
, . 15
63
, , 2010, 4
: (n = 5), (n = 10),
() . 4
14 . ,
, . ( 0,63 ) -3.
.
, , . ,
.
, , ,
.
.
( , ). ,
, ,
.
, ,
.
.
2005 . D.S. Rosenthal E. Dean-Clover /: , [13].
, . ,
, .
1990- . . . , ,
. , , [13].
, [8, 12, 14]. , [6, 7]. ,
[15].
[10].
,
,
[16].
. C.Y. Gu et al. (2004)
,
64
.., .., ..
, . ,
[9]. X.Qiu et al.
(2004) 2 12 (IL-2
IL-12), NK H-22 . , IL-2 IL-12,
NK . ,
, , [11]. J.M. Zhang
et al. (2004)
23 ,
[17].
,
, , .
. .. ( )
19782004 . [2].
(326 )
. 118
. , , , , , . , . 82%
( , , ).
75%
. 85%.
.
, .
34 2 64% , .
3 .
,
- .
.
.. (1989).
77 . 65
, , 2010, 4
[4].
.. (1996) [1]. -01.
1012
. 1 56
. 35 .
: , , , , . ,
, , , .
. - . , ,
( ), - .
, (1959) [5].
. .. [3].
100 -, ,
.
( 90%),
, ,
(, , ).
. .
, , , :
1) ;
2) , , ;
3)
( , , ).
.
, , , , .
66
.., .., ..
67
, , 2010, 4
V.A. Zhernov
Restorative Medicine Chair
Peoples Friendship University of Russia
Miklukho-Maklay str., 6, Moscow, Russia, 117198
The article deals with the results of the authors own preliminary results and the data of several
investigations on using reflexotherapy in oncology. The results of those works demonstrate its effectiveness and safety in such manifestations of malignant tumors and complex treatment complications as
pain syndrome, nausea, vomiting, edemas, immunodeficiency. In Russia the great experience in that
field was accumulated by the Medical Radiological Scientific Center and by Research Institute of Pediatric Hematology/Oncology of Russian Oncological Scientific Center. The large-scale investigations in
that field are underway in the US under the auspices of the National Cancer Institute. The well-tested
methods of reflexotherapy should be introduced wider into the oncological practice, the research on that
problem should be expanded.
Key words: oncology, reflexotherapy, laser.
,
.. , .. , .. ,
.. , .. , .. ,
.. , ..
. , 86, , , 117997
160 , . , ,
.
: , , , , .
, ,
, , [1, 5, 10].
,
,
[25, 79, 11].
,
.
160 , , 1988 2009 ., , .
, ,
- .
2 : .
,
.
69
, , 2010, 4
: , , , , , ;
, ,
, , , . 43
; 3 - , ; 10 ;
7 ; 30 ; 11 ;
7 .
, , ,
, , - .
, , , ,
, -, -, , . ,
( ) , .
max
1/2 50% .
99 -HIDA.
(142,4 25,2 /),
(102,2 14,7 /), (17,8 3,2 /) (20,4 4,5 /) , (53,4% 3,5) - (18,6% 1,2), (19,6% 0,5), -
(1,1 0,1), Tmax (25,8 1,6 .), 1/2 (48,0 1,7 .);
(2523,1 36,3 /),
(154,7 20,9 /), (58,7 4,1 /) (76,3 5,1 /) , (60,1 1,8 /), (43,8% 3,0), - (1,7% 0,1), - (10,1% 1,1), (24,7% 4,5), -
(0,8 0,1), (9,1 1,3 /),
(60,8% 2,3), (536 110),
(941 060), (405 055) , (50,8
2,8 .) .
70
.. . ...
101,
59 .
44 28 .
.
, , - , , , .
Milling (1961) . -4800
.
,
. , -, .
.
, , ,
, , ,
. .
.
: ,
, . . , ,
. , , , ,
, .
, .
.
, , , , 71
, , 2010, 4
,
,
, . (, -, ).
. ,
, , . ,
, .
,
.
.
Cossel ,
, , . . , ,
. . , , , . (. 1).
. ,
. , . . (. 1 ).
, ,
, , , , , , - -
, .
160 (100) (60) .
.
72
.. . ...
. 1.
:
) .
. 110; )
. 7000.
4-
, , , , , max 1/2 ,
, . 810 .
. 16 .
1216-,
2024- .
.
73
, , 2010, 4
48 . 11 ,
,
.
6,- 12-, 18-, 24- , 6, 12, 18, 24, 30, 36- .
, 6- 12- , .
12-, 24- .
, 1824-, 3036- (. 2 , ).
. 2.
:
) . . 180.
.
) . 9000.
74
.. . ...
, , .
.
22 . 6 , , .
,
,
.
.
,
, , , .
75
, , 2010, 4
+
CD25 CD4 0
+
.. , ..
29
., 2, , , 111020
.. , .. ,
..
-, 8, , , 117149
CD4+CD25+ - (T) - .
.
CD4+CD25+ ( ) , ( ). , . .
, . , .
: -, ,
, , .
, ,
(),
- CD25+CD4+ - (). , ,
, T [1, 2].
CD25+CD4+ , . FOXP3 (,
Scurfin), -2, CTLA-4- -4 (cytotoxic lymphocyte-associated, antigen-4) GITR- TNF (glucocorticoid-induced tumor necrosis
factor reptor) [3].
77
, , 2010, 4
T , ,
[4]
, , [5, 6].
[79]. ,
[8]. , ,
, , . ,
. [8, 9].
in vitro , , ,
-4 [10]. , .
( ) .
(CD4+CD25+-)
,
( ) () ().
. 15 59 81 , 9
61 85 9 30 72 - , 1- 2- 29 . .. .
- . () 6,3 110 /.
, .
-,
-
() . - 30 . 400 g
20 . , , . , , , ,
78
.. . CD25+CD4+ -...
, 10 . 250 g, .
EPICS-C (Coulter Electronics, Florida, USA).
Argon-Innova
90-6 (Coherent, USA) 488 . () CD8, CD4
CD25- .
: ( , - ) CD25 (
) , CD4 .
Microcal Origin 5,0.
. CD8+, CD4+, CD25+
CD4+CD25+ ()
CD4+ CD8+ . , , - , .
CD8+, CD4+ CD25+ 23 4%, 39 5%
0 0% . . 1.
1
,
()
()
()
CD4, %
45,70 3,40
CD8, %
17,30 1,80
, . .
2,90 0,50
CD25, %
0,20 0,04
0,52 0,17
0,89 0,28
CD4/CD25, %
0,11 0,03
: * < 0,05 .
,
, CD25+
, , , .
79
, , 2010, 4
, CD8+ , , . CD25+-
, ( ).
, CD25+ ( p > 0,05)
.
CD4+CD25+- ,
(. 1) , .
.
, CD4-. , CD4+CD25+-,
CD4+CD25+- CD4+-. , . 1, , ,
CD4+CD25+- CD4+-
. .
, . CD4+CD25+- .
80
.. . CD25+CD4+ -...
CD4+CD25+-
, ,
, [11].
. 2.
. 2.
, CD4+CD25+ . , CD4+CD25+- ,
-,
. .
[1] Adler A.J. Mechanisms of T cell tolerance and suppression in cancer mediated by tumor-associated antigens and hormones // Curr Cancer Drug Targets. 2007. 7. P. 314.
[2] Schlom J., Arlen P.M., Gulley J.L. Cancer vaccines: moving beyond current paradigms. //
Clin. Cancer Res. 2007. V. 13. P. 37763782.
[3] Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self // Nat. Immunol. 2005. V. 6. P. 345352.
[4] Curiel T.J., Coukos G., Zou L. et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival // Nat. Med. 2004.
V. 10. P. 942949.
[5] Sasada T., Kimura M., Yoshida Y. et al. CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression //
Cancer 2003. V. 98. P. 108999.
81
, , 2010, 4
[6] Ko K., Yamazaki S., Nakamura K. et al. Treatment of advanced tumors with agonistic antiGITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells // J. Exp.
Med. 2005. V. 202. P. 885891.
[7] Wolf .M., Wolf D., Steurer M. et al. Increase of regulatory T Cells in theperipheral blood of
cancer patients // Clinical Cancer Research. 2003. V. 9. P. 606612.
[8] Miller M., Lundberg K., Ozenci V. et al. CD4+CD25 T Cells are enriched in the tumor and peripheral blood and prostate cancer patients // J. Immunol. 2006. V. 177. P. 73987405.
[9] Yokokawa J., Cereda V., Remondo C. et al. Enhanced Functionality of CD4+CD25 high
FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer // Clin Cancer Res. 2008. V. 14. 4. . 10321040.
[10] .., .., .. . -
- in vitro // . 2008. 1. . 1015.
[11] Catalona W., Smith D., Ratliff T. et al. Measurement of prostatespecific antigen in serum a screening test for prostate cancer // New Engl. J. Med. 1991. V. 324. P. 11561161.
82
/
(/ IIIA)
..
. , 29, --, , 344022
NO ,
III. 36
/ III (1 ). 32 III
(2 ). 17 . 2- (NO) NO (iNOS) 26,86% (p < 0,05),
1- , , 53,26% (p < 0,05) .
(iNOS) 38,9% (p < 0,05) 54,90% ( < 0,05)
. 2- iNOS .
, NO ,
/ III.
: , , , , .
510%
. 90% , , [1]. , , .
() [2].
(NIDDK) / (/)
III. ( III) ( III) /.
NO / .
NO ,
- ,
. NO,
( ),
, , , ( ), NO / [3].
83
, , 2010, 4
NO
NO- (NOS). 3 NO: , . () NO
, , NO-
, .. (iNOS) [4, 5, 6]. NO [7].
NO , .
. 68 , . 36 III 1- ; 32 III 2- . 18 50 5 14 .
17 .
, , () , 4-
MearesStamey; (NIH-CPSI) (I-PSS), ,
, , ; : , .
NO
, ,
(NO
, ,
). , , NO (L- ) 37 24 ,
(- ) 15
540 [8].
t- Excel 2003.
, < 0,05.
.
IIIA NIH-CPSI
10,84 1,28 , 9,64 1,15 , 11,00 0,91 . III
: 10,9 1,1; 9,3 1,0 10,9 0,99 .
84
.. ...
IPSS IIIA
13,44 3,91, III 14,1 3,2 .
, 2- , ,
iNOS 26,86% (p < 0,05), 1- , ,
53,26% (p < 0,05)
. , 2,09 (p < 0,05)
NO NOS 1- 2-, / III.
1- NO- 38,9% (p < 0,05) 54,90%
( < 0,05) .
, ,
, iNOS
(. 1).
1
NO iNOS ,
1
2
NO [/ 210 ]10
,
,
26,82,0 0,62 * **
29,02 1,51* **
12,80 0,53*
18,71 0,79
17,50 0,40
20,90 0,64
,
31,91 0,80* **
18,9 0,61
20,60 1,0
: * (p < 0,05); **
1 2 , (p < 0,05).
NO ,
.
NO . NO , -, , / III.
NO / III, -,
[9].
, , NO ,
. ,
NO, iNOS. NO- (-4, -11,-13), . NO [10].
. , NO , / III.
85
, , 2010, 4
[1]
[2]
[3]
[4]
[5]
[6]
[7]
[8]
[9]
[10]
De la Rosette J.J., Hubregtse M.R., Meuleman E.J. et al. Diagnosis and treatment of 409 patients with prostatitis syndromes // Urology. 1993. 41(4). P. 301307.
Nickel J.C., Weidner W. Chronic prostatitis: current concepts and antimicrobial therapy // Infect Urol. 2000. 13. P. 2228.
.., .., .. NO- // . 2000. 4. . 3034.
.. // . 2000.
4. . 35.
.., .. : , , // ., . . . 2000. 4. . 1621.
.. . // , , . 1997. 1. . 4955.
.., .. //
. 2006. 2. . 7780.
.., .., .., ..
- // .
. . 1998. . 125. 1. . 4850.
.., .., .. . 2001. . 343.
.., .. //
. 2006. 2. . 7780.
86
0
.. , ..
-
4
. , 25, , , 115093
..
. -, 8, , , 117198
..
-
. , 15, , , 123098
,
- . 60
28 75 .
(), (), ().
35 ()
: (24%), (35%),
(32%), (11% 18%). 25 () : (70%), (44%),
(55%), (43%) (5%), .. .
: - , , .
, , , , [1, 6].
, , - ,
.
- 87
, , 2010, 4
, , [7, 8].
- , ,
[2, 5].
-
.
,
( ) , ,
, , [4].
, , ( , , ) [3].
60 28 75 - ().
, : 20 , (), (), (),
(TEOAE)
(DROAE). (), (), (, , ),
().
35 () , 76% . : I
37% , II 31,6%, IIIII 20%, IIIVI 5,7%
5,7%
.
(64%) (30%) 4 20 . (6%).
88
.. . - ...
. 1. . 52
. 2. . 52
SiSi- 52%
.
I
100110 .
( ).
7075 .
89
, , 2010, 4
,
I
III.
,
(37%), 40
.
, .
, :
(24%), (35%), (32%), (11% 18%).
.
() -
, ,
, .
50% , .
25 , , , 65%, ,
, 45% .
, : I 56% II 44%
8 20.
.
8% . (56%), .
DROAE
TEOAE
56% .
IIIV
IIIV, IVV.
.
90
.. . - ...
:
(70%), (44%), (55%),
(43%) (5%), .. .
. 3. . 60
,
. 4. . 60
,
91
, , 2010, 4
. 5. . 67
. .
1. , ,
, ().
2. - ,
,
.
3. , , .
92
.. . - ...
[5] .. //
. 1995. 2 . 2023.
[6] .., .. // . 2001 5. . 2224.
[7] .. . .: , 2008.
273 .
[8] Alexander Gutschalk, Christophe Michey Jennifer R. Melcher, Andr Rupp, Michael Scherg,
Andrew J. Oxenham Neuromagnetic Correlates of Streaming in Human Auditory Cortex // J
Neurosci. 2005. June 1; 25(22). P. 53825388.
V.I. Popaduk
The Department of ENT
Russian Peoples Friendship University
Mikluho-Maklaya str., 8, Moscow, 117198
N.A. Dayhes
State Scientific Clinical Centre of ENT
Gamalei str., 15, Moscow, Russia, 123098
Complete vestibulometric, audiological and otoneurological examinations were make in 60 patients from 28 till 75 years with sensory-neural hearing loss. Obtained data had compared to structural
changes and hemodynamic parameters of a blood flow on vertebral arteries, to internal carotids, and
also with a magnetic resonance imaging (MRI).
Perceptive cochlear-vestibular syndrome was diagnosed in 35 cases. The examination parameters
of the blood flow revealed structural changes vertebral arteries: hypoplasias (24%), deformations (35%),
asymmetries of diameters (32%). Occlusions and stenoses (11% and 18%) are diagnosed seldom.
In 25 cases with the central cochlear-vestibular syndrome diagnoses more rasping structural and
hemodynamic changes: bilaterial deformation vertebral arteries (70%), stenoses and occlusions vertebral arteries (44%), deformation internal carotids (55%), stenosis internal carotids (43%) and occlusion
internal carotids (5%).
Key words: vertebrobasilar insufficiency, vestibulometric, audiological and otoneurological examinations.
,
,
.. , ..
()
. , 12, , , 305035
, ,
, . ,
4 . , , .
, .
: , , ,
, .
() (), , , , (), () ()
[1, 3], .
, , . , .
,
( ), , .
,
, , , .
. 23 1
2- , 4 ( 3 (2008), 11 12
(48,5 1,8 ).
,
.
, II , ( 30 /2, 0,85
1,0 ). 25 . 14- .
94
.., .. , ...
(),
( ) ()
, ()
, W. Friedwald et. al. [9],
( /2,2). ,
,
, [8, 10, 11].
()
()- -, () [5]
[4]. III [4]
,
III [3],
(). , [3, 5]
().
. [7] .. (1999) (0,5104 ), ( 1 : 2 ),
(0,125 /), (0,8 /) ( ),
(5106 , ..) (7,3103 ).
.. . (1983) .
100 ,
, 30 , .
[6].
, 2 4
12 , . t- .
.
II ( 3,26 0,02 233/1 , -
5,49 0,04 /). 4
,
. 4 2,18 0,04 233/1 , 1,68 0,02 233/1 , -
4,12 0,02 3,42 0,03 / .
95
, , 2010, 4
-III
, ,
83,2 0,08% 92,1 0,3% , 1,1 0,03. 4 III 11,2%,
17%, 1,26 0,08%. 1
, .
, 9,33 0,2 ., 7,82
0,03 . 1,19 0,04. 4-
, , , , 2,9% 8,95% , 1,27 0,4,
(1 ) .
, , .
, 4 , .
. ,
4 . 41,4 0,04 .,
37,7 0,04 . (59,3
0,06 . 4 . 50,9 0,04 . .), 60,9 0,04,
56,2 0,04 ., 22 63,6 0,02 . 4 . 48,8 0,06 . . , , 75,2 0,04 .
63,8 0,06 ., 4 12 , 128,3 0,04 .
113,7 0,04 . 4 . , -
.
.
. , [1].
, ,
in vitro.
, ,
. 96
.., .. , ...
. .
, , , .
, .
III
, .
, ,
, .
, , ,
.
, ,
, , 4- .
1. , , ,
, , 4 , , .
2. 4 .
97
98
..
3
. , 29, --, , 344022
..
1
. , 29, --, , 344022
..
. , 127, --, , 344010
() .
,
, , ( )
. , .
, , - ,
. 104 .
: , , .
()
.
1030% [5].
, 4% ,
[1]. ,
- [3]. , - , - -.
(, ),
, , [8].
, [4].
99
, , 2010, 4
, , , , . , , ;
, , .; , ,
; , , . [2, 7]. ,
, , . ,
. ,
,
, , -, . ,
, , ,
,
.
. 104 , 26,3 5,9 , ,
, -
(, , ).
, FerrimanGallwey [6, 9],
, , .
,
, , ,
, ,
.
,
, ( 10 , 10 , 8 3) [5].
.
1. - : , , 20 , Ferriman-Gallwey > 8, .
2. ( 8 ), ( 180 ), , .
100
. ., . ., .. ...
3. ( : >
> 140/70 , () > 80 , /
() > 0,8, )
4. (, , , FerrimanGallwey > 15)
,
.
, , . :
1. 34- , , ,
, - 3 ,
();
2. (): / 100%.
, , 3 , - () .
4.
\ > 2%, .. .
1. - ()
17- (17-).
2. (), ,
.
= ( / /) / 22,5
ro = / / .
, , :
?
?
(, )?
( ,
.)?
?
. 1-
20%
, .
9%,
20 . 12% 101
, , 2010, 4
, ,
Ferriman-Gallwey , 8,
, .
80% , : - ,
. 51% ,
, ,
2% 43% .
31% , , ,
, .
17-. 27% \ 17-,
.
, .. \ , 6% .
. ,
, , , , :
( Ferriman-Gallwey > 15 ) [3];
, ;
, (
80 ), , , , , 20 .
102
. ., . ., .. ...
[7] Cibula D., Citcova R., Clerici A. Increased risk of non-insulin dependent diabetes mellitus,
arterial hypertension and coronary artery disease in perimenopausal women with hystory of
the PCOS // Hum Reprod. 2000. 24. P. 10501052.
[8] Rickenlund A., Carlstrom K., Ekblom B. et al. Hyperandrogenicity is an alternative mechanism underlying oligomenorrhoea or amenorrhoea in female athletes and may improve
physical performance // Fertil Steril. 2003. 79. P. 947955.
[9] Ferriman D., Gallwey J.D. Clinical assessment of body hair growth in women // J Clin Endocrinol Metab. 1961. 21. P. 14401447.
A.N. Rymashevsky
Obstetrics and gynaecology department 1
Rostov State Medical university
Nahichevansky str., 29, Rostov-on-Don, Russia, 344022
T.A. Dimitriadi
Regional Clinico-Diagnostic Center
Pushkinsraya str., 127, Rostov-on-Don, Russia, 344010
Hyperandrogenism is one of the pathology of endocrin system, which is more difficult diagnosed
at reproductive age of women. There is caeful history and assessment clinical presentation which dominate in diagnostics of hyperandrogenism in the contemporary stage. Laboratory tests run by strict reports are to confirm or disprove hypothesis about hyperandrogenism. There is given algorithm diagnostics of patients with hyperandrogenism, which is to reduce hyperdiagnosis of this pathology and
accelerate to diagnose properly. It Includes assessment hyperandrogenism affect on dermatologic,
metabolic, cardiovascular systems, that is why hyperandrogenism needs long-term treatment and careful
observation. 104 women have been examined with the clinical use of the algorithm diagnostics.
Key words: hyperandrogenism, pathology of endocrin system.
0
..
. , 33, , , 109341
- . .
- , ,
. ; , ,
, ,
; ; ; .
: - ; ;
; ; , .
[1]. , , .
, ( , , , , , , ..).
, , ,
.
22 1993 . 5498-1 [2]
:
; ;
- ;
.
.
104
.. -
( IV . 2.12.2000 . 139-). ( V)
: (. 27).
,
, 24 1995 . 181- [3].
, 181- , 24 1995 . [3].
, ,
28.4.2001 .
,
, [5].
, ( )
, .
, , , .
, , ,
, .
.
, , ,
, . : , , , .
26.06.2000 .
:
. 2021 2001 . 6
105
, , 2010, 4
, 20012005
2010 ,
2010 ., .
. 3.3 - ,
.
, 20012002 . 20032010 .
( 113 114 21.03.2003 .). , ,
07.08.2001 .
2000 .
-
,
, . -, -
( ) . : 09.01.1981 . 15
; 06.08.1981 826
, , , () ; 23.09.1981 1000 - ;
15.02.1982 . 134 - ;
10.05.1983 548 ()
; 21.12.1984 1440
, ,
;
11.07.1989 . 406
; 23.11.1993 . 273 ... ; 12.09.1997 .
270 ; 01.07.2003 296
; 22.08.2005 534 - .
106
.. -
. 27.08.1999 . 337
9 2003
241: : 040132 . : 20.08.2007 . 553,
11.03.2008 . 112, 05.05.2008 . 217, 23.04.2009 . 210 , . 07.07.2009 .
415
,
. 01.07.2003
297
.
31.01.2006 . 52
, 337,
.
,
: 03.06.2003 .
229 ; 07.10.2005 . 627
19.02.2007 .: , ; - ; , - .
. 13 10.2005 . 633 .
: -
. 9
( , , , );
. 4
(, , , , ,
, , , ).
10.05.2007 . 323
(), , - ( - , 107
, , 2010, 4
), , , , - ,
(). () .
.
: 09.03.2007 156
; 11.08. 2008 . 410
( )
; 06.07.2009 . 389
.
. . 22.10.2003 .
502 () . 22.01.2007 . 30
.
2004 . .
2004 , , . :
2223.11.2004 208227, 273
278 - .
05.11.2008 . 622 . ,
.
.
,
- , , : ;
, , , ,
; ; ; .
108
.. -
,
, . : ,
, , ,
.
[1] : . / .
. .. , .. . 4- . .: -, 2006.
[2] 22 1993 . 5498-1 .
[3] 24 1995 . 181-
.
[4] 24 1995 . 181-
.
[5] ,
,
. 28.04.2001.
109
..
. ., 18/1, , , 603155
..
. , 15, , 603001
-
- - 18 69 .
- , , , , , .
- .
: , , , .
, .
, , ,
,
[9].
,
- ,
, , ,
[7, 8, 9]. , - , . , ,
, ,
5080%
[1, 6, 10]. ()
,
, [5, 6]. - ,
110
.., .. ...
- , [1].
-, , ,
[3, 4].
-
, . ,
- .
- ,
14- , ,
.
20042008 . -
4500 ( , 276 ).
1865 (- 39%, 33%, - 10% 18%).
: 39 19,5% 4059 49%. 18
60 6% 25,5%.
,
, , -, - .
(-, , )
.
( ).
. ,
. , , , , , , .
.
, ( ,
) , .
,
.
. . - 111
, , 2010, 4
, ,
.
, , , , , . .
. : ; ; ; ;
; ; ; ; ; , (- ). .
- ,
[4, 9].
, 713 , , 610 .
, , - ; . 3 5
.
-
,
. ,
,
, , . ( )
,
1015% 5055%
.
- : ,
, - ,
.
, 112
.., .. ...
[2]
POINTS (FAST- , . ) [5].
, , .
.
,
- , ,
- .
, 95,4% ,
. -
. , , .
113
, , 2010, 4
T.V. Drubich
The division head of ship medicine
OOO Company of the river tourism of Volga steam navigation
pl. Markina, 15a, Nizhniy Novgorod, Russia, 603001
Is carried out analysis of the clinical effectiveness of the combination of the methods of physioand reflexotherapies with the landscape and the climatotherapy in the process of the health resorthealth-improvement treatment of the persons with various forms of vegetative disfunctions at the age
from 18 to 69 years under the conditions of river cruise. The control of course effectiveness was
achieved in the dynamics of clinico-functional indices, including data of [refleksodiagnostiki], [kardiointervalografiyu], questionnaires, which characterize the state of psychoemotional sphere, the vital capacity of lungs and dynamometry. The results of the health-improvement- health resort treatment of the
persons with the vegetative disfunctions under the conditions of river cruise confirmed its effectiveness.
Key words: vegetative disfunctions, integral of rezervometriya, [refleksodiagnostika], landshaftoterapiya.
0
, ,
.. , ..
, 9, , , 121069
,
()
. , , , ,
( ). .
- ( )
,
( , .. ).
,
, - .
: , , , ,
, , , .
, , ,
( ) - , ,
( 25 ,
25 , ). (), , , ( ), ( ),
, , (
). , ( ) : ,
. , , , - [19].
( )
. , , ,
, - .
()
(),
115
, , 2010, 4
, .
,
(?, ?,
, ),
. ,
: , (
).
, ,
.
( ?, ?,
?, ?), .
, .
: 1) () (
); 2) (
). , , (-).
,
( , , , ). ( )
,
. 20% (
):
. , , . , (
, )
( , ), .
, () (). , ( , , ,
, ( , )).
, . , . ( )
116
.., .. -...
, ( ),
.
,
( ), ,
(.. ).
( ). , , ..
, .
-. ,
,
.
, , ( ,
),
, . ,
(), , ( , ,
): .
: (.. ).
( ) .
. - ,
, .
1. . 56 , .
2. , (5 ) (20 ), , , , .
3. ( ).
4. - , () .
117
, , 2010, 4
5. , .
25 , , , ( 11 )
- .
[1]
[2]
[3]
[4]
[5]
[6]
[7]
[8]
[9]
.. . .: , 2002.
.. . .: , 2006.
.. : //
. 2009. 3. . 34.
..
// . 2009. 3. . 25.
.. . // . / . .. . ., 2009. . 102.
.. // . : , 1979. . 400420.
.. //
. .: , 1978. . 513.
.. //
. -: . 1991. . 6769.
/ . .. . . 1, 2. .: ,
1983.
118
.. , ..
. , 12, , , 125284
, .
.
: - , , .
XXI . , 50%
20 ,
.. , [5].
, .
. ,
. - , .. ,
, , , - , , .
.
, ( .., 1997). , . Survey on Sleeplessnes, Pain and the Workplace (1997 .),
[7].
119
, , 2010, 4
, ,
.
. 134 (
81 (60,4%) 53 (39,6%)) 19 75 .
: ,
, , ,
, , --
, [5, 6],
- () [1, 4], () [7].
. , : , , , , , , ,
,
, ,
, , , , . ( , ),
. - :
, , .
, , , ,
, .
- :
1) , - (6,
7Th1, Th2);
2) , (Th4Th5);
3) , - (Th3
Th6) , - ;
4) , .
, ,
. , : .
120
.., .. ...
, , , , , [2, 5].
(64 48%)
: - , c .
( ,
, - .)
70 (52%).
2 : 38
( -1) 19 70 ( ) , 32 (-1)
24 72 (, , , , , , , ).
21 . , 3 22 (57,9%) , 3 6 9 (23,7%) , 6 7 (18,4%) .
-
2 : 34 -2 25
74 ( ) , 30
(-2) 29 75 (, , , , , ,
, ).
21 .
3 19 (55,9%)
, 3 6 9 (26,5%) , 6 6
(17,6%) .
,
10 ,
, ,
( II )
24
121
, , 2010, 4
, [3].
, , [2, 6].
( ) 2 , 2 [2].
Statistica 6.0.
. .
, . 43 (61,4%)
, ; 12 (17,1%) , 15
(21,4%) .
-1 ( ) -1 ( ) 5 10 ( 8,7 2,1 8,4 1,7 ).
0 ... 5 , 2,4 0,7
-1 4,3 1,2 -1.
1
0 ( m)
1
1
38
32
8,8 2,1
8,4 1,7
5
10
6,8 1,3
7,8 1,6
3,8 1,4
5,1 1,4
2,4 0,7
4,3 1,2
:* ( < 0,05)
, ,
. .
.
11 18 -1 10 19 -1 ( 13,6 2,1 12,4 3,3 ).
13 28 ( 23,4 4,8)
-1 13 22 ( 16,9 4,3) -1.
2
1
1
38
32
12
26
11
21
: * ( < 0,05).
122
.., .. ...
, , .
- , 5-, 10- .
-2 ( ) -2 ( ) 4
9 ( 8,6 2,2 8,5 1,9 ).
0 ... 4 , 2,2 1,0 -2
4,2 1,1 -2.
3
0 ( m)
2
2
34
30
8,6 2,2
8,5 1,9
5
10
6,3 1,9
7,7 1,7
3,6 1,3
4,9 1,3
2,2 1,0
4,2 1,1
: * ( < 0,05).
10 19 -2
11 19 -2 ( 12,8 2,4
11,6 3,5 ).
15 28 ( 25,6 4,6)
-2 15 24 ( 16,3 4,6) -2.
4
0
2
2
34
30
13
12
24
20
: * ( < 0,05).
11 14 ,
14 17 . ,
4 ... 5 , 30%.
. ( ) :
, , , .
, .
123
, , 2010, 4
0
.. , .. , .. ,
.. , ..
, 1, , , 117593
- - Phillips Achieva 1,5, SENSE-Flex-M. ( , , ), FFE T2, TSE PD,
TSE PD SPAIR.
, .
,
, .
: , - , ,
, .
()
,
. : ,
, , 10% . 40% [1].
,
, , . M. Vahlensieck et al.
13% [2].
, ,
. 35 . 35 [3].
-
(prevalence)
.
125
, , 2010, 4
. 50 , 38 (76%) 12 (24%) , .
29 (58%) , , .
22 .
- Achieva Phillips 1,5,
Sense-Flex-M. - ( , ) [4],
2 () FFE_T2W, TSE
PDW,
TSE PD SPAIR, 3 , . 1.
1
TR, mc
500
834
4 903
5 000
TE, mc
20
18,4
30
30
TI, mc
0
0
85
0
ET
10
1
10
12
NSA
2
2
3
2
Thk./space, mm
3.0/0.3
3.0/0.3
3.0/0.3
3.0/0.3
[5, 6]
( , , ); (, ); -
(, , );
( , ,
, ); (
, , ); ( ); ,
, (, , ), .
, , , , -
, (II, III, V) [7],
- , .
-
, 90%
, .
126
.. . - ...
- , , :
, , .
,
.
. .
1- 56 (58%) , 21 1 ;
2- 40 (42%) ,
, .
, , - , II, III
V, ( . 2).
2
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
II, III, V
( HillSachs)
. (%)
56 (58%)
40 (42%)
22
32
28
12
I
II
III
IV
14 (64,0%)
5 (15,6%)
18 (64,3%)
3 (25%)
9 (40,9%)
4 (18,1%)
2 (0,6%)
0 (0%)
12 (42,9%)
7 (25%)
3 (25%)
2 (16,7%)
6 (27,3%)
18 (56,3%)
12 (43%)
5 (41,7%)
8 (36,4%)
3 (0,9%)
7 (25%)
1 (0,8%)
6 (27,3%)
2 (0,6%)
9 (32,1%)
0 (0%)
12 (54,5%)
9 (40,9%)
9 (28,1%)
4 (12,5%)
15 (53,6%)
9 (32,1%)
4 (33,3%)
2 (16,7%)
7 (31,8%)
6 (18,8%)
13 (46,4%)
4 (33,3%)
6 (27,3%)
7 (31,8%)
13 (59,1%)
5 (15,6%)
7 (21,9%)
7 (21,9%)
5 (18%)
9 (32,1%)
12 (42,9%)
1 (16,7%)
1 (0,8%)
1 (0,8%)
13 (59,1%)
4 (18,2%)
6 (18,8%)
2 (0,6%)
17 (60,7%)
6 (21,4%)
3 (25%)
3 (25%)
- ,
, 127
, , 2010, 4
, , ,
.
, ,
, , , , .
-
, (II, III, V), - ,
, , ,
, :
, .
1. , , , , , ,
(, ),
(, ).
2. ,
, , , , , .
3. , , , .
4. . [8].
[1] Bigianni L.U., Morrison D.S. The Morphology of the Acromion and its Relationship to Rotator Cuff Tears // Ortop. Trans. 1996. V. 10. P. 228.
[2] Vahlensieck M., Genant H.K., Reiser M. MRI of the Muskuloskeletal System // Thieme.
2000. P. 4775.
[3] Christine B. Chung and Lynne S. Steinbach. MRI of the upper extremity // Lippincott.
2009. P. 728.
128
.. . - ...
[4] David W. Stoller. MRI in Orthopaedics and sports medicine // Lippincott. 2007.
P. 2160.
[5] Burgener F.A., Meyers S.P., Tan R.K. et al. Differential Diagnosis in Magnetic Resonance
Imaging // Thieme. 2002. P. 334372.
[6] Vahlensieck M., Genant H.K., Reiser M. MRI of the Muskuloskeletal System // Thieme.
2000. P. 4775.
[7] .., .. - . // . . 2009. 104 .
[8] .. .. . .
.: , 2009. 192 .
574.24+612.11+615.27
0
,
. , ..
, 8/5, , , 113093
- . ,
,
(). ,
(79 , 70 ).
: , , .
, . , ,
. , , .
,
. () ,
.
() [1]
()
-
.
- , (. -, ()).
.
120 1825 , , (),
- () - () ().
130
. , .. - ...
, .
:
1 0 ()1 ;
2 ()1 ()2 67%
;
3 ()2 ()3
( 95%) ;
4 ()3 100% .
Microsoft Excel XP Statistica 6.0.
. . 1 , ,
().
(79 , 70 ).
, 40 70 ,
. 70 ,
,
, , .
( ).
,
.
1
( % )
70
2
9
7
13
7
10
3
6
6
10
21
8
79
16
7
8
13
3
8
1
1
1
8
24
13
131
, , 2010, 4
() ,
, .
, . 1 2,
67%. 2 95%,
. 120 15 ,
9 15 67%, 6 15 95%. ,
, .
, ,
.
.
. 2,
.
2.
(kMIN = 43%)
K.
()
( )
53
( )
46
()
69
( )
52
( )
49
( )
43
( )
( )
62
70
60
10
( )
48
11
( )
47
12
( )
46
13
( )
50
, [4, 5]. ,
.
k, 100% +100%. 132
. , .. - ...
. 0,95. -,
, - .
, , , , , .
, ,
, , , , .
,
, , , ,
12-, , , .
,
, .
. ,
. , ,
, . , [2, 3].
,
, -
.
133
, , 2010, 4
ESTIMATION ACTIVITY
OF STRUCTURALLY FUNCTIONAL SYSTEMS
OF THE STUDENTS LIVING IN SUBTROPICAL CLIMATE
Alaa M. Zourob, A.Ya. Chizhov
Department of Ecological Monitoring and Prognostication
Ecological faculty
Peoples Friendship University of Russia
Podolskoye shosse, 8/5, Moscow, Russia, 113093
In clause the results of definition to an estimation activity of structurally functional systems of the
students living in subtropical climate are given. Is established, that the special set of meridians, and also
orientation and degree of deviation them activity from own for group of average size electroconductivity of all meridians is characteristic for the students. So, the average sizes electroconductivity of all meridians of the surveyed students differ from those in control group in the party of a various degree of
increase (79 , at the control 70 ).
Key words: students, subtropical climate, method Nakatani.
..
. 7 , 67, --, , 344019
, , , .
1875 11 26 . ,
, . 65,9%, 23,6%. . 15,6 ,
30,2 , 7,3 . 17%
.
,
, ,
: , .
.
.
, , .
,
.
,
. : . 12-07 .
: , ,
, , , , , . 135
, , 2010, 4
, .
.
12-07 , .
, ,
, .
. , - , .
, . 3 .
,
, .
, , .. , , ( ),
, .
. 1875 11 26 . .
3000 , 3000 .
.
[1].
,
, .. .
20
[1].
. SPSS 15.0 for Windows Evaluation Version.
136
.. ...
()
( ). ()
,
( ).
:
, , , ).
( )
() :
0,04 / , 0,0927 / ,
0,1227 / , (, ..) 0,3227 / .
( , , , ).
- , : , , , ,
; ,
250 ;
400
14 ; 500
12 ; 500
23 [2].
(. 1).
1
0
( )
,
1829
3039
4059
6074
> 75
.
11,7
10,7
8,6
10,2
38,9
10,5
.
19,9
15,3
21,3
30,3
52,9
20,4
.
.
47,3
65,8
27,5
66,4
34,5
67,7
40,7
57,4
16,7
29,4
36,0
65,9
.
.
11,7
6,6
16,8
10,7
13,9
4,2
13,9
4,1
5,6
0,0
14,0
6,3
.
.
17,2
5,4
30,6
4,7
24,9
4,2
14,8
4,1
22,2
5,9
23,6
4,6
.
.
12,1
2,2
14,4
2,9
18,1
2,6
20,4
4,1
16,7
11,8
15,9
2,8
, , 2010, 4
4
(. 2).
2
( )
,
1829
3039
4059
6074
> 75
( )
.
.
22,2
6,2
11,7
32,0
8,6
17,8
31,1
6,6
14,7
38,6
9,7
23,3
41,2
25,1
33,4
30,2
7,3
15,6
()
.
256
291
409
108
18
1 082
.
497
450
832
122
17
1 918
753
741
1241
230
35
3 000
.
45,0
62,1
53,7
90,0
77,3
59,4
.
20,0
32,8
26,7
37,0
63,9
28,1
31,7
47,9
39,5
68,7
70,5
43,5
. .
75 (. 1).
. 1.
. ,
( 3039 ), 32 , ( 4059 ) 31,1 .
, 59 41,2 .
6075 75 , , (p < 0,05).
,
: 6,6 4059 25,1 75 , ,
4 1,6 .
15,6
, 30,2 , 7,3 .
138
.. ...
4 . ,
. 1829 , 3039 , 6074 , 40
59 ( 5 ), 75 ( 1,6 ), (p < 0,005).
, : . ( ) , , .
, ( 20 )
36% ( ).
. 3.
3
, %
32,8
32,1
32,6
, %
5,2
12,9
7,5
, %
8,0
10,8
8,9
, %
40,8
29,3
37,3
, %
13,2
14,8
13,7
. 3 ,
40,8%. ( 32,1%),
32,8%,
5,2% 12,9% . ,
(), , : 13,2% 14,8% .
, . ,
, 20 [1].
, , 17% . , : 536614 ,
. 139
, , 2010, 4
,
, , .
,
? ,
(76%
) 4059 , : , ,
,
, , : , , ,
,
1416 .
. 12-07
:
2008 (79% , ), ( 4059 50%
).
, , , , , ,
. , .
, : , ,
, .
,
, , .
, .
140
.. ...
COMPLEX RESEARCH
OF ALCOHOL PRODUCTS CONSUMPTION
AND ITS CONSEQUENCES FOR HEALTH
OF POPULATION OF THE ROSTOV REGION
S.P. Alekseenko
Department of hygiene nourishment and hygiene of children and teenagers
Federal State Institution of Health Center of hygiene and epidemiology in the Rostov region
7-ya Liniya str., 67, Rostov-on-Don, RUSSIA, 344019
Deficit of information, characterizing alcoholic situation, dictates necessity of perfection of information fund data, characterizing alcoholic situation. Examination of the alcohol consumption was conducted
by casual selection of the population at the age of 1875 years in 11 cities and 26 rural districts of the
Rostov region. The examination showed, that actually the women consumer less alcohol, than the men.
Among the women prevail occasionally drinking 65,9%, but among the men-systematically drinking
23,6%. Age dynamics of the amount of consumed alcohol was disclosed. The consumption of alcohol
drinks in general by selection makes up 15,6 g, calculated on basis of pure ethanol with big fluctuations,
for the men the present index makes up 30,2 g, but for the women 7,3 g. 17% of the adult population
of the Rostov region are involved into dangerous for health and life consumption of alcohol. The similar
complex system of information collection, its analysis may be considered as scientifically justified technology of monitoring, providing the institutions of Russian consumer supervision institution with hygienic
information, relating to consumption of alcoholic beverage by the population of the Rostov region.
Key words: alcoholic beverage, alcoholic situation.
0
..
-
. , 40, , , 362025
..
-
. , 8/2, , , 362025
..
-
. , 40, , , 362025
.
. -
.
: , , , , ,
, , .
, , , .
, , , , . 3- .
12%.
, ,
24% [1].
.
, 30%.
: 5378% , 3791% ,
6572% . 5000 [2].
142
. 1.
20002008 . (.)
: , , .
, , 498,5 2,6 100 .
(p < 0,1).
, ,
17,9% 2000 .
20,4 2008 .
2,5%. ,
.
143
, , 2010, 4
1- 2009 . 34,8%.
, , , ,
, .
1,2 2000 . 1,27
10 . 2009 . . ,
, , 1,7 , , .
(92,8%). I II 80%, III IV . 6170
III (64,2%), 71 I (53,5%). II (45,0%) (4060 ), .
2005 . I ,
III , ,
(. 2).
. 2. 20022009 . (%)
, ,
-
.
, ,
144
2534 . - , , .
[1] .., .. //
VIII : . ., 2005. . 7879.
[2] .., .., .. - //
: . . 3. 1998. . 510.
I.Ch. Mamsurova
Bureau of medical and social examination for persons
with diseases and defects of an organ of vision on RNOAlinia
Shegren str., 8/2, Vladikavkaz, RNOAlania, 362025
Z.R. Alikova
Chair of public health and public health services
North Osetia state medical academy
Pushkinskaya str., 40, Vladikavkaz, RNOAlania, 362025
Dynamics of disease indicators of glaucoma in RNOAlania tends to growth. Glaucoma stably occupies the first place in the structure of primary physical inability on an eye pathology. The high medical
and social importance of glaucoma specifies in necessity of perfection of struggle against a glaucoma in
republic, considering factors of its formation.
Key word: glaucoma, disease, prevalence, physical inability, tendencies, indicators, structure,
prophylactic medical examination.
145
.. , ..
,
-
. ., 76, , , 123007
- (2080%) . (2080%) 3 , - (2080%) 5 .
: , , , , ,
, .
, ,
, .
[1].
.
. , , , .
.
. 20% 80% , [2].
. .
, . , . , , .
- () . 100 ,
.
146
.., ..
. ( ) 1
. , 23 , , . ,
. (
80%, 20%), - ( 20%, 80%),
- ( 20%, 80%).
.
, 110 (. 1) 26,3 (2,1) //. 2550 .
13,8 (1,5) //. 50 16,7 //.
. 1. ( 80%, 20%)
50 16,7 //. (150 .). 10
26,3 //. ( 110 ). 2550
13,8 //. (2550 .).
26,3/13,8 = 1,9 .
.
,
, 115
(. 2) 21.4 //. 5060 .
7 //.
60 14,62 //.
147
, , 2010, 4
. 2. ( 80%,
20%) 60 14,82 //. (160 .).
15 21,4 //. ( 115 ),
5060 7 //. (5060 .).
21,4 / 7 = 3
, 525 (. 3) 21,06 //. 6085 .
5 4,21 //.
85 12,8 //.
. 3. ( 80%,
20%) 85 12,8 // (185 ).
20 21,06 //. ( 525 ).
6085 4,21 //.
(6085 .).
21,06 / 4,21 = 5,13
. (- - ). 148
.., ..
,
, . , , .
, .
.
.. , ..
.
. , 6, , , 173020
. ,
. .
: , ,
, .
( ) , , .
. , , . ,
, . ,
.
: 1
; 2 .
, , , ,
[2]. ,
. ,
[1].
. - , : , ,
. 2009 ,
350 . , .
-
.
- : , . - 150
.., .. ...
: 65% ; 35% 41
50 , 20% 30 60 , 16% 3140 9% 5160 . 50%, 31% ,
19%.
() . 70%
35% , , , , .
, , .
: 31%, / 20%, 24%, 20%,
5%. , 60%
3000 5000 . 5000 9000
19% , 10% 2500 11% 9000 .
, 56,6%
,
60 , ,
, ,
. ,
46,3% , , 36,9%
, , 16,8%
. ,
, , , .
,
, , 40%
, 33% 27% .
, . . ,
, .
( %)
14,0
1
23,1
49,1
1
30,8
20,0
1
28,0
3,1
1
15,1
5,4
3
8,4
151
, , 2010, 4
, ,
, ,
.
. 1 ,
.
. 1. , :
1) ; 2) , ;
3) ; 4) ,
, ; 5) ; 6)
1000 .; 7) 1000 3000 .; 8) ,
; 9)
. , , , ,
, , . : , , .
.
[1] .., ..
// . 2008. 8. . 2629.
[2] .., .. // . 2007. 7. . 1420.
152
.., .. ...
.. , ..
.
. , 6, , , 173020
.
. .
: , , , , , .
, , , .
: 1
; 2
.
2008 . 1.
. 1.
2008
. , , - 2008 .
. MS Excel.
154
.., .. ...
, , , ,
().
,
, , , .
. 2.
. 2.
2008 . 3.
. 3.
155
, , 2010, 4
.
19,1%, - 18,8%, 16,5% [3].
.
, .
,
,
, , - ,
, [3, 5].
. , , ,
, , , .
2008 2 5 (
, /3) , [4].
(, , , )
.
,
(. 1).
1
2008
2,3
0,72
5,97
2,45
9,93
. 2.
. ().
156
.., .. ...
, , , .
, 70%.
, [2],
, .
2
(n)
2008 .
I
II
III
IV
VVI
IX
X
XII
n
19
21
19
27
25
28
27
14
, max
r
0,45
0,1
0,25
0,1
0,01
0,1
0,58
< 0,05
0,54
< 0,05
0,31
< 0,1
0,6
< 0,05
0,34
0,1
, max
r
0,46
> 0,1
0,14
> 0,1
0,77
< 0,05
0,08
> 0,1
0,22
> 0,1
0,4
> 0,1
0,44
> 0,1
0,18
> 0,1
, max
r
0,18
> 0,1
0,12
> 0,1
0,18
> 0,1
0,20
> 0,1
0,10
> 0,1
0,3
> 0,1
: r ; .
[1].
, , , - ,
.
, .
, ,
.
, , .
, , (, ), ,
() ,
, , . , , , , , , ,
157
, , 2010, 4
, (, , , -),
, , , .
0
0,
..
.
. , 33, , , 450096
-,
, .
40,2% , , 41,3% ,
58,0% , 38,7% .
: , , -.
, , , , , [1].
, 510%
13 17 . , ( 1000 ) 114,
7090, 10 [2]. 10 15% .
(52,8%) ,
13% [4]. .. [3], , , .
, , .
.
.
, 103 , , , , , .
. 2007
400 -,
12 17 11 ( 54,2% 17 11 ).
- , 40,2% ; 38,6%,
159
, , 2010, 4
21,2%. , 50,9%
. , , ( 50,8% ,
54,1% ).
- 38,7% . 17,9% , 28,0% , 15,4% , 11,6% , 9,1% , 18,0% .
. , 58,1%
, 30,5% , 62,4% , 45,8%
. , 41,3% .
14,9 0,1 ,
8,2 1,2 . -, , , 58,0%
1516 . 60% , , 1 , . , 18,3%
34 , 12,3% 23 8,2% 1 . 4% ( ) , .
, , . , 39,4%.
, , 50,0% .
. , 52,9 100 -
; 39,8 , 15,3 , 27,6
, 24,3 100 .
12,9 0,1 . 15,2 0,4 , 36,5% ,
.
71,3% . ,
, (69,6%) (18,8%).
( 12 )
-- 18,8% ,
32,4%, 23,5%,
16,2%, , 8,8%, 2,9%, 16,2%.
160
.. - -,
[1] .. . // .
., 2000. 468 .
[2] .., .. //
. ., 2000. . 6668.
[3] .. //
. 1997. 4. . 4446.
[4] .., .. . .:
-, 2001. 568 .
161
..
. , 148, , , 410002
..
. ..
. , 83, , , 410012
.. , .. ,
. , .
. . , 112, , , 410002
,
- , 0,001
1 /.
: , , .
15 Enterobacteriacea [1].
.
E. coli [2].
. , [3]. .
20 E. coli 20 Enterobacter agglomerans, , - - ()
- .
0,9%- NaCl 0,001
1/ 100 (300 000 /),
.
162
.. . ...
.
100 - ,
24 37 , 24 .
(), (m) (p). E. coli,
,
30150 , ,
. 1.
1
E. coli
,
.
30
60
120
150
.
,
n = 10
978 89
876 121
1107 117
785 245
, M m
, n = 20
1
2
3
4
0,001 /
0,01 /
0,1 /
1 /
58 25***
39 19***
126 7***
19 8***
23 36***
46 14***
56 11***
,
.
30
60
120
150
.
,
n = 10
784 56
452 81
563 76
678 64
, M m
, n = 20
1
2
3
0,001 /
0,01 /
0,1 /
167 81***
78 90 ***
52 6***
119 89***
118 29***
37 31***
146 11***
86 41***
4
1 /
163
, , 2010, 4
1 /
. 30- 0,1 / , -
, 93% (p < 0,001). 0,01 /
91% , 30 . (p < 0,001).
.
, , , , ,
, .
164
N0
.. , .. ,
.. , ..
. , 2, , Russia, 614081
- , ,
N-
, .
: N- , , .
()
.
, ,
.
N- ,
[2]. .
-
, ,
N- . 3 ,
.
N- , . ,
, 95%. 140 142 .
, 105 , 0,5%.
- , Specord M-80
4000 400 1, . 3440 1 , (CONH2), 3200 1
(NH), 1632 1
(CONH2). - 1600,
1580, 1512, 1440 1.
165
, , 2010, 4
0,001% N- 95% , 190 400 217 258 378 ( 2500, 620 315).
N-
. ( ) ( ;
).
( ).
-- ( 26-11-17-89). N-
( ) 23
. ,
.
10 . - .
,
. N-
: (9 : 1); Rf
0,59 0,38.
,
( ). ,
N- .
, ,
.
[1, 3]. N- 1 2. ,
30 .
1
,
0,3028
0,3045
0,3016
0,3015
0,2985
166
%
0,3023
99,83
0,3034
99,64
0,2991
99,17
0,3002
99,57
0,2969
99,46
. = 99,53
S = 0,109
. = 0,30
. = 0,30%
.. . N-
2
( n = 5)
99,0
1.06.10.08
2.05.03.09
3.08.04.09
99,49
99,54
99,46
0,165
0,113
0,0944
., %
0,46
0,31
0,26
0,46
0,31
0,26
N-
.
[1] ( 42-0052-07) //
. .: , 2008. . 18. . 101104.
[2] .., .., .. . N-
, , // 2180656, , . 26.07.2000. . . . . 2000119954; . 20.03.02; . 26.07.00. 3 .
[3] 42-0269-07. .
0
..
69 .
. 2- , 31, , , 111401
- ,
.
,
,
, . ,
, .
, ( ) 1215 .
- .
: , , .
- ,
, , () .
, , , .
, , .
,
() () ( , ..
. -, 2003 . [21]; ... .. . , 2000 .; .
, ,
2003 .; . , [1].
168
.. ...
, -, (-), .
( , , -), (. .. , 2003 .) [2].
,
NO ,
, .
-
- .
.
,
, , .
, (- - ) (, )
.
[3].
.
, .
69 . 2003
2007 . 1412 . 17 65 : , , L4L5, L5S1 c 13 427 .; , ,
L4L5, L5S1 5 338 .; 330 .;
317 .; 7
48 .
, , (. 1)
169
, , 2010, 4
1
,
410
790
147
1 347
17 40
40 55
65
43
14
8
65
453
804
155
1412
.
. 2.
2
2
,
.
L4L5, L5S1
13
.
.
,
L4L5, L5S1
5
4
5
3
269
R
6
17
7
427
204
134
338
12
338
330
330
330
317
317
14
317
473
939
1 412
48
1 412
4
158
5
427
I 423 .
II 435
: , , , .
III 554 , , .
1. I 3547%, 5057%
38% . 3846%, 5360%, 12% .
2. II
:
4860%, 3849%, 23%; 5157%, 4348%, 1% .
170
.. ...
3. III
9498%, 26%,
;
8690%, 1015% , .
, .
[1] .. , , //
-
. 2003. . 1014.
[2] .., .., .. // . 2005. . 47. 5. . 446459.
[3] .. . , 2005. 510 .
171
,
3034
..
,
. , 121, , , 414040
- . 57,3% 3034 ,
. 3034 , (
) , 42,7%.
: , - .
, ,
[14]. - ,
, [5]. - .
, 2008 .
3034 . .
.
(-) 3034
(1759 ). Microsoft Excel. , ,
,
(-X).
.
. . 3034 6,8% ( 7,3%
, 6,5% 2002 .). - 4,8 0,9 3034 ,
2,9 0,5 , 1,9 0,4 .
, -, (11,3%), (8,6%), (7,3%),
(6,5%), - (4,9%), (4,8%), (4,5%), (4,3%), (4,0%),
(3,7%), (3,5%);
172
.. , 3034
2,9 0,1%.
- 3034 . : (13,8%), (10,3%), (7,4%),
(7,1%), (5,4%), (5,0%), (5,0%),
(4,7%), (4,7%), (3,1%). , - 30
34 : (7,8%), (7,5%),
(7,2%), (6,7%),
(6,3%), (5,7%), (4,9%),
(4,3%), (4,2%), (3,5%).
39,4% , (39,8%), 3034 (38,9%).
, ,
( 42,7%, 13,3%,
, - 11,3%,
6,6%, 5,5%), , - . 2008 . (78,3%). (21,7%)
: (5,3%), (4,3%), (3,9%),
(2,3%), - (1,7%).
- 3034 . ,
(47,3%) , (25,9%), (19,8%), (15,1%), (11,0%). - (14,2%),
(44,6%); , - (12,4%), (5,8%),
(54,1%),
(4,8%).
3034 -, (35,8%). (23,8%), (19,6%), (15,0%), (14,2%).
(13,4%),
(11,7%),
(69,0%) (22,6%), ,
- (9,8%), (6,1%), (34,0%)
173
, , 2010, 4
(31,8%), (5,3%),
(39,4%).
, 57,3% 3034 ,
. 13,2%, - 5,6%; 5,5% , 5,3% ;
4,6%. 3034 , ( ), ,
-, 42,7%, 29,6%
13,1% .
[1]
[2]
[3]
[4]
[5]
.. /
.. , .. // . 2006. 1. . 311.
.. (, , ) / .. . : , 2006. 120 .
..
. - / .. , .. // .
, 1999. . 711.
/ .. , .. //
I . : 2005.
. 3234.
..
: . ... . . . : .
.. , 2004. 16 .
174
.. , ..
. ..
. , . 8, . 2, , , 119992
..
, . ..
. , 13,
, (
) , .
: , , , .
- . , 2025%
712% [1].
60% [5]. 5065% , , , .
0,54,5% [1].
, ,
[2].
: ( )
2% [4]. ,
( , ,
- ),
[3].
, ,
. (), 29
1825 , (. , ... .. )
175
, , 2010, 4
6 ,
, - , .
, ,
, , , , ( ),
, , , .
: I,
(BDI),
(HDRS), , , (), - (LEQ).
13 .
. 1.
(. 1) , , [6],
.
, , . - ( 85% ).
. 1.
176
2. , , , ()
(. 2).
. 2.
3.
(
), 39,4 (
22,4 ), [7],
, , (
LEQ)
[8]. BDI ,
11,5, .
4.
46 , ( , 2 ).
177
, , 2010, 4
V.A. Agarkov
V.B. Shvyrkov Laboratory for psychophysiology research
Institute of Psychology Russian Academy of Sciences
Yaroslavskaja str., 13, Moscow, Russia, 129366
In this study we investigated anamnestic data, personal traits and types of somatic complains of
women with secondary normagonadotropic amenorrhea (functional hypothalamic amenorrhea FHA).
Among the majority of women with FGA we observed symptoms of latent depression. This finding may
help to optimize treatment regimen for patients with FGA.
Key words: secondary normagonadotropic amenorrhea, personal traits, FGA, depression.
178
..
. , 3, , , 394620
,
.
: , , , ,
.
. , . , [1].
.
, .
. 40 - 160,0 10,0 , 4 10 .
( ) . 2 ( ) 250 40,0% .
0,25% 25 /
24 . . 48
. [2]:
(), ();
, , ; .
. ,
( < 0,001) , 28,8% 11,5% . , 10,1% (. 1).
179
, , 2010, 4
. 1.
2,0%, 17,8% (),
17,4%.
: 15,0% ,
23,5% ; 12,7% 16,5%
.
: /
= 133,5.
( ) (-).
,
. 18,3% 2,64 .
66,7% (. 2).
. 2.
180
.. ...
. , :
,
;
, ;
, , .
[1] ..
// . 1999. . 7.
6. . 32.
[2] .., .. . .: , 1996. 282 .
.. , .. ,
..
. , 5, , , 150000
, (),
(),
, , . .
(100 ) , .
: , , , ,
, , .
. 1, 2
( = 0,0028, = 0,0047, p = 0,0071 ). 2 (p = 0,0065),
(p = 0,023), Tk (p = 0,0054) (. 1).
1
(n = 25)
(n = 28)
1 (*)
3,74 (2,004,01)
5,10 (4,966,13)**
2 (*)
4,72 (4,125,80)
7,11 (5,939,61)**
(*)
1,73 (1,661,83)
2,94 (2,684,01)**
2 (. )
10,64 (9,62411,63)
7,36 (7,2918,439)**
Htc (%)
(. .)
Tk (. .)
40,08 (39,1942,11)
0,182 (0,1600,190)
0,801 (0,7600,921)
45,04 (42,5846,75)**
0,335 (0,3200,398)**
1,103 (1,0731,109)**
183
, , 2010, 4
EFFECT OF PENTOXIFYLLINE
ON RHEOLOGY BLOOD IN RHEUMATOID ARTHRITIS
WITH SYSTEMIC MANIFESTATION
N.A. Vinogradova, A.A. Vinogradov,
N.V. Emanuylova
Department of Internal Medicine Propaedeutics
Yaroslavl State Medical Academy
Revolutionary str., 5, Yaroslavl, Russia, 150000
In people with rheumatoid arthritis with systemic manifestations were found significant changes
in hemorheological profile, including increasing the viscosity of whole blood, plasma viscosity, erythrocyte aggregation and deformability. This was combined with reduced transport capacity of blood. A
single infusion of pentoxifylline (100 mg) was accompanied by a positive shift of the rheological characteristics of blood, including red blood cell deformability and aggregation.
Key words: rheumatoid arthritis, blood viscosity, plasma viscosity, deformability, aggregation,
erythrocytes, pentoxifylline.
.. , .. , .. ,
.. , .. , ..
. ..
. , 68, , , 430000
.
: , .
,
() , .
,
, , , [1].
, GINA
(2006, 2007 .) (2008 .).
,
. , , (), ()
, [2].
. ,
.
50 ,
. 25 ,
250500 , 5
1 , 25 ,
( ). , 2- ,
( 1 (1) (). 1 (.. ,
.. , 2002 .).
185
, , 2010, 4
6 , .
6- I
16% , 2- , 32% , 8%
, 20% . II 28% , 44%, 12%,
32% . 6-
.
12- , I 96% , 92%
, 96% , . 12-
.
12- : I
20% 80% , 2030% 20% . II 20% 56% ,
2030% 36% , 30% 8% .
1 .
,
.
186
..
. ..
., 18, . 1, . 124, , , 129337
, , .
: , ,
.
, ,
.
,
, , , . .
, , .
; , ; ,
.
, ;
.
, ; , - , .
187
, , 2010, 4
. , (,
- -
..).
, ,
.
.
,
, .
, ;
. ,
, , ,
. ,
, - , , , , , .
, , , ,
,
. .. . , [1] . .
, ,
.
.
-, 188
.. ...
. ,
,
..
, ,
, . (2 ). , , .
. ,
, , . : , , , ,
.
[2].
.
, . :
;
,
;
, ;
,
,
;
, ,
;
;
-
, , - , , ,
, .
, 189
, , 2010, 4
, .
, ,
,
. , ,
, . (600 .), , .
:
..
. 3, .-, , 197110
, . .
: , .
. (
, ), .
, , . ,
, , .., ..
[1, 2].
, , , . , , .
. .
,
[1, 2].
; , -
191
, , 2010, 4
, ;
.
, , [3, 4, 5].
,
, . , 1982 1995 .
41,5% 14 . 1992 . 18,6 100 000 , 1979
1991 . 32,9%. , 25%
. 2,3
41,4 100 000 .
4% 2% 45 .
8 ; ,
3,5 . 8 [1].
(, , .) ,
-1- .
,
, , ,
. ,
, ,
.
.
:
1. ,
, .
192
.. ...
2. .
3. , , ,
.
4.
.
5. , ,
, .
6.
, , .
193
..
. , 190, , , 603126
..
-
. , 1-72, , , 603022
, .
: , , .
, , . , , , .
, .
,
.
,
- .
, ,
.
, ,
- .
.
,
-, , . , 194
.., .. ...
, .
.
(, ) , .
, , .
- 560 . , , 56 ,
12
(45,6%) .
(78%) . : 2029 ; 30 39 ; 40
49 ; 50 . 3039 .
, , , ,
- .
(, , ,
.) 57,8 2,1 100 , 54,2% - . , , , ,
,
.
73,6 1,9 100 .
.
, . ,
.
195
, , 2010, 4
ON IMPROVEMENT
OF COSMETOLOGY CARE BY PEOPLE
M.S. Guryanov
Department of public health and public health service
Nizhegorodskaya state medical academy
. Rodionova str., 190, Nizhniy Novgorod, Russia, 603126
N.N. Archipova
Clinic Byuti-spa
Okskiy sezd str., 72, Nizhniy Novgorod, Russia, 603022
Sociological survey of patients clinics of aesthetic medicine revealed preferences, and grievances
of patients in obtaining medical cosmetic services that can then be used to improve the cosmetic medical care to the population.
Key words: medical services, cosmetology, quality medical care.
.. , .. , .. ,
.. , ..
. , 89, , , 443099
, .
, , .
: , .
. .
.
. 25 20
, .
-02.
[1]. Statistia 6.0.
.
52,6% , 36,8%, 10,6%.
22%, = 0,007,
67% ( = 0,04) (. 1). , 60%
50% .
1
, ..
Kv, %
A max , ..
m
19,37 0,78
16,75 1,51
6,45 0,78
10,75 1,74, = 0,047
1,28 0,09
1,43 0,09
0,56 0,11
0,76 0,11
m
18,68 1,03
14,45 1,01, = 0,007
6,45 1,03
11,64 1,93, = 0,03
1,32 0,12
1,51 0,09
0,50 0,05
0,91 0,14, = 0,03
: , .
197
, , 2010, 4
. .
(. 1),
, , - , .
. ,
.
,
.. , E.. ,
..
. , 2, , , 614081
()
N-2-(2-)- , ,
.
: , , .
: , , .
: -, [4].
[1].
[5] (N-2-(2-)- ), ,
.
.
: , , , ,
.
: .
: . 0,01 1
3 ; ( , 0,0125 ).
. 0,01 1 ;
( 0,036 ).
: 196201 .
: 0,01 1 96% . 0,002 (100 )
-254.
5 ., 25% (17 : 6 : 5) . , 199
, , 2010, 4
, 15 . -
254 , .
: 0,15 ( ) , , 1 , 10 , 0,15 0,1% 0,1
- .
. 99%.
N-2(2-)- .
42-2-82 [3] 60 .
,
(
).
, 6 . (11,5 .) , . , .
N020(20)0
,
n=3
1
170909
031009
071009
2
+
+
+
H2SO4
.
3
+
+
+
170909
031009
071009
+
+
+
+
+
+
+
+
+
170909
031009
071009
+
+
+
+
+
+
+
+
+
170909
031009
071009
+
+
+
+
+
+
+
+
+
170909
031009
071009
+
+
+
+
+
+
+
+
+
170909
031009
071009
+
+
+
+
+
+
+
+
+
200
4
+
+
+
5
196197
199201
198200
0,5
196197
199201
198200
1
196197
199201
198200
1,5
196197
199201
198200
2
196197
199201
198200
2,5
196197
199201
198200
Rf
Rf .
n=3
n=3
, %
n=3
6
0,74
0,74
0,76
7
0,15
0,14
0,15
8
99,56
99,59
99,89
0,74
0,76
0,75
0,14
0,15
0,14
99,66
99,68
99,91
0,75
0,80
0,77
0,15
0,16
0,15
99,71
99,70
99,92
0,75
0,75
0,76
0,15
0,15
0,15
99,80
99,72
99,93
0,75
0,75
0,76
0,15
0,15
0,15
99,83
99,78
99,94
0,75
0,75
0,76
0,16
0,15
0,15
99,89
99,71
99,96
170909
031009
071009
+
+
+
+
+
+
+
+
+
170909
031009
071009
+
+
+
+
+
+
+
+
+
170909
031009
071009
+
+
+
+
+
+
+
+
+
170909
031009
071009
+
+
+
+
+
+
+
+
+
170909
031009
071009
+
+
+
+
+
+
+
+
+
5
3
196197
199201
198200
3,5
196197
199201
198200
4
196197
199201
198200
4,5
196197
199201
198200
5
196197
199201
198200
0,75
0,75
0,76
0,16
0,15
0,15
99,93
99,89
99,98
0,75
0,75
0,75
0,16
0,16
0,16
99,95
99,94
99,99
0,75
0,75
0,75
0,16
0,16
0,16
99,97
99,96
100,00
0,75
0,74
0,76
0,17
0,16
0,16
99,98
99,99
100,03
0,75
0,74
0,76
0,17
0,16
0,16
100,01
100,02
100,13
, , :
C
10
10
115
t = t +
lg = 60 +
lg
= 19 C.
lg A
lg 2
2030
:
10
10
2030
C
t.. = 20 +
lg
= 20 +
lg
= 29 C.
lg A
3 365
lg 2
3 365
, N-2-(2-)-
5 19 29 .
[1] : 12- . / . . 1. .:
, 2008. . 488492.
[2] . . 42-2-72. ,
, 1972 .
[3] . -42-2-82. .
. 1983 .
[4] .. // . 2000. 2. . 2534.
[5] .. .. ,
// . . 2000. 7. . 472475.
201
, , 2010, 4
..
-
. , 70, , , 660049
..
. . .. -
. , 124, , , 660021
.
3
, , , .
: , , , .
, ,
. , ,
. [1]. ,
, , , ,
, [2].
. - 3
. -
1053 .
, t- , .
. (.). 2006/07 . 203
, , 2010, 4
0
2006/09
2006/07 .
2007/08 .
2008/09 .
47,2%
37,8%
18,8%
< 0,05
24,2%
7,9%
27,3%
< 0,05
10,5%
28,8%
13,6%
< 0,05
3,7%
9,4%
14,5%
< 0,05
6,2%
2,9%
2,5%
< 0,05
1,2%
6,9%
6,8%
< 0,05
3,7%
4,9%
11,1%
< 0,05
2,4%
0,9%
5,1%
< 0,05
2008/09 . - 27,3%,
- 18,8%,
- 14,5%.
3- - , 10,8% 2006 .
6,4%.
2007/08 . - 2,6%. - 28,4% 3-
. 2006/08 . 18,3%, 2008/09 . 15,2%.
3,7%.
,
, .
.
r = 3873.
, , 2006/09 . ,
, .
204
.., ..
L.I. Valentinovich
Chair Managements of public health services of economy of pharmacy and ON
Krasnoyarsk state medical university of prof. F.V. Vojno
Charles Marxs str., 124, Krasnoyarsk, Russia, 660021
The work purpose to estimate disease of students of medical college. In dynamics of 3 years
deterioration of a state of health of students at the expense of a pathology of respiratory system, LOR
bodies, sight, nervous system is observed.
Key words: students, college, disease, a state of health.
IIIII
.. , .. , ..
. ..
. , 8, . 2, ,
IIIII
- IIII . 150300 II 160, .
: , , , , .
, - , .
-- () ,
- . , ,
. , I.
, , , . , ,
I, II.
150 1 ; 300 . 1 . 24 .
.
206
, ,
. , .
()
( ). , , / ,
, ,
,
.
, , .
, AVOID . / , ,
, , .
20- . ,
, II, -
.
(, Promo-Med, ) (, Novartis Pharma, )
,
. .. ( 23 . ),
, , .
122 , 3565 , - IIII ( 94 , 30 /2) II
III . 1 300 160
(58 ), 150 (62 )
160 . 4 .
, .
, 150 160 , 4 17,4 1,7 . .
207
, , 2010, 4
CLINICAL APPLICATION
OF DIRECT RENIN INHIBITOR ALISKIREN
IN COMBINED THERAPY OF PATIENTS WITH ARTERIAL
HYPERTENSION AND METABOLIC SYNDROME
O.V. Dralova, M.L. Maximov, A.S. Ermolaeva
Department of Clinical Pharmacology
I.M. Sechenov MMA
Trubetskaya str., 8, p. 2, Moscow, Russia
The article presents the results of clinical application of direct renin inhibitor aliskiren in combination therapy in patients with arterial hypertension and obesity. The antihypertensive efficacy of aliskiren in
combination with valsartan was demonstrated as dose-dependent, and was well tolerated and high safety of
this combination therapy.
Key words: aliskiren, arterial hypertension, valsartan, combination antihypertensive therapy,
metabolic syndrome.
.. , ..
2
- , 40, , , 656038
.
24,2% , .
: , , , .
.
[1, 2].
- .
. .. (1988) - . 156 -
1218 , 15 0,5 .
67 , ( I), 89 ( II). :
() 8 ; () 31; I 34;
II 14; III 9; 60 .
30.12.2003 . 621
. () , .
-10.
BioStat V.4.03 1998.
2- .
.
. ()
61,2% , , 52,8%
(2 = 0,158, = 0,691).
(. 1).
209
, , 2010, 4
1
( %)
,
I (n = 67)
61,2
12,4
4
16,4
6
,
II (n = 89)
52,8
0*
18*
27
2,2
: 4
, , , 2
, ( = 3,000,
= 0,083).
,
, , 24,2%
, 57,6% (II ),
18,2% -.
. 2,
: - 53%;
18,2%; - 24,2%;
7,5%. : 15,1% , , ; 7,8% .
2
(%)
10
( 40)
( 41)
( 43)
(H00H59)
(I 51.8)
(I 42)
(G 24)
(N 15.9)
, , (J 20 J 39)
(I 35.0)
(I 31.2)
(I 34.8)
(K 29.9)
(S00T07)
I (n = 67)
29,4
5,9
0
5,9
41,2
0
17,6
0
29,4
0
0
0
0
58,8
II (n = 89)
32,9
6,1
20,4*
22,4*
12,2*
6,1*
12,2
10,2*
6,1*
14,2*
4,1
2
7,8
2*
.., .. ...
< 0,006). , , , .
. -,
, , 24,2%; 57,6%, 18,2%,
.
.
, , .
[1] ..
// - . . .. /
.. . XV. 4, 2008. .: . , 2008. . 6566.
[2] .. . . .: , 2004. 168 .
..
60
. , 1, , , 111123
..
-
,
() .
92 ( 19 28 ), 22,3 1,9 .
67 ( ) 25 . () 4 : 1- 25 ; 2- 24
; 3- 22 ; 4- 21 . , - , , . IQ . , .. .
, , , 114 8,1; 103 23,1; 113 15,2.
. .
: , , , .
. ( IQ) 1015 ,
,
[1, 2, 3].
,
(), .
, ( 4) [4,
5]. , ,
212
.., .. ...
, , 2010, 4
. IQ :
1 ; 2 ;
3 ; 4
IQ (70%),
IQ 20% 10% .
IQ 54,2%,
45%.
IQ (63,6%) IQ
(36,4%). IQ (71,4%) IQ (28,6%) (. 1).
1
IQ
IQ
120
10% (n = 2)
110119
70% (n = 18)
45,8% (n = 11)
36,4% (n = 8)
28,6% (n = 6)
90109
20% (n = 5)
25% (n = 6)
40,9% (n = 9)
28,6% (n = 6)
29,2% (n = 7)
22,7% (n = 5)
42,8% (n = 9)
8089
214
.., .. ...
, , , , -
, , ,
(. 2).
2
14,8 1,7
12,2 1,2
13,4 1,6
31,2 2,2
28,6 3,3
24,6 2,3
12,5 1,6
29,1 2,5*
25,06 3,8*
24,0 2,0
28,3 2,6*
24,0 3,0*
22,0 3,7*
27,8 2,6*
23,9 3,8*
21,1 4,3*
10
11
: 4 , 5 , 8 , 9 , 10
, 11 . * (p < 0,05).
. , ,
, .
.
215
, , 2010, 4
J.Kh. Talipova
West-Kazakstan state medical university
Lenina str., 75, Actobe, Kazakstan, 030020
The authors investigated influence of autoimmune thyreoiditis (AIT) in the phase of euthyreosis and
subclinic hypothyreosis on the level of the intellectual development. There were examined 92 persons
(mean age 22,3 years old). Among them there were 67 pts with AIT (basic group) and 25 healthy people. Intellectual level in AIT was examined in 4 groups. The 1st group of 25 pts is controlled; the 2nd of
24 pts with euthyreosic AIT; the 3rd of 22 pts with subclinic hypothyreosis; the 4th of 21 pts with
manifestal hypothyreosis. There were used clinic, ultrasonic investigations, determing free thyroxin fraction, TTG. The evaluation of mental development with calculating intellectual index IQ was investigated
by means testing of D. Veksler method, adapting by A. Yu. Panasyuk. Data received revealed, that average total, verbal and nonverbal parameters in control group were 114 8,1; 103 23,1; 113 15,2 respectively. AIT development was accompanied by the decrease of intellectual level by data of the same tests.
There were revealed lower levels of memory volume in AIT, than in control group. Conclusion: AIT was
accompanied by decreasing intellect and memory in all investigated groups.
Key words: autoimmune thyreoiditis, clinic hypothyreosis, intellect, memory.
.. , .. , ..
. , 2, , , 614990
() . .
.
: , , .
(), [1].
.
.
, , [2].
(LD50, , )
.
20042009 .
,
(40,74%). .
, 55,6% , 44,4% (. 1).
54% ().
. 1. 20042009 .
.
217
, , 2010, 4
(. 2)
()
(66%), (19%)
(15%).
. 2. ,
() , - -
[3, 4]
, 358 LD50, , .
, 230
, 0,43% , 10,0%
, 10,87% 78,70% .
( ).
:
, , , .
, .
( , , ).
( ).
.
218
. .
..
. , 27, , , 211440
.. , .. ,
.. , ..
. , 3, .-, , 197110
..
. . , 50, , 308000
.
: , , .
,
. ,
, [1, 2].
.
. 114 ,
. 1- (56 .) -,
, 2-
(58 .) . 64,8 3,4 .
.
.
12% , 27%, > 0,05. , .
, , > 0,05
(. 1).
220
.
1
()
1,5 0,6
3,4 0,7
< 0,05
1,2 0,5
3,2 0,4
< 0,05
1,4 0,3
3,5 0,5
< 0,05
. , 99,4 0,4%
, 23,2 2,3%, 17,2 2,1%.
. : 98,2 0,4% ; 22,3 2,1%,
24,2 2,1% .
: 98,6 0,2% ,
21,4 2,1% ; 18,3 1,7%. , > 0,05.
. , , .. 21,5 2,1%
, 16,5 1,5% , 24,1 1,7% .
,
.
15,3 2,5%, 11,3 1,7% 13,1 2,5%
.
3,1 1,0% , 10,6 15,7% 9,5 1,3% . 11,9 1,6% ,
11,3 1,4% 9,7 1,4% .
29,1 2,4% , 34,5 2,3%,
34,3 2,2%.
.
.
221
, , 2010, 4
N.. Kunitsyna
Medical Centre Pokolenije
Khmelnitskogo av., 50, Belgorod, 308000
The problems of non-drug treatment and rehabilitation in elder patient with depression and diabetes mellitus are presented in this article.
Key words: diabetes mellitus, elders, depression.
,
..
. , 1, , , 400131
, , .
,
.
: , , , .
() 90 100%
. ()
6 3 .
. , 78 .
[2, 3].
.
. 104
2 12 , ()
50 () 54 .
, , .. , .. [1].
. .
.
. , , , 54,0 7,1% 55,6 6,8%
,
(, ) ( > 0,1). 52,0 7,1%
51,9 6,9% ( > 0,1)
.
(38,0 0,9% 51,9 6,9%; > 0,1).
(60,0 7,0% 53,7
6,8% ; > 0,1). 6 (22,0 5,9% 9,3 4,0%; > 0,05).
223
, , 2010, 4
n = 50
n = 54
p1 m%
32,0 6,7
16
30
p2 m%
55,6 6,8
10,0 4,3
17
31,5 6,4
18
36,0 6,9
32
59,3 6,7
18
36,0 6,9
22
40,7 6,7
4,0 2,8
15
30,0 6,5
16,7 5,1
7,4 3,6
()
: P12 c .
.. ,
, . ,
- ,
, (10,1 0,3 10,9 0,3; > 0,05).
, , ,
, . , , .
()
..
,
. , 310, , 355000
. . (1905 .) 400 . , .
XIX .,
.
. . ,
. .. ., ,
, , . , . ,
.
,
4 1 .
: , ,
.
, .
. . , 1905
- , . ,
. : , 37 , 7
10 . -
, .
.
.
1. , .
2. 4 .
226
.. ()...
3. .
4. .
. I, II, III, V, VI, VII, VIII,
IX . , , 80 120 .
1. ,
.
2. : .
: 20 1999
. :
1. 20
.
2. 20 , , .. .
3. .
10
. 3
. , 4 .
20 2003 . 34
. 1,5
..
.. , .
. ,
,
.
() ,
.
. , , 3 , , 20 . ,
, (, ).
227
, , 2010, 4
[3] .. . // . 1996. 2.
. 2932.
[4] .. // .
1993. 5. . 2125.
..
. , 89, , , 443099
..
. , 12, , , , 443041
118 () 45 88 . 63,6% . (94,9%), (49,2%) (40,7%). 25%
44,3% (p = 0,025). . 75 75,8% , 63,6%
. : . , ,
, .
: , ,
.
, , 2010, 4
SPSS 11.
. , 36,4% .
,
(. 1).
1
(%)
(n = 66)
(n = 118)
84,8
94,9
0,020
()
89,4
94,9
19,7
49,2
< 0,001
1,5
40,7
< 0,001
28,8
44,1
0,042
71,2
54,2
0,024
71,2
92,4
< 0,001
86,4
87,3
77,3
83,9
10
42,4
54,2
11
36,4
48,3
: / .
, , (89,4%),
(84,8%) , (86,4%).
(71,2%) (71,2%). (42,4%) .
(94,9%; = 0,02), , ,
(94,9%; 89,4%).
(92,4%; < 0,001).
(49,2%, 19,7%; < 0,001)
40,7% (
1,5%; < 0,001). .
230
.., .. ...
(54,2%) (48,3%).
(. 2).
(r = +0,209; p = 0,023),
(r = +0,197; p = 0,033). ,
, -
.
2
(n = 66)
(n = 118)
%
58
87,9
105
89,0
4,5
44
37,3
< 0,001
6,1
42
35,6
< 0,001
48
72,7
97
82,2
1,71 0,10
2,44 0,11
< 0,001
,
(n = 37)
,
6074
(n = 48)
,
75
(n = 33)
23
62,2
27
56,2
25
75,8
13
35,1
26
54,2
19
57,6
11
29,7
21
43,8
20
60,6*
29
78,4
42
87,5
32
97,0*
12
32,4
24
50,0
21
63,6*
. : * p < 0,05.
231
, , 2010, 4
35,1%
60 54,2% (p = 0,083) 57,6% (p = 0,062).
.
.
75 , 60
(p = 0,01). ,
(97,0%)
(78,4%; p = 0,021). ,
(p = 0,01).
. (r = 0,227; p = 0,014).
(16,7%) (39,4%).
1.
, , , ,
, . .
2.
75 . .
3.
.
232
.., .. ...
O.V. Krasnoslobodskaya
Railway Road Clinical Hospital, Samara
Agibalova str., 12, Samara, Russia, 443041
We studied treatment adherence in 118 patients with atrial fibrillation (AF) who were between the
ages of 45 and 88 years. 63.6% of patients with arrhythmia to take a medicine irregularly. Patients consider as the reasons of an irregular drug intake a large quantity of tablets (94,9%), side effects (49,2%)
the bad control of arrhythmia and pulse increase (40,7%). Only 25% of men and 44,3% of women (p =
0,025) had strict adherence. The patients who know about complications of disease to take medicines
more regularly. 75,8% of patients are more 75 years irregularly accepted medicines, 63,6% from them
considered harmful constant reception of medicines. Conclusions: Patients with atrial fibrillation have
low treatment compliance. The factors improving compliance are the personal motivation of patients,
good informing about diseases and their complications.
Key word: atrial fibrillation, treatment compliance, therapeutic training.
0
..
. -, 41, , 173003
, , 235
, .
.
: , .
,
- () (, ), , ,
[68].
, , , [15]. , .
, , .
.
, ,
235 .
(, )
( ) . , ( 40)
: ( , ), 234
.. ...
, ; : / 1,0, , ,
, () , ,
, (
0,560,48).
, , . Child-Turcotte
(1964) .
(710 ), (1115 ) ( 15 ) .
, 0,70.
( 0,64)
( 0,56).
, 0,80. , , 80%
.
,
. , ,
.
, - , ,
. , , ()
.
,
.
7080%
.
.
235
, , 2010, 4
(HELIANTHUS TUBEROSUS L.)
NNP K
.. , .. ,
.. , ..
. , 2, . 4, . 22, , 357532
NNP K.
NNP K : = 4,5,
1 : 10, 48 60 .
: , , ,
NNP K.
(), .
,
, , , , [3].
12 NNP K [2].
().
[1], - ( ).
NNP K ,
FAO/WHO (JECFA)
(FCC) , .
NNP K , , : = 5,0,
1 : 15, 15 , 50 .
NNP K
, .
237
, , 2010, 4
. , ..
. , , , .
NNP = 4,25,3,
. :
4,2; 4,5; 4,8; 5,0; 5,3.
: 1 : 15,
15 , 50 .
. 1.
1
, %
4,2
5,72
4,5
5,83
4,8
4,79
5,0
3,51
5,3
3,28
. 5,83% = 4,5.
- , 1 : 30,
. . 2.
2
NNP
, %
1 : 30
3,34
1 : 15
3,51
1 : 10
4,50
1:6
4,80
1 : 6, NNP K
, . 1 : 10.
.
3, 6, 9, 12, 15, 18, 21, 24, 27 .
. 3.
238
.. . ...
3
, .
, %
2,57
3,32
3,36
12
3,47
15
3,51
18
3,65
21
4,69
24
5,32
27
5,36
24 .
27 .
NNP K, 4065 .
. 4.
4
, %
45
3,26
50
3,51
55
5,20
60
5,37
65
5,40
65 NNP K. . 60 65 , 60 .
, NNP K :
= 4,5, 1 : 10,
24 60 .
239
, , 2010, 4
[3] Panouill M., Thibault J.F., Bonnin E. Cellulase and protease preparations can extract
pectins from various plant byproducts // J. Agric. Food. Chem. 2006. 54 (23).
. 89268935.
..
, ,
. , 287, , , 454021
() ( 35 . .) . :
.
: , , .
, ,
, , , , .. [2].
:
.
.
(n = 11 904).
(n = 332 , 90 , 92 , 100 50 )
( ). : ,
,
(1, ) . , 20,7 1,13 .
12 (v = 25 /), 3 241
, , 2010, 4
.
Cardiofax.
()
, . I (2000 .) (2004 .), 140/90 . .
(3-1, 3-3). .
(2) , 2
, LT. .
. I SPSS 11,0, STATISTICA 0,6.
(), (SD). ,
. () 0,05.
. 36 (10,8%) . (15,6%) (20,7%).
. 3 (6,0%)
(. 1).
1
(+)
()
n = 332
.
36
296
332
%
10,8
89,2
100
n = 190
, n = 100
, n = 92
.
%
.
%
0
0
19
20,7
100
100
73
79,3
100
30,1
92
27,7
n = 90
.
14
76
90
%
15,6
84,4
27,1
, n = 50
.
3
47
50
%
6,0
94,0
15,1
, , , ( < 0,05).
.
242
.. ...
. , ,
[1].
.
,
, ,
.
- , - ,
, , . , (2)
27,77 . ., , 34,67 . . () ( 5-
) 2 ( < 0,05)
(. 2).
2
2
2 ( . .)
2 ( . .)
2 5 . (. ..)
, n = 190
, n = 100
, n = 92
29,54 0,12
31,74 0,28*
, n = 90
37,27 0,78
, n = 50
39,12 0,78
27,60 0,38
27,77 0,45*
34,67 0,88
37,08 0,99
29,61 0,36
28,00 0,37*
34,46 0,37
37,29 0,63
: * .
.
, (10,0%), (6,0%). ,
,
.
. 1. ,
, 10,8%.
, 243
, , 2010, 4
.. , .. ,
..
-277, . , 48, , 614990
( ).
103 18 .
: , , , .
- .
. [2]. [4]
. , [3].
( ), Staphylococcus aureus, Streptococcus spp., Proteus
spp., Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli. [1] 103104.
24
, . , : ,
, (, ); . .
18 ( ) 48 ,
103 (. 1).
245
, , 2010, 4
1
,
.
0
3,75
10
3,75
10
6,5
10
9,5
12
3,5
3,5
10
10
3,75
15
10
18
10
3,5
, %
3,75
10
3.75
10
3,5
10
3,75
10
3,75
10
3,5
10
3,75
10
10
3,75
10
10
3,75
10
10
10
3,75
10
10
10
10
10
10
10
10
3,75
10
3,5
10
3,5
10
3,75
10
3,75
10
3,75
10
3,5
10
3,75
10
3,75
10
3,5
10
3,75
10
10
3,5
10
3,5
10
246
..
. , 102-59, , , 150054
.. , .. ,
.. , ..
. , 5, , , 150000
.. , .. ,
..
. , 5, , , 150000
. , .
: , , .
,
(). , c [1, 2]. , .
()
[3].
,
, .
: 20 , II III J.H. Kellgren J.S. Lawrense (1957) [5]. 56 (5263) 8 (512) .
2 : 1) + ( 12 ) 11 (55%); 2) + ( 12 ) 9 (45%).
: -
247
, , 2010, 4
1
3
WOMAC
WOMAC 1
WOMAC 3
+ (n = 9)
65 (6070)
30 (2045)*
60 (5065)*
64 (6375)
50 (4252)*
66 (5972)
+ (n = 11)
78 (7080)
57 (5060)*
72 (7076)
75 (6679)
64 (6165)*
77 (7281)
: * < 0,05
Statistica 8.0
(StatSoft, USA). () (Q25Q75). p < 0,05.
: ,
20% ( < 0,05),
WOMAC 12,9% ( < 0,05).
, 1 + + WOMAC 53,8% ( < 0,05) 21,8% ( < 0,05);
27% ( < 0,01) 14,8% ( < 0,05) .
3 +
(7,7%, < 0,05) ,
WOMAC ( > 0,05).
( > 0,05).
WOMAC
.
, 1
, . .
. ,
. ,
, ,
.
248
.. . ...
-, , .
1. WOMAC .
2.
.
[1]
[2]
[3]
[4]
Hinman R.S., Hunt M.A., Creaby M.W. et al. Hip muscle weakness in individuals with medial knee osteoarthritis // Arthritis Care Res (Hoboken). 2010. V. 62. 8.
P. 11901193.
Amin S., Baker K., Niu J.et al. Quadriceps strength and the risk of cartilage loss and symptom progression in knee osteoarthritis // Arthritis Rheum. 2009. V. 60. 1.
P. 189198.
Jawad A.S., Irving K. Drug treatment modalities in patients with chronic osteoarthritis of the
hip or knee // Saudi. Med. J. 2007. V. 28. 3. P. 375378.
.., .., .. . // - . 2001. 3. . 58.
249
.. , .. ,
..
. -, 8, , , 117198
. , , ,
3 , ,
, 4 (p < 0,05).
, , , , 3 4,
(p < 0,05).
: , , .
, , () ,
.
[1, 2, 5
.]. , , ,
, .
,
.
.
. 345
2030 ( 195 150 ) ( () 69 () 1922 ) () . , (. . )
.
-. [3].
: (, ),
(, ) ()
( = /, /2).
250
, , 2010, 4
1
(M m)
( )
n = 51
n = 48
n = 47
n = 49
2,16 0,12
2,38 0,11*
2,21 0,13
2,08 0,09
2,41 0,11
2,65 0,13*
2,52 0,11
2,39 0,09
112,6 2,5
99,3 2,3
103,5 2,8
115,4 3,4*
93,4 3,3
91,4 2,6
95,4 1,8
101,2 2,8*
2,57 0,08*
2,36 0,09
2,23 0,07
2,45 0,08
1,81 0,06*
1,63 0,05
1,59 0,06
1,74 0,05
7,86 0,28*
6,93 0,18
5,23 0,21
6,31 0,19
11,6 0,31*
10,4 0,28
8,36 0,26
9,45 0,29
11,4 0,5
12,1 0,4
12,9 0,6*
11,8 0,5
13,5 0,4
14,8 0,6
15,5 0,8*
14,2 0,6
7,65 0,34*
6,32 0,29
5,69 0,23
6,93 0,31
8,78 0,41*
6,92 0,31
6,18 0,27
8,53 0,29
2,06 0,05*
1,79 0,06
1,55 0,04
1,97 0,05
2,65 0,07*
2,14 0,05
1,83 0,06
2,39 0,08
347 15
308 16
296 18
375 22*
319 13
286 8
277 11
328 15*
( )
n = 39
n = 38
n = 36
n = 37
2,48 0,11
2,65 0,12*
2,55 0,09
2,35 0,11
2,86 0,12
3,07 0,13*
2,95 0,11
2,65 0,10
101,5 2,7
94,5 2,1
96,3 3,1
108,1 2,6*
88,7 2,1
83,6 1,9
86,1 1,7
93,5 2,2*
2,32 0,06*
2,11 0,05
2,03 0,04
2,24 0,05
1,63 0,05*
1,41 0,04
1,37 0,05
1,55 0,06
9,79 0,33*
7,59 0,22
6,45 0,19
8,85 0,25
12,3 0,29*
10,9 0,19
9,87 0,21
11,3 0,23
9,32 0,8
10,6 0,6
11,8 0,7*
9,93 0,4
11,1 0,7
12,9 0,8
13,7 0,6*
12,2 0,5
10,8 0,4*
8,13 0,33
6,31 0,19
9,33 0,26
12,3 0,4*
10,4 0,29
8,11 0,28
11,1 0,32
2,28 0,06*
1,88 0,05
1,69 0,04
2,02 0,05
2,97 0,07*
2,31 0,06
1,83 0,05
2,53 0,07
402 23
385 27
356 19
417 31*
384 19
359 22
323 18
396 27*
, /
4 , /
3 , /
, /
, /
, /
, /
, /
, /
4 , /
3 , /
, /
, /
, /
, /
, /
: : * < 0,05.
1822
.. , .. ,
..
. -, 8, , , 117198
, -1 .
.
: , .
, , .
.
, , ,
,
, [1]
.
,
.
, .
- , , , . ,
, , . 254
, ,
, , .
- - -1
,
, .
. 14 ,
1822 ,
10 2 . 6
8 .
, , , . , ,
, .
, . (HI-s) = 2,35 0,04
; PMA = 65,2 3,2%; SBI = 45,3 0,13%. .
, ,
. ,
-1 .
-1 : , , B1, ,
, . -1
1,5 ,
. . , , , , , , ,
, , , ,
. : , , , , . ,
, ,
[3].
255
, , 2010, 4
: 2
23 , ,
-1 , .
1
. ( ) 34 .
. (
, , ) 2- . 56
, ,
, : OHI-s = 1,2 0,05 ; PMA = 12,8, 2,30,%; SBI = 25
0,11%. 14 : OHI-s = 0,6 0,1 ; PMA = 1,0 0,3,%; SBI = 6,2 0,13.
, ,
, ,
.
.
3 . ,
. 6
: ,
. OHI-s = 1,6 0,1 ;
PMA = 20,0 0,3,%; SBI = 36,5 0,13,
.
.
6 .
. , -1
,
.
, ( ).
- .
256
[1] .. -
,
: . ... ... .; ., 2000. . 338.
[2] . : . . ... ... .,
2005. 135 .
[3] ..
. ., 2005. . 1640.
.. , .. , .. ,
.. , ..
. , 89, , , 443099
.
, (II) (40%).
: , , , .
, .
[1].
.
. 92 ,
(187 ). Sysmex KX-21 (Roche),
STA-Compact (Roche). .
SPSS 12.0.
. 50 (27%). 65% , 16% , 19%
, . 28,9 0,7, 33,9 1,6 ( = 0,029),
, .
78,3% .
(II) (40%),
0(I) (40%). (IV)
. 0(I) - . (II) .
(III) , . (II)
,
(. 1).
50% ( = 0,011), , 12% ( = 0,024), , 28% ( = 0,003), , , 15% ( = 0,022), 258
.. .
15
610
0(I) 16100%
(II) 18100%
(III)16100%
(IV) 0
0(I)9100%
(II)9100%
(III)5100%
(IV)0
90 /,
7089 /
70 /
63,0
72,0
94,0
0
33,0
33,0
60,0
0
6,0
11,0
0
0
67,0
44,0
40,0
0
31,0
17,0
6,0
0
0
22,0
0
0
,
, , III, ,
, .
. ; (II) ; 30 , , III,
.
259
0 ()
.. , .. ,
.. , ..
. , 281, , , 426034
285 -
. 100 , 140 , 50 .
, , (),
, .
.
, .
: , - , , .
, -
, . , , ,
- , [1, 2, 3, 4].
.
290 : , , .
100 (I ) , 140 (II ) , 50 (III ) . ,
- () , , .
, ,
, Shimasonik SDL-310.
ELECSYS-1010, ,
(, , ). 55,0690,0 /, 8,357,8 /.
SYSMEX -1000. 260
.. . ...
, , 2010, 4
[1] .. -
: . ... - . . , 1970. . 2528.
[2] .. - // . , 2003. . 2832.
[3] .. // , - .
, 2006. . 1518.
[4] .. // . 2007. 5. . 1415.
262
.. . ...
340.67:543:615.214.24
/
.. , ..
. , 2, , , 614081
..
-
. , 12, , , 614002
-. .
: , , -.
.., .., .. /
, , 2010, 4
9.65
7.31
20000
18000
16000
14000
12000
10000
8000
6000
4000
2000
0
7.50
8.00
8.50
9.00
9.50
10.00
10.50
Time-->
Abundance
Ion 234.00 (233.70 to 234.70): 00778.D
7.31
24000
22000
20000
18000
16000
14000
12000
10000
8000
6000
4000
2000
0
7.50
8.00
8.50
9.00
9.50
10.00
10.50
Time-->
. 1. ,
9,65 . 7,31 .
ChemStation G1701DA.
(. 2).
266
.., .., .. /
Response
Ratio
70
60
50
40
30
20
10
0
0
0,5
1,5
2,5
Amount Ratio
Curve Fit: Linear
. 2.
0,12,5 /. r2 0,996.
Q 1000
Cx =
,
a 1000 1000
x , /; Q ,
, ; , , .
,
,
.
., 47 , 2010 . .
- .
, - (. ). , - . , ,
0,22 /. , .
2,55 /.
267
, , 2010, 4
[5]
[6]
[7]
Wyss P.A., Radovanovic D., Meier-Abt P.J. Acute overdose of Zolpidem // Schweiz. Med.
Wochenschr. 1996. V. 126. 18. P. 750756.
Lichtenwalner M., Tully R. A fatality involving zolpidem // J. Anal. Toxicol. 1997.
V. 21. 7. P. 567569.
Levine B., Wu S.C., Smialek J.E. Zolpidem distribution in postmortem cases // J. Forensic
Sci. 1999. V. 44. 2. P. 369371.
de Castro A., Quintela O., Concheiro M. Determinacion de zolpidem plasma por cromatografia Liquida de alta resolucion y deteccion de fluorescencia // Rev. Toxicol. 2003.
V. 20. . 146.
Olubodun J.O., Ochs H.R., von Moltke L.L. et al. Pharmacokinenic propeties of Zolpidem in
elderly and young adult: possible modulation by testosterone in men // J. Clin. Pharmacol.
2003. V. 56. P. 297304.
Gaillard Y., Gay-Montchamp J.P., Ollagnier M. Simultaneous screening and quantitation of
alpidem, zolpidem, buspirone and benzodiazepines by dual-channel gas chromatography using electron-capture and nitrogen-phosporus detection after solid-phase extraction // J. Chromatogr. 1993. V. 622. P. 197208.
, , ; /
. D.R.A. Uges, University Hospital Groningen, The Netherlands. 1996. . 26.
1. 16 .
S.S. Kataev
Department of forensic chemistry
Perm Kray Bureau of Forensic Medicine
Fontannaya str., 12, Perm, Russia, 614002
The solid-phase extraction (SPE) and gas chromatography mass-spectrometry (GC/MS) methods have developed for the quantitative determination of zolpidem in whole blood specimens. The procedure has successfully applied in case of non-mortal poisoning.
Key words: zolpidem, solid-phase extraction, gas chromatography mass-spectrometry.
268
340.67:543:615.214.24
.. , ..
. , 2, , , 614081
..
-
-
. , 12, , , 614002
- .
: , , .
- - ,
, .
- , ,
.
(10 ).
. , [1], , [2].
.
,
(0,21,3% ) [3]
( 3,8 ).
- (/) .
/ [4]. (), .
269
, , 2010, 4
. , .
() 12 (Supelico);
Agilent 6850, -5MS
30 0,25 0,25 ;
- Agilent 5973N (Agilent, ); -4030,
-2 ( , ); -, 440, 40200, 200
1000 15 ; AccuBond II EVIDEX 200 /3 (Agilent);
( Sanofi Aventis, ).
..
. .
10,5 10
( 1). 6, 12
24 ( 2). 20 , . 2 20 ( 0,1 /), 1 0,1 4,6 .
. 2 95% 2
0,1 (pH 4,6). 1,0 /. 1 0,1 (pH 4,6); 1 0,1 1 10% . -- (1 : 3) 2 ( I);
-225%
(4 : 1 : 0,1) 2 ( II). II 60 .
/, -
(SIM) m/z,
235, 307, 219
188, 215, 246. , 0,1; 0,5; 2,0; 5,0; 10,0 /
( ). (LOD) 10 /.
(LOQ) 25 /.
. . 1 2. 1 2 .
1
( 1)
1
2
3
X
S, %
270
, /
0,29
0,25
0,24
0,26 0,03
10,18
, /
0,05
0,04
0,04
0,04
0,04
0,03
12
24
S, %
X
0,045 0,007
15,71
0,04 0
0,035 0,007
20,20
Abundance
TIC: 02929.D
7.58
260000
240000
220000
200000
180000
160000
140000
120000
100000
9.62
80000
60000
40000
20000
7.00
7.50
8.00
8.50
9.00
9.50
10.00
Time-->
. 1. . 2,0
6 10
Abundance
Ion
Ion
Ion
Ion
Ion
Ion
7.57
180000
170000
235.00
219.00
219.00
188.00
215.00
246.00
(234.70
(218.70
(218.70
(187.70
(214.70
(245.70
to
to
to
to
to
to
235.70):
219.70):
219.70):
188.70):
215.70):
246.70):
02929.D
02929.D
02929.D
02929.D
02929.D
02929.D
160000
150000
140000
130000
120000
110000
100000
90000
80000
70000
9.62
60000
50000
40000
7.58
30000
20000
10000
7.45
9.62
0
7.60
7.80
8.00
8.20
8.40
8.60
8.80
9.00
9.20
9.40
9.60
Time-->
. 2. ,
(. 1 2),
1 , 6,5 , 2, 12
271
, , 2010, 4
. , - , ,
. [5], , ,
, P450.
, ,
. ,
, 10
(LOQ),
.
[1]
[2]
[3]
[4]
[5]
Levine B., Wu S.C., Smialek J.E. Zolpidem distribution in postmortem cases // J. Forensic
Sci. 1999. Vol. 44. 2. P. 369371.
Logan B.K., Couper P.D., Couper F.J. Zolpidem and driving impairment // J. Forensic Scince.
2001. Vol. 46. 1. P. 105110.
Hempel G., Blaschke G. Direct determination of zolpidem and its main metabolites in urine
using capillary electrophoresis with laser-induced fluorescence detection // Journal of Chromatography B. 1996. Vol. 675. P. 131137.
.., ..
- // . 2009. 5.
. 165167.
Olubodun J.O., Ochs H.R., von Moltke L.L. et al. Pharmacokinenic propeties of Zolpidem in
elderly and young adult: possible modulation by testosterone in men // J. Clin. Pharmacol.
2003. Vol. 56. P. 297304.
INVESTIGATION OF ZOLPIDEM
IN REAL URINE SAMPLES AT THERAPEUTIC DOSES LEVEL
Y.A. Khomov, .. Krylova
Department of Pharmaceutical Chemistry FDPO PSPA
Pharmaceutical academy
Polevaya str., 2, Perm, Russia, 614081
S.S. Kataev
Department of foresic chemistry
Perm Kray Bureau of Forensic Medicine
Fontannaya str., 12, Perm, Russia, 614002
The results of determination of zolpidem in urine by solid-phase extraction (SPE) and gas chromatography mass spectrometry (GC/MS) after single therapeutic doses are presented.
Key words: zolpidem, solid-phase extraction, gas chromatography mass spectrometry, single
therapeutic dose.
272
.. , .. , .. ,
.. .. , ..
. , 1, , 400131
, ,
.
: , ,
.
, (IQ)
. , ,
IQ [1].
. [2, 3, 4], IQ
33%. (EQ) ,
66% [5]. ,
IQ .
(EQ).
: (EQ =
= 169 ), (EQ = 121168 ), (EQ = 81120
), (EQ = 4280 ) (EQ = 41 ).
(IQ). : (IQ = 131 ), (IQ = 116130 ), (IQ =
= 85115 ), (IQ = 8470 ) (IQ = 69
). , [6].
510 17 34 .
363 (71,2%) 147 (28,8%) .
(59,6%) EQ, EQ (40,4%). 45,5% -
273
, , 2010, 4
274
.. .
[1] .. ( ) //
. 2003. 34 (318).
[2] . . , IQ.
Bloomsbury, 1996.
[3] . : / . , . , . ; . . .: , 2005. 301 .
[4] Boyatzis R.E., Goleman D., Rhee K. Clustering competence in emotional intelligence: Insights from the Emotional Competence Inventory // R. Bar-On, J. D.A. Parker (eds.). Handbook of emotional intelligence. San Francisco: Jossey-Bass, 2000. P. 343362.
[5] ., . EQ: . 2007.
[6] .-., ., ., . // Psychologies. 2007. 18 (). . 2433.
.. , ..
. , 1, , , 400131
..
. , 28, , , 400131
..
. , 28, , , 400131
. , .
: , , .
( ) 75% .
, ,
- .
[4].
, , .
- -
(
, ). , -
. , .
,
,
121810, .
276
.. . ...
. ( , ) 121810,
, () [3, 5]. , [5, 7],
. (HV)
( ) -3 200 = 1,96
.
20 ,
. , n = 120. , , [7]
( ), ,
HV.
.
: ( ); (TiN);
(ZrN).
-6 . - () ( ) 500550 ( 10 000 ) 1012 .
2 105 . .
56 .
.
. 1.
( ,
0,3%) ,
, .
( 45%) .
, , - , ( ,
) , ,
. , - , , , .
277
, , 2010, 4
1
()
HV
()
3 947
(%)
2 697
32
2 165
45
()
89,5
118
48,5
(%)
0,2
0,3
0,2
, [2],
. . 1 2
, . , ( ) (
), , ,
( ) . , ,
,
, .. .
. 1. ( )
[2]
(
) , .
278
.. . ...
. 2. ( )
() ()
,
. (, ). , -,
. , ,
,
, .
.
121810 [8].
, .
, (). , ,
[2],
, , .
, , ,
.
279
, , 2010, 4
. 3 .
( = 500600 ) ( 50%).
- , ( )
13001400 . ( ) 35%.
. 3.
121810 [9]
, , () ,
(HV 3950 ; . . 1) , . 4. .
, , , .
( ) , 1000 .
(r, Fe)23C6
. 10501100
. , (50%); (550 ). , ..
,
.
280
.. . ...
. 4.
(500)
. 5.
ZrN ( 500)
, 121810
. , 500 800 .
.
.
TiN ZrN ( -6) , , 500550 .
, (. 5).
. . . , , ,
.
. ,
,
. , , , .
[1] , .. : //
. 1999. . 2831.
[2] , . . // . 2002. 1 (29). . 364369.
281
, , 2010, 4
A.S. Stolyarchuk
Strength of materials chair
Volgograd state engineering university
Lenin avenue, 28, Volgograd, Russia, 400131
A.F. Trudov
Materials technologys chair
Volgograd state engineering university
Lenin avenue, 28, Volgograd, Russia, 400131
The durability comparative analysis of samples after different technologies of bent wire denture
clasp treatment proved statistically significant declination of its density characteristics after titanium
and zirconium nitride plasma spraying on its surface.
This declination is accompanied by experimentally found change in microhardness density distribution after plasma spraying (especially after zirconium nitride plasma spraying). The density declination in comparison with its initial state is one of the main reasons of bent premature denture clasp destruction in human mouth cavity exploitation.
Key words: bent denture clasp, removable, laminar denture, microhardness.
282
.. , ..
. , 281, , , 426034
..
,
.
. , 8, , , 119992
..
, 3
. , 52, , , 426000
923 . 70 (7,58%
0,008), 24 (34,28% 0,05) 44 (62,86%
0,05) .
: , , .
, , .
. ()
500 11
80 . 502 2004 745 2008 . 75,8% 0,9 24,2% 1,2 .
[6], .
[4, 5, 9].
283
, , 2010, 4
.
. 923 ( 32,33 9,73 ) . : -
, -125, -19-9, , ( - ).
(760/923 ),
(163/923 ).
, ( X,
1999) [2]. :
(n = 734)
(n = 189). 32,40 9,49 33,38 10,25 (p = 0,213).
Statistica 6.0 .
. (700/923 ).
(-, ), , , .
, 5
, .
(223/923 )
:
143 923 (15,49% 0,01) 30 923 (3,25% 0,005).
: (r = 0,094, p = 0,004); (r =
= 0,166, p < 0,001); (r = 0,122, p < 0,001),
(r = 0,182, p < 0,001), (r = 0,230, p = 0,03) (r = 0,195,
p = 0,021), (r = 0,246, p = 0,002).
,
, ( = 0,008)
284
.. . ...
, , 2010, 4
286
.. . ...
SURGICAL APPROACH
TO RESTORING REPRODUCTIVE FUNCTION
IN PATIENTS WITH TUMORS OVARIAN
E.P. Kuznetsova, F.K. Tetelytina
Chair obstetrics and gynecology
Izhevsk state medical academy
Komunarov str., 281, Izhevsk, Russia, 426034
K.G. Serebrennicova
Medicine of female with a obstetrics and gynecology course
Moscow state medical academy name Sechenova
Moscow, Trubeckaya str., 8, Moscow, Russia, 426034
R.Z. Halilov
MSP 3
Promushlenay str., 52, Izhevsk, Russia, 426000
Operated 923 patients with benign ovarian tumors. Organ-operative treatment with subsequent
post-operative therapy helped restore have 70 patients (7,58% 0,008). Among the 24 patients (34,28%
0,05) with the primary infertility and 44 (62,86% 0,05) with secondary.
Key words: benign ovarian tumors, surgical treatment.
0
0
..
. , 6, , , 460000
- -
, . 20002009 .
. , , 2009 66,09%,
67,66%.
: - , , , .
( 22
1993 . 5487-1 . .) , - ()
, , .. [1].
- () , ,
[2, 3].
28.03.1998 . 53-
[4] .
, , .
, (
025/, 003/, , .). , -, ,
.
(
2000 2009 .) -
- , . .
288
.. - - ...
. , 2000 19 504 . ,
, 2004 20 274 .,
17- , 2009 13 337 .
- 1516-
().
3 10%. . 2000 60,16%, 2009 66,09%.
, ,
, 2000 - 25,2%; , 24,3%; 12,1%.
61,7%. 2- 7,3%; 6,8%
6,4%. 2009 - 21,4%; , 23,0%;
19,9%, 64,4%. 2-
10,9%; 5,6%
3,8%.
, : ,
( , , ), (, ). .
-: ,
, , , , .
-: . , , , .
, - ,
1, 2 3. 1 ,
; 2
; 3 , , .
289
, , 2010, 4
-
( 2000 2009 .) : ( 86,1 89,5%),
( 63,7 81,6%); ( 80,9 92,5%); ( 56,4 100%);
( 90,8 100%).
,
.
, (
, - , - - .) . ,
-
,
.
18 27 , ,
.
, , 17%.
(62,9%)
2000 (67,6%) 2009 .
,
. 2,2 8,4% .
,
.
, ,
, .
,
-
290
.. - - ...
291
..
. . , 50, , 308000
..
. , 3, .-, , 197110
..
1
. , 96, , , 308015
..
. , 85, , , 308015
, 708 , .
: , , .
-.
- , - [2]. - .
-
-.
. 708 -
( 60 73 , 65,2 3,4 , 302, 406 ).
.
. , ()
. 176 000 , -
292
.. . ...
, - . -
[1], .. . 22 (
). - p.
. , , 4 - .
,
. -
. : ,
; , ,
; ; -;
- ( ); , , ; ;
; ; ; ; ;
.
, , , ( ), .
, .
-: , , ,
; , , , ; ;
; ; ;
-.
. - -
,
, - .
293
, , 2010, 4
ABOUT QUALITY
OF OTHORYNOLARINGOLOGICAL AID FOR ELDERS
N.. Kunitsyna
Medical Centre Pokolenije
Khmelnitskogo av., 50, Belgorod, Russia, 308000
.V. Perelygin
Department of clinical gerontology
Institute of Bioregulation and Gerontology
Dinamo av., 3, S-Petersburg, Russia, 197110
L.Yu. Varavina
1st Belgorod city poloclinic
Belgorodskij av., 96, Belgorod, Russia, 308015
S.L. Speranskij
Department of general surgary
Belgorod State University
Pobedy str., 85, Belgorod, Russia, 308015
The own scientific criteria of quality of gerontological othorynolaringological aid are presented in
this article.
Key words: elders, medical aids quality, othorynolaringology.
, 0
N0
.. , .. , .. ,
.. , ..
. , 2, , , 614081
N- , -, 1H- -, , ,
, , .
: N- , , , .
N [1] , N- .
N-
1 .
,
, , 95%.
-, 1H- -.
- 3400 1
(CONH2) 1670 1 (CONH2). 3200 1.
1H - Tesla
BS-567A ( 100 ) ,
.
(CH2, = CH2) 3,66 ..
5,2 .. .
(=CH-) 5,466,2 .. 6,467,55 .. (C6H4, NH). (NH2) 8,01 ..
- -
HP-6890 c -5973 . 1 . :
D-5MS, 30 0,25 0,25 ; :
70 (2 ) 20 /. 280 (10 .) 280 (10,5 .); -
295
, , 2010, 4
280 ; 60,7 ; ;
40550 ...
5109 / 11,09 . -
m/z 176,1 [M+], m/z: 160,08 [-NH2]+, 132,07
[M-CONH2]+, 105,11 [C6H5CO]+, 76,10 [C6H4]+, 55,08 [NHCH2CH = CH]+, 44,03
[CONH2]+, 40,06 [CH2CH = CH]+.
, N- . [2] 38,0% 51,6%
1 4 . [3],
,
38,0 . [4]
62,4%. N-
: 50 1250,0 (1126,01387,0) / [5].
,
N- ,
. N- 19 . N-
, . , , [6].
, N-
, , , ,
.
296
.. . , - ...
.. , ..
,
. , 1, , , 400135
. , .
: , .
, ,
, . ,
[1].
, -
- .
. , , .
. 84 1 . ( 45 39 ) 18 72 .
(PBAPI, Williams & Thorn, 1989) [2]. : I ,
; II ;
III ; IV
, . ,
.
. , IV
(. 1).
1
I
24 (28,6%)
12 (50%)
II
36 (42,8%)
20 (55,6%)
III
20 (23,8%)
8 (40%)
IV
4 (4,8%)
3 (75%)
,
.
298
.., .. ...
.
III,
II.
. .
.
[1] .., .. .
// . . 2009. . 1114.
[2] Williams D.A., Keefe F.J. Pain beliefs and the use of cognitive-behavioral coping strategies //
Pain. 1991. Vol. 46. P. 185190.
.. , .. , .. ,
.. , .. , .. ,
.. , ..
. ..
. . , 15, , , 430032
51- , . ,
, .
: , , .
, , 32-
[1]. .
[2, 3]. 51- ,
,
1 , . 50 ,
2. 16 .
. ( ) 2.
(84%, < 0,05)
, 82% .
(60%) .
58% ( < 0,05) . 54% , 64% , 58% ,
300
.. . ...
55% . 39% ,
. .
,
, , (. 1).
,
[4]. , (. 2).
, .
. 1.
150
. 2.
. .
200
,
, , .
, ,
,
. . , , ,
.
301
, , 2010, 4
LINICAL MANIFESTATION
AND PHATOMORPHOLOGICAL ILLUSTRATION
OF MASSIVE HYPOXICAL INTRAVENTRICULAR HEMORRHAGES
IN NEWBORN BABIES
L.V. Ledyaikina, L.A. Balyukova, T.I. Razdolkina,
E.I. Naumenko, V.S. Vereshagina, E.L. Samoshkina,
L.I. Dzubich, S.V. Garina
Chair of pediatric
N.P. Ogariov Mordovian State University
Luxemburg str., 15, Saransk, Russia, 430032
We did a prospective study in newborn babies who had transferred from antenatal hypoxia of a
fruit and birth asphyxia. The authors made multifactor analysis of 51 case records of newborns to investigate the clinical features of intraventricular hemorrhages. The spent researches revealed the most frequent clinical symptoms: falling of a muscular tone and disappearance of suckling and swallowing reflexes, apnoea attacks and tachycardia.
Key words: impelent activity, apnoea attacks, eye semiology.
.. , .. , .. ,
.. , .. , ..
1
. , 29, --, , 344022
-100 1- . .
: , , , .
() . , , . , , ,
[1]. () .
() [2]. -100 ( 1), , (15%- , 2). .
() . , (), (G-SH), (), , () ().
, .
< 0,05 t-
.
1- (. 1) 1-
, 2 . 2-
( , . 2) 3 , 6 .
, - ()
, , [3], .
1- , 3 .
2 , -
303
, , 2010, 4
. 1- . 2- .
1
, , G0SH (/ ), (/ ),
4
(10 / ), (/ )
( 1), m
263 0,10
1 .
3,0 0,08
3 .
2,79 0,10
10 . 3,33 0,08*
1 . 4,14 0,13*
2 .
2,70 0,20
3 .
2,90 0,10
6 .
2,80 0,10
GSH
0,280 0,01
0,320 0,02
0,290 0,02
0,370 0,03
0,42 0,03*
0,40 0,03
0,30 0,05
0,29 0,02
260 9,50
272 9,37
242 14,9*
154 9,96*
54 7,30*
298 22
260 6
244 4,6
126 4,05
98 7,12*
94 6,07*
63 8,01*
25 5,52*
150 3,2*
123 5,09
131 6,0
253 11,20
199 7,3*
209 7,38*
153 8,38*
102 7,18*
280 15,3
270 9
270 9
8,80 0,48
7,90 0,2
7,0 0,4*
5,40 0,5*
2,90 5*
10,7 0,08
9,1 0,3
9,1 0,3
21,1 0,96
28,2 0,73*
25,8 0,75*
34,9 0,83*
36,4 1,26*
25,3 1,2
21 0,9
21 0,9
2.
, , G0SH (/ ), (/ ),
4
(10 / ), (/ )
, m
2 .
GSH
2,63 0,1
0,28 0,01
4,11 0,09* 0,18 0,01*
260 9,50
290 2,64*
3 .
6 .
305 2,64*
297 6,28*
182 3,08*
176 9,40*
511 5*
323 5,1
21,1 0,96
19,24 0,5
( 2) (. 2).
23 .
6 . , , [4]. 1-
1- . 23
(. . 1). 1- . 2 .
G-SH 1- .
2 .
( 2) 6 . G-SH 23 .
, ,
1 .
304
.. . ...
3 , G-SH, , -, ,
.
.. , ..
. , 1, , , 400131
, ,
II .
: , , .
, , .
, , , ,
, , . 510% .
, , , , - [1].
, , .
, , 45-
[2], . , , , ,
.
:
.
2000 2007 . 9 4365 (6 , 3 ), -
306
.., .. ...
. .
. 22,5 .
, . 21 , , .
23 . , :
, . ,
[3].
, 1214- . , , ,
.
(, , , , ) [4]. . , .
307
, , 2010, 4
TREATMENT OF COMPENSATIVE
HORIZONTAL INCREASED DENTAL ABRASION
OF THE SECOND DEGREE
I.V. Linchenko, F.N. Zukanova
Chair of orthopedics stomatology
Volgograd State Medical University
Square of Fallen Fighters, 1, Volgograd, 400131
Preliminary orthodontic treatment with using of ondental plastic cup directed to the reconstruction
of myostatic reflex permitted us to find prosthetic space for production of aesthetic crowns and bridge
like prostheses in patients with generalized, horizontal, compensative, increased attriction of the second
degree.
Key words: Ondental plastic cup, increased attriction, myostatic reflex.
.. , ..
. , 1, , , 400131
()
() .
.
: ATC/DDD , , , .
ATC/DDD ().
[2].
[1], [5, 6]
- () .
: , ,
, .
. 216
IIIV , 234 , 2009 .
5000 . , ,
. , , .
,
[3].
(DDD) 100 .
DDD 100 [6].
. ,
, -
309
, , 2010, 4
310
.., .. ...
[1] .., .. // .
2009. 2. . 6468.
[2] .., .., ..
: //
. 2009. 1. . 8692.
[3] About ATC/DDD system. Oslo: World Health Organization Collaborating Center for Drug
Statistics Methodology // http:// www.whocc.no/atcddd
[4] Langsetmo L., Platt R.W., Ernst P., Bourbeau J. Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort // Amer. J. Crit. Care Med. 2008.
177 (4). P. 396401.
[5] Mc Ghan R., Radcliff T., Fish R. Et al. Predictors of rehospitalisation and death after a severe
exacerbation of COPD // Chest. 2007. 132 (6). P. 17481755.
[6] World Health Organization. Introduction to Drug Utilization Research. Oslo, Norway,
2003. P. 147.
.. , ..
-
. , 227, , , 443001
,
, ,
.
.
: ,
, , .
, , ,
[2, 3].
, . , , ( ), [4].
. (20002009 .)
1254 (
. 152/).
.
1. .
2. - .
3. .
4.
().
,
.
37 , -
312
.., .. ...
, , , ,
. 20002009 . 2632- [1].
20002009 .
(). 87,7%. 2009 .
2008 . 2,2 . , (
125- ),
(, )
, - ,
- .
, ,
- .
, ()
3,6%, 2009 . 1,7%.
0,2%.
2009 .
.
22 ,
, , , , [4].
, , , , , .
41,6%, 2009 .
42,3%. .
( )
62,1%.
2009 . , , - .
313
, , 2010, 4
59% , - , . ,
, .
- , -
(14 )
.
2.2.2006-05 [5].
,
, .
, ,
. , ,
,
,
, .
, -
(,
. 362-1/), , / , ,
- 12- ( ),
.
, ,
, -
314
.., .. ...
,
, , , .
,
, - , -
, .
[1] . -
2009 .. ., 2010. . 224.
[2] .. , // .
. 2001. 1. . 19.
[3] ..
// . . 2001. 5. . 15.
[4] .., .., .. // .. . 2002. . 5. . 333336.
[5] .
. 2.2.2006-05. .:
, 2005. . 129.
detectability problem of professional pathologies, objectiveness in estimation marks working conditions class, which gives a possibility to establish the workers disease character. We made well-founded
conclusion about the necessity changes to the working conditions estimation criteria.
Key words: production and working harmful factor, professional sickness rate, working conditions class, insurance event.
315
..
. , 28, , , 614990
..
. , 14, , , 614022
(, 2001).
, , ,
, , .
.
: , , .
- , . , 10%
. , ,
.
.
.
[1]
. ,
18
.
316
.., .. ...
,
, , [2],
. , . 14 , 5 ,
: , ,
, ; 5 , : , , , , ; 4 ,
: , , , . ().
, .
, ( ) .
- ,
. (
)
.
(). , , . 1.
1
(%)
()
,
,
,
1024%
2549%
5074%
,
75100%
1525
2550
2035
1015
1014
1524
1019
59
59
514
59
14
04
04
04
00,9
. N., 21 , :
- (2004), 5 , . . - 21 . . 2.
317
, , 2010, 4
2
N.
1*(
, )
(,
)
2*(
, )
**
30
30
30
10
10
10
37
55
111
16
19
50
49
53
135
108
108
160
74
93
235
100
100
100
()
(),
(), %
10
10
10
445
489
866
49,0
(), %
5,1
. *1 ; 2 ;
** , ..
, .
, ,
. , . 18
, () (, )
, , , .
318
.., .. ...
V.A. Bronnikov
Social Work Department
Perm State University
Sivkova str. 14, Perm, Russia, 614022
The article represents an integrative approach to the evaluation of complex rehabilitation of disabled
people based on the International classification of functioning of health and vital activity restrictions (ICF,
2001). There is an algorithm of the evaluation of complex rehabilitation process considering dynamics of
indices that reflect communal, productive, social and professional activity abilities of a disabled person and
also a degree of his or her participation in different social relationships. The final evaluation of rehabilitation effectiveness is given on the basis of comparison between achieved results and initial parameters and
takes into account the degree of vital activity restrictions of a disabled person.
Key words: disabled people, complex rehabilitation, effectiveness.
.. , ..
. ..
. , 8, . 2, ,
, II II . ,
.
: , , , ,
.
() -- ()
, - , ,
. --
- , - .
,
, II. II , ,
, ,
, . II, : AT1, AT2, AT3, AT4,
.
II
1-.
1- II ().
.
. 150
45 .
1-.
(, Promo-
320
.., .. ...
Med, )
(), . .. ( 23
. ), , ,
II .
81 , 35
70 , 16 . 1 160 (39 ), 320 (42 ).
: , ,
. , , , , ,
. 20 200 / - ( , -, , ).
.
II ( < 0,05). , , 160
, 4 11,4 1,1 . .,
10 13,9 1,4 . ., 16 15,7 1,5 . .
( < 0,05); 4 160
8,6 0,6 . ., 8 11,1 1,0 . ., 12
11,5 1,1 . . ( < 0,05). , 320 ,
4 13,1 1,3 . ., 8 15,2 1,5 . ., 12 17,3 1,6 . . ( < 0,01);
4 320 9,9
0,9 . ., 8 10,8 0,8 . ., 12 12,3
1,1 . . ( < 0,05).
, ( < 0,05). (%), 12 .
- (
20 /, 50 / 100 /), :
, 160 , 10 (25%), : 2 20 / ( ), 4 50 / ( 20 /), 5
100 / ( 50 /), 1 100 / ( 20 /);
, 320 , 16
(38%), : 3 20 / ( ),
321
, , 2010, 4
5 50 / ( 20 /), 5 100 /
( 50 /), 2 100 / ( 20 /), 1 50 / ( ).
. . (, , , , )
2%, .. 12 .
.
,
, , .
, .
10 II
.. , .. ,
.. , ..
. ..
. , 8, . 2, ,
II,
, .
,
.
: , II, .
-- ()
- .
() - , , . II . ,
II 1-, 1- II ().
( )
, ( ).
CHARM, Val-HeFT, SOLVD,
ELITE II HEAAL.
, II ,
,
AT1.
.
23 . . 53 (34 19 ) 45 70 IIIII
() NYHA. 40 2
.
323
, , 2010, 4
1040 , 125250 . 2 80 2 . 16 .
IIIII NYHA,
( ) III ;
( ) 30% (), .
: ,
,
, ,
. ,
6- , , BNP ( - ). .
Sonos-5500 (Hewlett Packard) 380A (Toshiba) ,
2- ( ).
6- .
BNP 24 16
. BNP -,
(-) Triage Meter, Biosite, USA. BNP 200 pg/mL. Wilcoxon.
< 0,05. , SE.
6- , , , II NYHA. 28
II NYHA 4-
160 (80 2 ) 13 ( 9 I , 4 0 ), 14 , 1 III NYHA. III NYHA
(25 ) 11 ,
2 16 I NYHA.
.
4
(160 2 )
15%.
III . ( ) 16 17%.
324
.. . 1- II...
CLINICAL EFFICACY
OF AT1 RECEPTORS OF ANGIOTENSIN II VALSARTAN
IN THE PHARMACOTHERAPY OF PATIENTS
WITH ARTERIAL HYPERTENSION
AND CHRONIC HEART FAILURE
A.K. Starodubtsev, M.L. Maximov,
O.V. Dralova, A.S. Ermolaeva
Department of Clinical Pharmacology
I.M. Sechenov MMA
Trubetskaya str., 8, p. 2, Moscow, Russia
Angiotensin receptor II, combining high efficacy and good tolerability, are one of the main groups
of drugs for the treatment of chronic heart failure. The study examines the efficacy of valsartan in the
clinical picture and laboratory parameters in the treatment of patients with arterial hypertension and
chronic heart failure.
Key words: valsartan, BRA, chronic heart failure.
325
..
-
. ..
, 135, , , 119049
..
. , 6, . 4, , , 129164
, - - , - .
: , , -, .
,
,
[14]. - .
,
[2, 3].
[2, 4] , (-) , , - , - [3].
,
- .
- .
. - ,
160200 . [2]. () () () 35 .
5- (5,
10, 15, 20, 25, 30 35 ). 8000 .
6000 2 .
326
.., .. ...
.
(), () () Morfokvant (Karl Zeiss), [2].
-
Excel Statistica-5.
. [2] , , , 8000 .
- ,
- - . , 95% [5].
,
5 15
,
(. 1). 20- 26%, 23%. 25- .
. 1. ( % , 100%)
() ()
327
, , 2010, 4
.
, 15-, 25- 30- ,
.
-
, . -
. ,
(. 2).
. 2.
.
( . . 1)
15 20 . 25-
. 30 .
5-
, , - . 15, 25 30 , ,
.
. 20-
, ,
328
.., .. ...
- [2, 3]. -
,
, - [5].
, ,
- - .
-
, .
L.M. Mamalyga
Chair of anatomy and physiology of human and animals
Moscow State Pedagogical University
Kibalchich str., 6, Moscow, Russia, 129164
Influence of deadaptive on RNA quantity changes in neurone-glia system of monoaminergic nucleuses of a brain is studied. Action of a hypoxia during the different periods deadaptive is accompanied
by the greatest vulnerability of cellular structures of dopaminergic and serotoninergic nucleuses of a brain,
it limits functionalities of systems stress-limiting.
Key words: hypoxia, deadaptive, neurone-glia, RNA.
329
..
. , 3, -, , 197110
.
.
: , .
- (, .: , ) (110 ) (30
300 ), (< 10 /2).
( 1 ), .
- ( , ),
( , , ), ( ), ( , ) [1, 2].
,
[1, 2].
.
, , [3, 4, 5].
- .
.
-
62 ,
( ,
), 61,2 0,4 ( 32 .,
30 .).
(. 1).
330
.. ...
. ,
.
- .
( , ,
, ,
), -
.
1
,
, /.
2
74,3 1,7
74,9 1,4
4,6 0,44
4,6 0,49
2,3 0,45
2,4 0,66
75,1 1,8
75,1 1,5
4,6 0,33
4,5 0,98
2,4 0,56
2,4 0,31
, /( )
1 444,6 128,2 1 012,2 122,5* 1 442,8 132,4 1 429,9 99,8
5
, /( )
14,6 1,6
14,6 1,2
14,4 1,4
14,6 1,1
, . .
.* , p < 0,05.
331
, , 2010, 4
, ,
- , , . -
(, ).
001
.. , ..
-
. , 95, , , 690022
..
-
. , 4, , , 690005
-01 , .
.
: , .
. ,
,
,
. , .. ,
. ,
.
. ,
.
. ,
.
, , . ,
, (), -01 (
. 0222004/0892-04 18.11.2004 .).
-01 , , -
333
, , 2010, 4
, ( ),
-.
[2, 4].
-01
(463 .) . .
,
: (225 .)
(238 .) , : 19/1019/2029/30 .
.
, : (), (), ();
() , - . , ,
[3]. t- p- ,
. 6.0.
, , ,
() () () .
19/1019/2029
( 3,9 0,4; 4,9 0,4;
5,0 0,5 . .), (3,1 0,4; 3,4 0,4; 2,5
0,5 . .), ( ). 30
, ,
2,9 , , ,
( 1,7 0,4 2,2 0,4 . .)
. ,
,
,
-
,
334
[1].
, ,
,
. , , 0,20,4 . ., .
.
,
. , (),
, ,
, 13- ,
. 5 . .,
c
. 4-
9 55,4%, 49,2% . 1019 4- , , 75% 60,3% , , , .
2029/30 , 4-
(57,4% 59,6%),
(56,5% 57,1%). -, , . , -
, , 1019
.
19 , 1019 ,
2029 , 30
.
(r > 0,91),
, .
r = 0,83, .
(r = 0,83), , -
335
, , 2010, 4
. .
,
, , - 19 . .
.
, ,
, , 2/3 . 19 57%
( 49%) 2029 (93%) (
79,4%). , - , . 2029/30
, , .
.
, ,
, . , , , , ,
(, , , ).
, , - -, , -, .
-
.
, , ,
. - - .
- ,
10
, 10
19 .
336
M.S. Tulupova
Medical Centr Paracels
Novoivanovskay str., 4, Vladivostok, Russia, 690005
The use of DgKDT-01 technology for preventive medical examinations helps to differentiate examined patients by integral health indexes, uncover the structure and features of pathological process. It
helps to discover diseases on early stage.
Key words: health, new diagnostics methods.
5
( )
.. , .. ,
.. , ..
5,
. 6- , , , 443029
- ,
. ,
, , , . .
: , ,
.
.
2008 30 18 ,
0,05 100 000 .
5 . ,
, .
, , , , -, .
.
. 5 26.10.2008 ,
, , 39 .
, 3 ,
, ,
.
: , , , . .
. . . , , .
. , , . ,
338
.. . ...
, .
- . , . , , - , .
. . ,
120 . . , . 26 . , . . .
: , .
. .
. , .
120 . . 3- BL.
v. Gravis, .
0, 0.
9- (, , ), 18- . 12-
: , ,
, , , ,
. 26-
. 19-
( , , , , ). 39- .
: , , BL (+)
v. Gravis. , . .
. .
. ,
( , , , , ),
.
6 , , (
2 , 63 / 8,1 . ).
(8%), - , 195 .
. . Ig G k EBV IgM k CMV,
( 12.11.08- 0,746, 26.11.08- 1,608).
: , ( ), , . , , .
339
, , 2010, 4
(, , ), ,
3 / , 3 , , (, , , , ), , ( , ,
1, 6, 12), -2, ,
(, , ). 39- .
, . ,
( , , , ), ( - , , 95, 47, 45RO,
8+).
, - [3, 2].
.
, . , , Ig
-1 [4].
II IV ,
- [1].
, - . ( )
,
, [5].
, . , .
,
, .
. , ,
. -
340
.. . ...
, . , . , , , . ,
[5]. , , .
341
,
..
, 8/5, , , 115093
..
21
. , 28, , ., 140009
..
.
. , 14, , , 115533
..
, 8/5, , , 115093
,
. , .
, .
: - , , , - .
,
[1].
,
,
. ,
. , ,
, .
, , . -
342
.. . , ...
. , . .
- [3].
.
:
21 , - ,
.
. - 21,
, : ( , ), ( , /, , ),
( , /, , ), ( , /3),
- (/), (, ,
, /, , %), ( , , %) .
.
.
,
. ,
, - ,
- , - .
2 :
13 510 . 397 ,
95% .
() ,
,
(1000 ).
343
, , 2010, 4
() .
[2].
. .
, . .
,
1,5 . , , .
,
.
( 23 ) .
. - .
,
1923%, 3045%. ,
1,31,6 . .
(, )
.
.
100% :
1,22,5 ,
1,22,2 .
. 1.
1
( 1000 )
344
M1
(13 )
94,8
28,4
52,1
71,0
80,6
9,5
4,7
4,7
345,8
m1
20,2
11,4
15,3
20,2
18,7
6,7
4,7
4,7
32,8
M2
(510 )
219,8
4,7
108,9
94,8
246,4
37,9
42,7
28,4
783,6
m2
30,7
4,7
21,4
17,7
29,7
13,1
13,9
11,4
30,5
3,4
2,2
0,9
4,7
9,8
< 0,05
< 0,05
> 0,05
< 0,05
< 0,05
.. . , ...
, , - , - ,
[2].
(< 0,05) - ,
.
. 1 2.
. 1.
13
. 2.
510
345
, , 2010, 4
- , , . , - , .
. 3.
. 3 .
- 2,3
, ,
9 . , , 3 . 2,1 .
- 3 .
, .
, . ,
.
53%, 67%, [3].
346
.. . , ...
V.A. Nazarov
Secondary school 21
Pobratimov str., 28, Lyubertsy, Moscow Region, Russia, 140009
A.S. Kondrashova
Directorate, Testing laboratory
Southern District of Education Department of Moscow
Visokaya str., 14, Moscow, Russia, 115533
A.Ya. Chizhov
Department of Ecological Monitoring and Prognostication
Ecological Faculty
Peoples Friendship University of Russia
Podolskoye shosse, 8/5, Moscow, Russia, 113093
The article studies the influence of environmental factors on the childrens organism of whose
health is an indicator of the ecological situation. School buildings and facilities in many respects do not
meet the standards imposed on such institutions. In this research, measurements were made of physical
factors of the school environment, assess the health status of students.
Key words: sanitary survey, the health of children, physical factors, the maximum allowable levels.
347
A.. , ..
, 8, , , 127051
- .
, .
-, ,
.
: , , .
,
, , , ,
.
-.
(benchmarking), -, [4].
,
(). PIMS ( )
.
1970 1980 .
Fuji,
Xerox, HP, Dupont, Motorola, Chase, Kodak, Procter&Gamble, IBM, Boeing .
. ,
348
A.., .. ...
, ,
.
, : , , , , .
,
, :
; -
, , ; .
-
. ( , , , .) , , .
, .
,
.
( , ). , . : , -, .
,
,
SWOT- - .
, ,
.
- -
,
.
349
, , 2010, 4
, ( , ).
[1, 2, 3].
500 20
20082009 ., .
(26,7%), (20%), (9%), (9%), (5%)
. , ,
(62% ), (27%) .
10- .
, (9 ) (8 ), (7), (6), (5), (3).
, ; ; ; .
: ,
, 2645 (55%),
(65%) (25%). 2645 (32%) (48%)
(50%) (35%).
- , 2645 (45%) (40%) (52%) (20%).
96 (
5 70%) ,
, , .
, , (75%), (58%), (45%),
(36%), (30%).
350
A.., .. ...
-
(65%), (57%), (45%), (35%), (20%).
(72%), (65%), (52%) :
-
- (85%);
, (67%);
- (58%) .
(63%), (58%),
(53%),
(49%), (41%).
, (68%),
(57%), (32%).
.. , ..
.. , 4
, - . :
;
;
15 , 10- .
- .
- .
:
= / *10.
, , ,
.
, ().
351
, , 2010, 4
;
;
(
)
(,
..);
;
;
,
;
;
;
, ;
;
;
;
(, ..)
;
;
;
;
;
,
;
;
;
;
;
;
;
;
;
. -, , .
352
A.., .. ...
0
.. , .. ,
..
. , 89, , , 443099
70 - . ,
.
II . III
.
: , , , ,
.
[3]. -
[1, 3]. , [2].
-. ( ) ,
.
( ), , , , , , [5].
: - 2- 3- - .
: 70 . 1-
20 2- , 2- 18
2- , 3- 32
3- . 26 .
, , , , , , -6-.
354
: 2- . , 34% ( < 0,05) 31% ( < 0,05). , , , -6 50% ( < 0,05), 27% ( < 0,05)
49,7% ( < 0,01) . 3- . 17% ( < 0,05),
, , , -6- 25%, 20%, 24% 22% ( < 0,05). 1-, 2- 3- 47% ( < 0,05), 28% ( < 0,01)
105% ( < 0,01). ( ) 1-
2- , 2- . 3- - .
. 2- ,
. (3- ),
, , .
355
, , 2010, 4
.. , ..
. , 48, , , 614990
. , : II, 200 VV, 500.
: ,
.
,
, . : , , [1].
.
.
: ( I) ( II)
c ( 12, 301,
302, 500) , 200 VV Pharma R 972 V [2]. :
,
[1]. . 1.
1
I
II
12
301
302
500
R 972 V
200 VV
, %, , %,
24
24
0,75 0,01
0,03 0,01
5,13 0,01
0,21 0,01
4,38 0,01
0,18 0,01
5,53 0,01
0,23 0,02
16,12 0,02
0,68 0,01
4,38 0,01
0,18 0,01
1,06 0,01
0,04 0,01
8,23 0,02
0,34 0,02
, %,
48
1,19 0,01
6,78 0,03
8,48 0,01
8,44 0,01
18,20 0,01
6,99 0,06
1,19 0,15
,
%, 48
0,02 0,01
0,14 0,04
0,18 0,01
0,18 0,01
0,38 0,01
0,15 0,06
0,03 0,15
11,93 0,21
0,25 0,21
,
\
,
/
357
, , 2010, 4
. 1 , R 972 V ,
302 18,20%. 500
(0,0200,146). 500 .
508,39 1200,48, 500.
( 1 : 2, 2%) : 1 IX, , I; 2 IX, , II; 3 IX, ,
12; 4 IX, , 301; 5 IX,
, 302; 6 IX, , 500; 7 IX. . 2.
2
, %,
24
1
2
3
4
5
6
7
()
14,40 0,02
18,31 0,01
14,70 0,01
16,60 0,01
16,67 0,02
14,70 0,01
28,71 0,01
, %,
24
0,60 0,01
0,76 0,01
0,61 0,01
0,69 0,01
0,69 0,02
0,61 0,01
1,20 0,01
, %,
48
,
%, 48
,
/
21,70 0,05
26,56 0,01
23,30 0,04
24,07 0,03
23,83 0,01
21,20 0,01
46,27 0,02
0,45 0,05
0,55 0,01
0,48 0,04
0,50 0,03
0,49 0,01
0,44 0,01
0,96 0,02
458,09 0,03
526,30 0,02
444,44 0,07
472,37 0,05
458,09 0,01
465,12 0,01
250,00 0,01
,
, ,
, ( )
2 . 6 500 (4,61 /), . 1.
. 1.
358
.., .. ...
[1] .., ..
// - 21 .
, 2003. . 286288.
[2] // . 2005.
6. . 30.
.. , .. ,
.. , ..
. , 40, , , 656038
Wistar . , .
: , , .
.
.
.
.
. 30
Wistar 180 250 .
10 . 1 ., 2 ., 3 .
.
. .
(23,2 6,47 ), , . ,
-. ( 5 4,7 ), . 17,9 9,67 .
(18,5 6,25 ), . - . .
(10,3 7,1 ),
.
. 15,0 7,60 . .
360
.. .
18,0 7,00 . , , ( , , ).
, .
(21,4 15,60
), .
16,5 6,51 . , .
. .
.
.
.
.. , .. , .. ,
.. , .. , ..
,
. . , 8, , , 153034
. .
: , .
( . communicatio ) , [4].
, - .
-, - , , ,
. : - , ,
, , , ,
- [1, 3, 5].
, ,
- ,
,
[2]. , .
: .
. : 4 . , 2
. , 13 . .. . ,
362
.. . ...
. .
: , . . ,
,
. 25
.
, , ..., .. .
14 , , , , : 12 3 , 2 .
430 .
() . 450
, : 120 , 130 , 200 .
.
. ,
, .
56,8%. , :
;
; ,
; , - .
15,7 , 66,5% .
: ; ;
,
363
, , 2010, 4
; , ; .
.
, , , , -, , -, . ,
.
. (); ;
, : ,
, ; - II .. ;
XXI ; , , , ; .. ,
.. . .. , ,
( .. // . 1980. 11. . 145148).
- , - .
.
, , . ( , ,
, ,
, ..), , , ..).
, , ,
( ), . , , , .
,
.
, .
364
.. . ...
: ( , ) 33,5% ; 73,7%,
13,4%;
6,7%; 46,9%; 66,7%.
:
: ? 86,6% , ; 13,4% , . : ? 100% , . :
, ?
100% : . 13,4% : . :
,
? : 26,7%; , 73,3%.
, , ,
, .
.
0,8, 0,7.
, 24,5%, 29,8%, 32,2%.
: , ;
. ,
. - .
. , 1,5 ,
,
.
-
365
, , 2010, 4
, : ; ,
; ; ;
; - ; ;
,
, .
366
.. , .. , .. ,
.. , .. , ..
,
. . , 8, , , 153034
. 5 ,
, .
: , , .
,
, ,
, [1, 2, 3].
; , , , ;
; ;
. 5
: -, , , ,
.
, , ,
, ,
. , , .
: .
. : 4 . , ., . -
367
, , 2010, 4
-
.
, ,
. ,
, 256 , 320 , 196 ,
210 .
984 (256 , 320 , 196 , 210 ). : (,
), (, ),
, (, ).
, . 2 : .
t- .
.
. , 18,5 ,
74% . - ,
65,5% ,
68,5%, 67,8%,
62,4%, 63,5% (p > 0,05).
:
, , . ,
45,5%, 48,6%,
44,8%, 46,7% (p > 0,05);
: 55,6%, 60,0%, 59,8%, 62,4% (p > 0,05); : 57,8%; 57,6%, 55,7%, 56,9% (p > 0,05).
,
57,6% , 71,2%, 60,5%, 45,6%, 58,7% (p > 0,05).
: , , . ,
368
.. .
56,9%, 57,4%,
55,6%, 53,9% (p > 0,05); : 52,5%, 58,7%, 57,3%, 55,5% (p > 0,05);
: 46,7%, 40,5%,
47,5%, 41,2% (p > 0,05).
- , 78,9% , 81,2%,
84,5%, 82,2%,
83,4% (p > 0,05). - : , ,
. , -
18,5%, 18,9%, 21,4%, 19,3% (p > 0,05); : 14,5%,
16,8%, 17,3%, 16,5% (p > 0,05); : 12,3%, 14,5%, 13,2%, 14,1% (p > 0,05).
, 45,6% ,
30,5%,
34,5%, 31,4%, 30,9% (p > 0,05).
:
, , - . ,
18,5%, 18,9%,
21,4%, 19,3% (p > 0,05);
: 14,5%, 16,8%, 17,3%, 16,5% (p > 0,05); -
: 12,3%, 14,5%, 13,2%, 14,1%
(p > 0,05).
,
73,2%
,
75,2%, 78,9%, 72,7%, -
369
, , 2010, 4
370
.. .
11,6%, - 10,8%,
7,8%, 5,6%, 12,5%.
, ,
, ,
.
0
..
. , 3, , , 305041
..
. ..
. , 10, , , 394036
- : - , , , , .
: , - .
.
, ,
. ()
[2, 5].
30 58% , 1036% , ,
, .
, , , ,
[1].
: ; - ,
, ; ; , , ; ;
; , ; , [4].
-
, , , : - ; ; ; ; .
372
.., .. - ...
2637
67,5%
48,4%,
39,4%,
12,2%
:
. 57,6%,
40,1%
58,5%
67,9%,
32,1%
:
28,4%,
18,3%
:
44,6%,
28,6%
. 1.
-
, ,
10 ,
, . , , .
.
. ,
63,7%, ( ) 40,6%
. (36,3%) -
373
, , 2010, 4
. , ,
.
, , (79,1%)
, . (20,9%) : - 16,1%, 2,9%, - 1,6%,
0,3% .
, , , - .
, ,
(29,8%), (51,3%)
(18,9%).
,
- .
(73,6%) , .
, , ,
, : , .
(13,4%) .
. ,
, .
- ,
. , 28,3% ; (29,9%), ,
1 4 . ,
(29,7%) ,
. , ,
. (62,9%), , .
1,6% , (98,4%).
, -. ,
374
.., .. - ...
(52,3%) (23,5%). ,
(12,3%) (68,9%). ,
, : (41,9%), ,
(23,8%), (18,3%), (17,9%), (17,3%), , (8,9%), (3,9%). , ,
. , , , , .
, ,
. , (36,1%) . :
17,3%; , , 17,2%; 12,1%.
,
() : 10,2%, 31,6%, 58,2% (. 2).
. 2.
(%)
. , . 3.
: 2,53,0
; 2,02,49 2,0
.
375
, , 2010, 4
. 3.
( )
, , , 3 , 2,86 ,
2,79 .
, , (2,362,21 ). 1,93 ,
, , , .
58,4%, ,
. , 37,8% .
- (47,1%)
(22,3%), .
, , , . , , ,
. 4 .
, (38,739,1%).
61,3% , . , , ( 48,8% ). -
376
.., .. - ...
(12,1%),
, .
. 4. (%)
(I-PSS) [5]. , (42%) , (34%) 24%.
, : (38%);
(30%),
(24%).
, - 48,3%;
46,2%; () 37,1%;
18,9%,
5,8%.
. , (53,5%) ; (32,4%) ; 12,9% , 1,2%
. , , (98,8%)
, .
, , , -
377
, , 2010, 4
.
, .
.
, ,
.
, -,
, , .
[1]
[2]
[3]
[4]
[5]
[6]
.., .. , // , .
2001. 5. . 1819.
.., .. //
. 2004. 5. . 2526.
.., .., .. . // . 2001. 7. . 1133.
.., .., ..
// . 2008.
. 16. 17. . 11341138.
.. //
. 2001. 5. . 1619.
: / . .. . .: ,
2000. 560 .
MEDICOSOCIAL RESEARCH
OF PATIENTS WITH CHRONIC PROSTATITIS
A.I. Ovod
Kursk state medical university
Karl Marks str., 3, Kursk, Russia, 305041
M.D. Mukovnina
Voronezh N.N. Burdenko state medical academy
Studencheskaya str., 10, Voronezh, Russia, 394036
Comprehensive medicosocial analysis of patients with chronic prostatitis is carry out in some directions such as socio-demographic characteristic, self-appraisal of medical culture, opinion of risk factors, attitude to disease, quality of life.
Key words: prostatitis, medicosocial research.
378
.. , ..
.
. , 6, , , 173020
() . , . . - . ,
.
: , .
1993 . , , - . ,
90 .
, 10 (. 1).
20002001 . 2006
. , . 20 29 ,
.
. 1.
1998 2008 .
, , , , , .
379
, , 2010, 4
. , 37 ( ) 60 .
. 2.
(), , - .
. 6,80
(. 100 10) 6290,00 . (. 800).
. 2.
-.
2 .
.
15 30 , , , , .
(. 3).
10 . .
, . , ,
(). ,
, 2 3 (. 1). 3
, 2.
380
.., ..
. 3.
1
, .
, .
% ,
, .
, .
%
1
200
3 798,10
70
2
3
200
200
2 712,80
2 122,60
0
100
4
200
3 262,60
40
394,10
4 273,97
0
2 912,80
51,40
2 374,00
436,40
3 637,16
80
534,25
100
291,28
80
339,00
40
909,28
381
, , 2010, 4
, ; ; ; .
EONOMIC ASPECTS
OF UROGENITAL CHLAMIDIOSIS TREATMENT
L.B. Okonenko, E.S. Egorova
Pharmaceutics Department
Novgorod State University named after Yarosiav the Wise
Derzhavin str., 6, Velikiy Novgorod, Russia, 173020
The investigation of urogenital chlamidiosis treatment in the Novgorod region has been conducted. The incidence of urogenital chlamidiosis in the region has been analyzed as well as the assortment of drugs available in the municipal chemist's shops. Sociodemographic picture of a patient with
UGC has been designed. The most commonly applied drug protocols have been revealed; of them the
most effective and suitable ones have been chosen considering the treatment of side-effects.
Key words: chlamidiosis, parmacoeconomy.
..
. , 46, , , 614070
() [1].
: , (), .
383
, , 2010, 4
(. 1) , .
. 1.
OEG (3S) ; M
(. 2) , ,
.
. 2.
OEG (3S) ; M
(. 3) , , . ,
.
384
.. ...
. 3.
OEG (3S) ; M
, ,
. 2
25 .
385
..
. , 1, , , 400131
..
. , 78, , , 400005
..
. , 78, , , 400005
, , .
: , ,
.
()
. ,
,
[1].
: , 60 , .
, , ,
.. [2]. , ,
.
386
, , .
. 1315 .
71 , . 108 13-
, .
,
60 , .
. : 1 (
); 2 ( ); 3 (
).
, (64,2%) . 29,4%,
6,4% .
, , , , , . , ,
, ,
, . ,
,
, .
.
, , , , , .
,
-
387
, , 2010, 4
. ,
, ,
. Se, Sp
[3].
, .
, [4].
,
Se ( 54% 87%), ..
. Se Sp (31% 10%).
Se Sp ,
.
(55%
38%), , , .
Se (69% 87%), Sp (100% 76%),
(80% 100%).
,
,
.
388
DIAGNOSTICALLY EFFECTIVNESS
OF MEDICAL CONTROLS METHODS EVALUATING
FUNCTIONAL CONDITION OF TEENAGERS BACKS
L. Osadshaya
Faculty of normal physiology
Volgograd State Medical University
Pavshih Bortcov square, 1, Volgograd, Russia, 4000131
A. Bogachev
Faculty of Theory and methods of adaptive physical culture
Volgograd State Academy of Physical Culture
Lenina avenue, 78, Volgograd, Russia, 400005
I. Gretskaya
Faculty of Sports Medicine
Volgograd State Academy of Physical Culture
Lenina avenue, 78, Volgograd, Russia, 400005.
We evaluated the sensibility, the specificity and the diagnostically effectiveness of the main indexes of functional condition of teenagers backs, which are used in methods of medical control of their
physical training.
Key words: medical control, the functional condition of back, diagnostically effectiveness.
.. , .. ,
..
. , 1, , , 400131
, .
: , , , , .
,
, , , (
), . , , , ,
, / [2].
,
, ,
[1, 2, 3, 4, 6]. , , , .
,
[1].
,
, [4].
.
( ,
, ).
( 5
). -
390
, , , ,
, , ,
, , .
, , , , [2].
:
1 , , ;
2 ( )
, ;
3 ;
4 .
. , - ,
-, , -, , , .
, [4].
,
.
5,5 [6, 7], , .
.
: ,
, ,
. ,
[2, 7].
,
. ,
[2].
, : -
391
, , 2010, 4
, , , ..
. ,
.
.
392
.. , ..
. . ..
. , 6-9, , , 614051
,
. .
: , , .
, . ,
, , .
, , .
,
, . , , , .
. [2].
, .
, , ,
, , .
.
. 12 ( ), 90 87,1% 96,7% . 30
, , , 30 2 . .
30 -
393
, , 2010, 4
( ). 30 . . 2
(). (). (t),
(rs), 2.
(),
(), (), (),
(), () -,
(. 1). + ,
+ + + , + + , + + .
, , .
,
( 70%). - [1, 3].
(. 1).
(p < 0,05, 2). ,
, .
2 , . , , , ,
, . ,
, ,
, .
1
, / ( m)
394
0,032
0,011
0,146
0,092
0,052
0,016
0,023
0,003
0,036
0,006
0,026
0,001
0,176
0,033
0,033
0,009
0,087
0,021
0,039
0,01
0
0,073
0,010~
0,158
0,017*
0,078
0,012*
0
0,026
0,003
0,036
0,01
0,058
0,018~
0
0,071
0,013~
0,127
0,0,21*
0,024
0,012
0,009
0,004
0,075
0,137
0,017~
0,051
0,050
0,059
0,01
0,018
0,036
0,055
0,011
0,016
0,068
0,119
0,026
0,012
0,068
0,142
0,013
0,014
0,243
0,266
0,029
0,027~
0,036
0,011
0,100
0,02
0,040
0,009
0,042
0,012
0
0,012
0,004*
0,103
0,019
0,051
0,010*
0,042
0,006
0
0,100
0,012
0,288
0,056~
0
0,255
0,021~
.., ..
1,137
0,078
1,687
0,073
1,623
0,017
0,323
0,010
0,330
0,069
0,533
0,026
0,394
0,019
. .
: , , .
, , .
, , ,
, - (, , , ) (
ARDS, ) , ,
, (. 1).
. 1.
( .., 2005)
395
, , 2010, 4
,
, (.
. 1). , , .
,
, , . ,
.
.
/ (. 1)
, .
(46 ): /, . :
/ (), (rs = 0,863, < 0,01); / () (rs = 0,901, < 0,01) () (rs = 0,893, < 0,01).
,
. , , , .
, , ,
, , [1, 3]. ,
, ,
. . ,
.
, , .
[4]. , -
.
[5]. , , , , . ,
.
396
.., ..
, , , , ,
.
..
. , 3, .-, , 197110
.
.
: , .
.
.
, 1950 . 50
214 , 1975 . 350 , 2000 . 590 , 2012 .
1 100 , 15% .
, 75 . 1999 .
30 , 19% , 3,2
80 . 19992009 . .
.
,
[3]. , - .
, , - . , ,
[3]. - , 30% [3, 5, 6, 7].
, , ,
,
[1, 2, 4].
. , - .
[8, 9].
398
.. ...
.
: 37 33 . . 6064 ., 68,2 3,4 .
. . 1
(M m) (p < 0,05).
1
(M m) (p < 0,05)
()
()
16,42 4,01*
12,41 4,40*
1,12 0,23*
6,04 0,20*
12,62 4,10
15,34 4,31
1,22 0,21
6,2 0 0,23
. * p < 0,05.
, ,
,
, . .
, ,
.
.
,
,
. ,
, , ,
.
.
.
399
, , 2010, 4
.
, . .
400
( . )
..
. , 6, , , 184511
..
,
. , 15, , , 185035
. 1539 22 ,
. - , , ; -
.
: , , , , .
.
, [5, 9].
- ,
( )
( ) [2]. c 22 20%
50% [2].
, 94,3% [2, 7].
[5, 8].
[7, 9]. 1652% [6, 9]
[7].
- (25,8%) (4070%) [5, 8, 9]. , ,
[5, 6].
() [9]. . ,
401
, , 2010, 4
10 , ( 2 ) [3].
,
[2, 8, 9].
,
, [8, 9].
1019 .
, , , , , .
, , 3040%
, 5060%, 7094% [7, 8, 9].
1,23,5% ,
[2, 4, 6]. , ,
[1], .
,
.
. 1539 ,
22 . 867
, ; 511
, , ;
161 .
.
. , (. 1). ,
23,7223,99%, .
1
0 .
402
2002 .
61 700
14 804
2003 .
60 800
15 415
2004 .
55 000
15 176
2005 .
53 700
14 135
2006 .
53 000
14 135
2007 .
52 600
12 637
2008 .
52 300
12 408
10,1
13,4
6,74
9,6
3,3
10,3
13,3
9,92
4,8
3,0
9,7
14,5
6,7
3,8
4,8
10,7
14,5
6,36
8,7
3,8
9,8
12,7
8,55
7,7
2,9
9,1
12,9
4,42
12,5
3,8
9,8
11,6
6,0
11,9
1,8
.., .. ...
, . ,
(867 56,37%). 4 : 2002 336 (38,75%)
, 2008 83 (9,57%).
, .
511 (33,22%) . : 61 (11,94%) 2006 83
(16,24%) 2008 . (222 43,44%). 8 (336 65,75%).
(337 65,95%), 189 (36,99%) .
161 (10,47%)
. ( 2,84% 1,44%),
(18,63% 9,32%.) 67 (41,61%)
, 17,39% .
389 (25,29%) .
166 (84,26%)
. (127 76,51%).
(39 23,49%)
22 . 53 (13,62%)
.
, - , 22 (41,51%) . 4 (1,03%) ,
.
. 2 ,
.
-
.
19 29 .
1619 .
(66,08%), (50,81%).
. 80,18% .
. , 922 (59,91%)
-
403
, , 2010, 4
n = 867
.
( )
( )
,
26,23 4,24
507
58,48
101
11,65
317
36,56
278
32,06
310
35,76
13,49 0,71
16,93 0,71
332
38,29
n = 511
.
%
n = 161
.
%
27,43 8,49
203
39,73
27
5,28
161
31,51
257
50,29
334
65,36
29,74 0,71
72
44,72
81
50,31
44
27,33
97
60,25
86
53,42
13,14 0,71
17,5 0,71
24
4,7
13,24 2,83
17,58 0,71
39
24,22
353
2
107
40,72
0,23
12,34
129
19
18
25,24
3,72
3,52
51
13
21
31,68
8,07
13,04
338
185
197
38,99
21,34
22,72
22,26
69,9
71,51
11,53
234
177
75
45,79
34,64
14,68
81
26
69
50,31
16,15
42,86
109
292
316
115
21,33
57,14
61,84
22,5
22
108
105
19
13,66
67,08
65,22
11,8
193
606
620
59
22 . , , .
.
404
.., .. ...
E.G. Gumenjuk
Department of obstetrics and gynecology
Petrozavodsk State University
Kirova str., 15, Petrozavodsk, Russia, 185035
In article the analysis of the developed demographic situation in the Kola Polar region is carried
out. 1539 patients with reproductive losses in terms till 22 weeks of pregnancy are surveyed. Risk factors of artificial abortion, miscarriage, ectopic pregnancy are distinguished; the social and medical portrait of women with reproductive losses is composed.
Key words: demographic situation, pregnancy, early reproductive losses, risk, preventive strategies.
,
..
. ., 18/1, . , , 603155
..
- ,
. , 210, --, , 344113
, .
,
, , (, ), . .
: , , , .
-
,
.
[5].
- - .
()
, :
, , ,
[2, 4].
(),
[1].
:
, .
. 85 ( 33 2,1 ), .
(60 )
406
.., .. ...
(25 ). 2
( 30 ) ( ).
, (, ,
-, , )
25- -, ,
(. ) (. ). / .
.
. .
, , , , (
, ). - , 5 [3].
,
.
.
, , , 2.
,
. : ()
LF VLF,
. ( < 0,05) ,
. .
. 1.
1
LF,
2 536 1 138
615
483
2 655 1 323
614
416
VLF,
1 566
852
641
205
1 499
791
468
203
LF/F
2,2
0,8
2,1
0,8
1,6
1,8
,
2 094
2 964
711
586,1
1 987
2 422
611
702
(p < 0,05)
,
407
, , 2010, 4
. . 2, 3, 4. ,
2 mv. 67 , 10.
2
68,1%
30,1%
61%
43%
11%
6,6%
12,6,%
7,1
20,9%
63,3%
26,4%
49,9%
3
4,1
4,7
4,0
4,6
3,8
4,3
3,6
4,1
3,7
4,6
3,7
4,4
5,5
6,3
5,4
5,6
5,3
5,8
5,5
6,0
4
0
( )
,
.
135 1,43
127 0,12
,
. .
91 0,71
82 0,71
85 0,72
79 0,72
(mv)
m. frontalis
10 1,1
8 1,3
.
, ,
.
[1] ., ..
. .,1997.
[2] .., .. //
, 2007.
[3] ..
: . . ...
... --, 2006.
[4] .., .. - . . , 2007. . 511, 2030.
[5] .. -
// . ., 2009 . 14.
408
.., .. ...
V.V. Matveeva
Medical Unit, doctor of recovery medicine
Lenina str., 210, Rostov-on-Don, Russia, 344113
Control of apparatus biocontrol course efficiency followed on dynamic of clinical symptoms, electrocardiogram indexes, ardiointervalographic, questionaries characterizing condition of psycho emotional
sphere. Rehabilitation results of the patients who got BOS therapy proved its efficiency.
Key words: vegetative disfunctions, biocontrol apparatus, heart rate variability.
.
.. , ..
. -, 8, , , 117198
,
, , . , .
: , .
. (20072008 .),
, 40% .
, ,
,
.
23 1- .
, , 3
2- .
, , , 72% - , , . 82% - : ,
, , , .
.
8 15 ( 1 . ). 420 ,
124 (29,5 0,014%) . , ,
410
.., .. ...
. , .
(65 0,09%).
.
.
.
7 12 , 13 15 .
.
. 1.
(. )
,
45 0,09% 55 0,09% 715 .
. 2.
.
. 32 0,09% 712 .
1315 47 0,09% .
411
, , 2010, 4
. , , 36,3 0,09% .
(33 0,09% 31 0,09% ).
(5 0,09%).
, ,
. . , .
. ,
, .
, 7090%.
. 90% , 80%, 70% [8]. ,
.
() . .
, . 85%
,
. 3 6% , , . , , 10 [6].
, ,
, , .
, , - ,
.
:
1. (, , , ).
2. (, , , , ).
3. , (, , , , , , , , , ).
4. , ( , , ).
412
.., .. ...
5. (
. li, ).
. .
( 2.1.4.1074-01). . ,
.
: 0,40 / ( ), 0,05 / ( ),
27,28 / ( ), 0,24 / ( ),
6,9 -/ ( ),
2,86 2/ ( 2 2/ ).
. a ( 0,3 /) , , , - ,
, , .
, , .
. -/ (= / .),
(1 / = 2,804 . ), (1 / =
= 5,005 . ), (1 / = 50,050 . ).
3,03,5 -/.
, , (, ), , ,
, .
. (
1,5 /) .
,
0,71,5 /.
(
5 2/, , , (n4), ),
(, , , , , , , )
( (2+), , ).
413
, , 2010, 4
, , , ,
, . , 2 2/,
.
, , , , , .
, ,
. . ,
.
(3% 1984 .
. ),
(30% . 2009 .).
[1] .. . ., 2009.
236 .
[2] .. . ., 2005. 230 .
[3] .., .. . .: , 2001. 32 .
[4] .. (, , ): . ... . . . , 2002.
[5] William V., Messer L.B., Burrow M.F. Molar Incisor Hypomineralization: Review and Recommendations for Clinical Management // Pediatric Dentistry. 2007. 28:3 P. 224232.
414
.., .. ...
[6] Rogan W.J., Brady M.T. and the Committee on Environmental Health, and the Committee on
Infectious Diseases Drinking Water From Private Wells and Risks to Children // Pediatrics.
2009. 123. P. 11231137.
[7] Lygidakis N.A., Dimou G., Marinou D. Molar Incisor Hypomineralisation (MIH). A retrospective clinical study in Greek children. II. Possible medical aetiological factors // European
Archives of Paediatric Dentistry. 2008. 9 (4). P. 207217.
[8] .. . ., 1998.
.. , ..
. -, 8, , , 117198
.. ., .. , ..
. , 8, , , 125315
, , . ,
, , .
: , , -, , , , .
, ,
, , . ,
, ,
[6]. ,
.
, .
.
38 ( 22 16) 19 25 :
(..) 18 , () 20.
CPITN,
[5]. , ,
.
416
.. . ...
CPITN 6 (). : , , , 45 , 6 .
() , - (, , , ) [2, 3].
. () , ,
. Statistica 6.
. ,
.
70% 72,2%
.. (. 1). . : 27,8% ..
30% .
1
(%)
..
27,8%
30%
16,7%
45%
50%
25%
, 45
5,5%
0%
, 6
0%
0%
, , ( CPITN). , (. 2), ,
1,6 , , .. 0,5 .
2
( )
..
4,6
3,9
0,5
1,6
0,8
0,5
, 45
0,1
0
, 6
0
0
-
( 400 ) ,
(. 1).
417
, , 2010, 4
. 1. ,
(..) (..)
400 5067
[4].
-
(. 2), ,
.
. 2. ,
() ()
, ,
..
.
418
.. . ...
,
(, .).
, , , .
[1] .., .. /
: . . .: - , 1987. 166 .
[2] .., .., .., .. . : , 1987. 256 .
[3] .., .. .
: , 2002. 397 .
[4] ., ., . . // Cathedra. 2006. . 5. 3. . 4649.
[5] .. . .: -,
2001. 216 .
[6] Klokkevold P.R. Risk Factors // J Calif Dent Assn. 1999. 27 (2). P. 135142.
PROPHYLACTIC DENTAL
CHECK0UP WITH ADDITIONAL USE
OF LASER CORRELATION SPECTROSCOPY
R.S. Prosvetov, V.I. Torshin
Department of normal physiology
Medicine faculty
Russian Friendship People's University
Miklukho-Maclay str., 8, Moscow, Russia, 117198
419
..
2
. , 85, , , 308015
.. , .. , ..
. , 3, -, , 197110
..
. . , 50, , , 308000
- . .
: , .
-
[1, 2].
- .
: 1582 , - .
. 32,2 2,7% , .
,
, > 0,05. ( > 0,05)
(25,1 2,5%),
(18,3 2,2%).
(29,3 2,6%), < 0,05. , (12,4 1,9% ) , < 0,05. (27,3 2,5%), (31,4 2,6%).
34 : 79,3 2,3% , 68,1 2,6%, 79,2 2,3%.
420
.. .
, 12 :
17,3 2,2%, 29,0 2,6%, 21,1
2,3%. , , 5
6 (1,7 0,7%).
. 41,7 2,8% 6 10
, 52,1 2,9% 11 15.
.
6 15 (11,2 3,2 ) . 6 10
36,1 2,8%, 11 15 57,9 3,1%. , , , . , 6 10 18,5 2,2% , 11
15 53,5 2,8%, 16 20 21,0 2,3%.
,
. 12,1 1,9% , ; 9,2 1,7% ; 7,3 1,5%
; 6,2 1,4% .
37,5 2,8% .
9,2 1,6%
, 7,1 1,5% , , .
12,3 1,9%
, 11,4 1,8% , 8,1 1,5%
. 52,2 2,9% , 42,4 2,8%.
.
, . , - , .
, .
421
, , 2010, 4
N.. Kunitsyna
Medical Centre Pokolenije
Khmelnitskogo ave., 50, Belgorod, Russia, 3221042
In modern medicine the physiotherapy is one of the main methods o treatment and rehabilitation.
This problem in elders is presented in this article.
Key words: elders, non-drug treatment.
*
.. , .. ,
.. , ..
,
. , 4, , , 614990
. . , .
: , .
,
(),
.
. - , .
Zn2+, Cr3+, V4+ .
[1]. V4+ .
() [2]. ,
,
, - ,
() .
.
, 12
. 2 : 1 ( 1). 34 , ,
. - . .
* ( 08-03-00488).
423
, , 2010, 4
1
14
180280 .
170 /. 50 / 2% . 2% . [3].
(), 50 /. . 1.
1
,
/
1
1
50
50
, %
30
120
0,0
4,4
7,2
+11,9
,
/
3
3
50
50
, %
30
120
2,7
17,2
1 2
19,7* *
40,0**
50
20,5*
30,4*
50
32,9*
**
1
42,8**
50
7,4
***
10,2
2
2
50
50
3,8
8,6
9,4
8,0
2
2
50
50
6,6
+2,6
10,3
50
41,1***
19,2*
1
**2
69,3***
50
4
4
50
50
4
4
50
50
9,4**
7,5
48,8*
16,7
38,4**
13,0
12,8
69,0**
23,8
60,2**
, 16 5
, . , , .
( 4).
, 3.
424
.. . ...
, .
.. , ..
. , 10/1, , , 603005
.
: ,
, .
,
, , , .
, , . , , . .. , .. .
: -, , ,
; -, - - [1].
- .
, ,
- . ,
. ,
, . , - ,
,
, , , . , , -
426
.., .. ...
, .
, , ,
.
, ,
,
. .
1128 , 62%
38% . , : 24 ; 25 45 ; 46 60 .
, .
: 11% , 41% , 23% , 25% , .
, , (78,7% ) ,
- , . :
? 65,6% ; 15,1%
; 10,2% ,
;
6,7%
; 2,4% , , . : ?
37,6% .
, 38,8% , ,
,
.
: , ? ,
41,3% , . , , 52,7%
, 45,2% , 34,6% 27,5% , 27,1%
,
9,4% , 5,8% -
427
, , 2010, 4
, 2,3% ( , 100,0%).
,
, ,
, .
0
.. , .. ,
..
. , 46, ,
- () . , ,
, - .
: - , ,
.
- (), , .
.
, , , , . , , , ,
[1, 2].
. .
6 . ( 2009 .
2010 .) . .
: , , , .
.
1086 .
(75,6%), (24,4%), ! (20,73%),
(4,88%) (2,44%). , ,
30 (92,24%), 81,24% .
, 50% . ,
[3]. -
429
, , 2010, 4
(87,7%) , , ,
, .
, , - ,
-
. (45,29%) , , 592 (54,71%) ,
.
,
- 5,82% . .
,
.
,
. ,
: Vichy (92,7%), Lierac (70,15%), Bioderma (66,64%), La-Roshe (59,43%) Ducray (8,87%), Avene
(6,93%) Galenik (6,01%).
. 005-93
( 91 5800 ) : (, , , ),
, [3].
. , .
. , - : .
[1] Rivers J.K. The Role of Cosmeceuticals in Antiaging Therapy // Skin Therapy Letter.
2008. 13.
[2] . -
: . . ... . . . ., 2009. 29 .
[3] 005-93 (. 30.12.1993 301.
430
..
. , 11, , , 357538
- .
: , , .
(, , , , , , ) [1].
- . [2].
- .
.
, 2
.. ().
,
3[2-[4-(6--1,2--3-)]]-6,7,8,9--2--4-[1,2-]-4-.
( = 910).
:
, 10 , = 910.
10 .
. , 5 95%. 2,5
50 95% .
200300 1 . . 1.
238 2 , 275 2 , 282 2 253 2 .
. -
432
.. ...
.
: , , .
. 1.
. 1.
1
2
( i )
2,013
0,022
0,000484
2,001
0,034
0,001156
2,012
0,023
0,000529
2,044
0,009
0,000081
2,055
0,020
0,000400
2,083
0,048
0,002304
= 2,04
S = 0,0129
= 1,74%
SD = 0,032
RSD = 1,55%
3%.
, 1,74%.
1,50. t < t(P, f), .
- , .
. 2.
433
, , 2010, 4
2
, /
0,002
0,00015
0,306
0,001
0,0002
0,402
0,002
0,00025
0,499
0,003
0,0003
0,599
0,001
0,00035
0,699
0,001
0,0004
0,741
SD = 0,032
S = 1740
LOQ = 0,00018 /
,
0,00018 / .
(. 2).
. 2.
(/)
,
0,00020,00035 /.
,
- .
[1] Cambell M., Young P.I., Smith J.M., Thomas S.H.L. The use of atypical antipsychotics in the
management of schiizophrenia // British Journal of Clinical Pharmacology. 2000. 6.
P. 432438.
434
.. ...
DEVELOPMENT SPECTROFOTOMETRIC
OF THE TECHNIQUE OF ANALYSIS RISPERIDON
IN TABLETS AND IT VALIDATION
I.P. Remezova
Faculty of toxicological chemistry
Pyatigorsk state pharmaceutical academy
Kalinin rosp., 11, Pyatigorsk, Russia, 357538
For development of the circuit of the toxicological analysis risperidon the technique of its definition in tablets is offered spectrofotometric and carried out it validation.
Key words: atypical antipsychotics, spectrofotometric the analysis, risperidon.
..
, 8/5, , , 113093
,
-
.
: , , .
,
, . .
(7090 )
. , : , , ,
, .
, .
- .
( ).
() [1].
,
. ,
, , .
, , , , , , , -
436
.. ...
. ,
: -,
, , ;
-, ,
(.. ); -, , , , ,
; ,
, , , , , ,
, , ,
, , .
. ,
( ) , ,
.
, ,
. , ,
; , , . , - .
,
? , ! ,
, , , ,
. , ..
, , .
.
. ,
- ,
, /.
, ,
, ,
. ,
, , .
437
, , 2010, 4
,
. , , .
- .
, , , , - -
, [2]. , ,
, .. .. . , -
.
, ,
.. , . , . , .. , . , .. , .. , .. , .. . .. ,
,
. - [3].
(). 2000 - (. ),
: (). ,
, .
.
2006
.
.
:
II
;
438
.. ...
II III ;
V (96 ..) .
, ,
.
[1] .. //
. 2008. 44. 83 .
[2] .. XXI //
. .: , 2008. . 1. . 11.
[3] .. . : . .: , 2000. 343 .
.. , ..
. , 106, , , 620049
..
-
. , 12, , , 620012
, .
: , , , .
, , , . , , 6 ,
1517 , 94,5% , , , 30% [1].
( , ,
) ,
,
,
,
[3].
,
,
.
,
.
, ,
.
.
90 (. )
440
45 , (. ) 45 ,
, 40 50 .
SPSS 11.5 for Windows Statistica 6,0.
. 1.
1
(%)
(%)
40
64,3*
40
50
60
28,5*
30
71,4*
50
57,1
50
28,5*
10
0
(%)
(%)
70
45,5*
40
63,6*
40
27,3*
30
27,3
70
72,7
30
45,4*
0
9,1
: * p < 0,05.
- .. [2]:
, , , . ,
,
, ,
, , ,
, , .
: : (),
.
,
. , 71,4% , 30% ,
64,3% 40% .
60%, 50% ,
28,5% , , .
(70%) (40%),
441
, , 2010, 4
45,5%
27,3% . . ,
40% 27,3% ,
30% 45,4% , , , .
, , , , ,
- ,
.
.
[1] .. . : , 1991.
90 .
[2] .. : . ... . . . ., 2002. 196 .
[3] ..
: . ... . . . , 2002. 181 .
L.A. Sarapultseva
Chair of life safety
Russian State Professional-Pedagogical University
Mashinostroiteley str., 12, Ekaterinburg, Russia, 620012
Research objective was the definition of main goals and incentive motives to conducting a healthy
way of life among pupils of graduation classes, taking into account their gender and a geographical arrangement of an educational institution.
Key words: healthy way of life, school, pupils, graduation classes.
442
..
. , 2, , , 614990
. . .
.
: , .
.
, [1].
, [2, 3], ,
. , - , ,
.
,
. ,
, .
.
.
( , .). ,
, . 24 558.
443
, , 2010, 4
, , .
(146 .), (164 .) (164 .) .
(73%) , . (
) 58%
,
(61% 59% ) . (80% 85% ) (80%) . , ,
(62%), (70%).
. , ,
, ,
.
:
; , ;
;
;
;
;
;
;
;
;
;
, ;
, ;
.
.. .. [2].
, . HTML HTML. HTML- (.).
HTML-.
.
927 .
444
.. ...
. .
, . .
54 .
, 20 . , , .
21 . , , 18 .
3,1, 4,3.
(K) :
a
K =
,
a ; .
445
, , 2010, 4
0,63, 0,78.
, , , .
, . , ,
. , (94%), (76%).
, .
74%
, : ; ; .
.
446
0
,
.. , ..
. , 2, , , 614990
- ()
, . .
.
: , ,
- , , ,
, .
() .
. ,
.
-
() [1].
, 3 .
: .
,
, , , , ; ; , .
,
, , , , , , , .
Microsoft Power Point :
1. (32 ).
2. (40 ).
3. (62 ).
447
, , 2010, 4
. ,
, .
-,
. 23 , .
, , , .
23 ,
. .
Google Groups.
http://groups.google.com/group/farmhimia.
, .
.
3 ,
,
.
, ,
.
, 17,4% ,
47,8% , 34,8% .
,
, . ,
. : ,
, ,
.
,
. : , 3,03,5;
448
3,54,5; 4,55,0.
.
10 , , - , , ,
. (), [2]:
= /,
, .
.
(. 1).
, , ,
.
. 1.
. .
[1] : , , / .
.. . .: , 2003. 508 .
[2] .. . ., 1995. 336 .
449
, , 2010, 4
.. , ..
,
. , 54, , , 625023
..
. , 54, , , 625023
..
,
-
., 76-, , , 123007
, ,
. 1 3 .
: , , .
3 , [1, 3, 5,
6, 7, 8].
,
, , , ,
, , .
. .
5% [7, 8].
, , , [2, 4].
. ( 65 95%)
.
451
, , 2010, 4
: ,
[3, 4, 7, 8].
[2, 4, 9]. ,
.
.
.
40 , . , 25 (62,5%) 15 (37,5%) .
:
IIIII 5% ;
1 3 ;
3 ;
(
, ..), ;
;
100% .
.. .. 3 . ,
[7, 10].
1- 14 IIIII , 5
15% ( ), 8 (60,5%) 6 (39,5%) .
2- 13 IIIII 16
29% ( ), 8 (60,5%) 5 (39,5%) .
3- 13 IIIII
30% ( ), 9 (69,2%) 4 (30,8%)
.
,
: ,
, , .
- . , 37- ,
452
.. .
.
( Beckman Coulter, ) Epics
XL ( Beckman Coulter, ): CD3 ( -); CD4 (- -); CD8 (- -); CD19 (-), ( CD4/CD8).
, , G
TURBOX plus ( Orion Corporation Orion Diagnostica, ).
.
. [9].
IBM/PC
(SPSS-11,5 for Windows).
U- . m ( ). (), 0,05
( < 0,05).
.
,
( 3 7- )
. . 1, , CD3, CD4, CD8 CD19
( ). , , CD3 CD4
5 15% . 16 29% 30% CD3 CD4
( < 0,05).
( < 0,05) CD8, , ,
: ,
CD8 (),
.
CD19 . 5 15% CD19 ( < 0,05)
2 . 15 29% 30% D19 .
453
, , 2010, 4
1
( m)
.
.
1
(n = 14)
2
(n = 13)
3
(n = 13)
10,43 1,01*
9,36 0,82
12,41 2,22
7,57 0,29
4,04 0,46
2,54 0,21*
2,53 0,45*
3,7 0,23
2,29 0,36
1,46 0,14*
1,28 0,27*
2,0 0,14
10 /
CD3
10 /
CD4
CD8
CD19
Ig
9
10
10 /
1,28 0,25
0,76 0,1
0,56 0,11*
1,15 0,23
0,43 0,12*
0,29 0,06*
0,24 0,08*
0,76 0,08
3,8 0,7
3,9 0,7
4,1 1,4
1,5 2,5
10 /
/
1,04 0,2 *
0,58 0,07
0,52 0,14
0,43 0,05
0,43 0,02*
0,76 0,12
0,65 0,12
0,63 0,11
Ig M
1,04 0,15
1,48 0,41
1,62 0,26*
0,90 0,17
Ig G
6,45 0,8
5,76 0,48*
4,37 0,47*
8,56 0,57
10 /
10 /
.
: * (p < 0,05) .
.
, . 1,
, G. Ig
. 30% Ig ( < 0,05). ,
.
Ig G, ,
. ( < 0,05) Ig G 2 3- .
1- ( < 0,05)
Ig A.
. ,
. ,
, .
,
CD3, CD4, CD8, CD4/CD8 Ig M,
.
, 84,6% 30%
.
,
. 1 3
.
454
.. .
[1] .., ..
: . . . II . ., 2008. . 35.
[2] .., .., . . // . . . 2006. 6. . 5354.
[3] .., .., .. .
: , // . 2004. 4. . 5154.
[4] .., .., .. . ,
: . , 2000. 18 .
[5] .
. , 2008. 39 .
[6] .., .. / . . .: , 1990. 512 .
[7] .. . , 1997. 207 .
[8] .., .., .. : .
.: , 2000. 480 .
[9] .., .., .. . .
: - . . . ., 1997. 352 .
IMMUNOLOGICHESKY INFRINGEMENTS
AT CHILDREN DURING THE SHARP PERIOD OF BURN ILLNESS
S.P. Saharov, V.V. Ivanov, O.V.Ananeva
Tyumen state medical academy Roszdrava
Odessa str., 54, Tyumen, Russia, 625023
V.N. Ananev
Institute of medical and biologic problems
Russian Academy of Sciences
Horoshevsky highway, Moscow, Russia, 123007
The immunodeficiency of a cellular link of the immunity which expressiveness is in direct dependence on weight of a current of a burn shock and the area of the amazed surface of a body develops
in the sharp period of burn illness at children, that, or their combination as a result leads to sepsis and
pneumonia development. The indication in appointment immunoreplaceable an immunostimulating
therapy for preventive maintenance and treatment of infectious complications are children at the age
from 1 year till 3 years with a heavy burn shock and infringements in a cellular link of immune system.
Key words: burn illness, children, immunity.
455
,
,
..
. 339 , 14, --, , 344015
..
1
. 339 , 14, --, , 344015
, . - . , .
: , , , , , .
456
.., .. ...
: () 29 ,
1 , () 4 ,
3 , 4 ,
() 3 .
44 , 3 17 (), 1991 .
8 . / 1,0 (22/22).
111 , 3 . 1-
25 : ,
, , . 2-
10 : , , . 3-
76 (,
, ), 2 1
.
,
4 .
1- 14 (, , ), 20062010 . -
. 2 1-
-23 ( , ).
2- 11 ( , , ), 20062009 .
- , . .
3- 17 , 2006 , .. .
2 ,
- .
4- 2 ,
2006 , ,
.
, 36,4% ,
; . , 1-
100%, 3- 11,8%. 100%- 2- 4- , -
457
, , 2010, 4
, ;
,
.
E.V. Polevichenko
Department of pediatrics 1
Rostov State Medical University
339 Shooting Divisions str., 14, Rostov-on-Don, Russia, 344015
The characteristic of the hospital register of children with asplenia, living in the Rostov region is
presented. The differences in prophylectic of a pneumococcal infection at children of various clinical
groups have been established.
Key words: pneumococcal infection, asplenia, register.
.. , .. ,
.. , ..
-
. , 85, , , 308015
..
. , 27, , , 211440
(NSE)
. .
: , , .
,
.
[1, 2]. , , H. Kubesova (, , ) , - (NSE) . ,
-
NSE , . 48 [3].
NSE
.
. 104 . 56 60
64 ( 62,3 0,9 ), 48
, , 4 1 -
; 2 , () 1- 2- ; 3 ,
() IIII
459
, , 2010, 4
( ); 4
1- 2- IIII .
NSE , . 1.
1
NSE
NSE, /
(M m)
69,4 3,3
(M m)
1
2
3
4
+
,#
,#
93,6 2,7*
94,9 3,5*
136,1 2,1*
142,2 3,7*
: * p < 0,05 ;
1 2.
p < 0,05
NSE 69,4
3,3 /, , ,
93,6 2,7 / (p < 0,05).
NSE , 94,9 3,5 / (p < 0,05). NSE
136,1 2,1 / (p < 0,05).
NSE ,
142,2 3,7 / (p < 0,05).
(
) ( )
,
- .
1. NSE.
2. : NSE , , .
[1] .. // : . , 2008. . 5.
[2] .., .. . .: , 2008. 788 .
[3] Kubesova H. Akutni stavi v geriatrii. Praha: Galen, 2009. S. 7.
460
.. . ...
A.N. Ilnitski
Department of Medicak Rehabilitation
Polotsk State University
Blokhina str., 27, Polotsk, Russia, 211440
The problem of correlation between polymorbidity and neuronspecific enolase is presented in this
article.
Key words: neuronspecific enolase, elder, polymorbidity.
.. , ..
. , 3, , , 450077
19982008 . ( 57,9%)
( 43,5%)
( 69,0%).
.
: , , .
. , , [2, 4].
, [1, 3]. ()
19982008 . ,
() - () .
, ,
, . .
57,9% 16,9 1000 1998 . 7,1 2008 .
,
69,0% ( 8,4 1998 . 2008 .) (. 1).
(p = 0,8, = 0,002).
,
, 47,7% (8,6 1998 . 4,5
2008 . 1000 ). 50,3% 60,2%.
(r = 0,8, = 0,002). , 2008 . 84,0%.
462
.., .. ...
. 1.
1000
1000 19982008 .
, ,
. 1998
2008 . 45,3% ( 17,2 9,4 1000 ).
(r = 0,66, = 0,03) (r = 0,74, = 0,009),
(r = 0,6, = 0,04).
,
(. 2). , 19982008 . 54,2% ( 10,7
4,9 1000 ),
35,3% ( 6,5 4,2 1000 ),
, , 8,9% ( 37,8
46,7%).
. 2.
19982008 . (%)
463
, , 2010, 4
: ( 49,6%),
( 51,5%) ( 52,1%).
,
92,3% ( 5,2 0,4 10 000 ).
. , 20 . 19982008 . 8,96% ( 6,7 6,1 10 000 ).
, ,
, 47,7 1998 . 44,6%
2008 ., , , 25,1% 2008 ., .
12,5 11,1%.
( 3,9% 6,5%). 1998
2008 . 3,0 5,1%, 2008 . 0,4%. 19982008 .
(2 = 13,3, = 0,01).
, 19982008 .
( 57,9%) ( 43,5%) . ,
, ..
, . ,
,
, , .
- .
464
.., .. ...
.. , ..
. , 1, , , 400131
() () () ,
. .
: , , , .
() .
- [1, 2]. ,
,
[3].
.
: 2004 2009 .
. 683 , 2009 . 2004 .
.
8000 .
/.
, ,
. , ,
(-DDD ) [4]. DDD/100 -. DDD
[5].
466
.., .. ...
467
, , 2010, 4
..
- ...
. , 173, , , 360004
50 . 15 . 500 25- . ( 50 200 ) .
: , .
, , , (
, , , ..). , , , .
, , [4],
[2]. [3] .
.
. 1 . . ,
.
50 , 40
55 (47,08 10,19) 13 30 (17,73 6,06). : , , . 1,0, .
. 5
5 . ( 100 ) ( 500 ).
( 50 200 ).
469
, , 2010, 4
( 2269921) [1], .
. .
()
2
50
200
0
0
0
0
(.)
6
10
15
0,32
0,24
0,54
0,24
0,88
0,28
0,52
0,24
0,96
0,28
1,16
0,22
20
1,12
1,42
0,22
0,18
( = 50 ) 0 ().
5 ., 6 . , 20 .
1,12 0,22, 25- . . = 200
, 25- .
. 500 , ,
15 .
.
25- .
470
( )
..
. , 28, , , 214019
. ,
12,3 .
: , .
, (, , , ), [2, 4]. ,
[1, 3, 5]. ,
.
1995 2008 . 68 : 37 (54,4%) 31
(45,6%). 2039 (78%)
(75,4%). 48 ,
32; 6; 6; 1 .
- 23 ,
12 ( ),
15- , 2 , 8 . 75% , , , , ,
, . 25%
.
4 . -
2 , 22- , 37- . 6 7 .
, , ,
471
, , 2010, 4
2 8; 34,5 5,2 .
, , - . ,
.
, . , , , .
. ., 30 , , , .
, , , , 1,52 17 .
. , , ?. , . :
, , - IIIII . : 4 N 0, St III, . . II.
() : 4+. - ().
- , ,
. . :
- 4+; - 4+4+, 1 : 160; 4+. :
8 .
7 . . , : 6 , .
, ,
: 6
(). 2,4 N 3 . 38,5 .
, 4+4+ ( 1 : 20).
,
. :
, . :
, .
( ) -
472
.. ...
. , , , .
.
,
.
4 . , , , .
, [2, 4].
. ., 54 . . 9 : 40 . . 2 .
, . : ,
, , , . , , , , . : 3,3 /,
2040 , . 8,61012/, 61 /.
. 4+, 4+ ( 1 : 40). : 6 (). . . .
18- , 9- .
(
, , ) .
,
. .
.
473
, , 2010, 4
()
.
12,3 . .
.. , .. ,
.. , ..
. , 2, , , 614990
. .
: , ,
.
. ,
, , : ,
.. , , [1].
.
() ,
() , , ,
- .
,
.
,
, .
2003 [2].
, 2003 2009 17
48 , .
, , , , .
:
.
( , , ).
475
, , 2010, 4
(.),
.
.
()
1 : 200 000, .
:
1. , . .
2. , .
, , , ,
.
, ,
, .
476
.. .
[1] : 2 . . 1. . / .. ,
.. , .. .; . .. . .: , 2004.
352 ., [16] . . .: .
[2] .. / .. , .. , .. , .. // / 15: :
. . 2: , , 29 5
2009 . , 2009. . 563569.
.. , ..
, ,
. 9 , 5, , , 625016
. ,
.
: , , .
, ,
. . , , , . .
. , , .
, .
. .
.
. , 56 .
. : 1 ,
; 2 , . : ( ) ( ).
.. .. -
478
.., .. ...
, , ,
, . -
, .. , .. , .. , .. , .. , .. .
. - ;
, -
, , ; () ; ,
, , 2, 34 , , . . ;
. , 34 , .
, .. . ,
1- , : 80%, 92%,
2- 2%. 1
.
, .
1- 40% 84% . 2-
9%. 1-
. , , , , .
, 1
. 1- 71%,
50%.
,
, ,
. ,
479
, , 2010, 4
, , .
1- ,
, . , .
. , ,
70%
,
.
.
In this work the results of studying of speech breathing in preschool-age children with pseudobulbar
disartria were showed, with using of special breathing methods. The positive influence of speech breathing
formation was exposed, both as on the development of speech, and as on the child person in all.
Key words: speech therapy, speech breathing, pseudobulbar disartria.
..
. , 2, , , 614990
.. , ..
. , 2, , , 614990
- . .
, .
: , , ,
-.
,
, ,
[1]. , ,
, [2].
. -
, , ,
. , , , , .
.
, -
.
.
481
, , 2010, 4
. ,
. 123 , :
, , () ,
. 97% , 3% .
25 60 , 1 30 . 48%
( ) , 8% , 39%
-, 7% ( )
() , 7% -,
6% , .
93% , .
(93% ), (92%), (86%),
(73%) . ,
52% , 64%.
84% .
,
, (. 1). , ,
. ( 25%) ,
(. 2). 95% ,
-, 87% ,
.
,
, :
;
;
;
.
.
, .
482
. 1.
. 2.
127
66 ( 23 ) . HTML
.
, .
.
483
, , 2010, 4
, . , ,
, .
, .
,
, , . , .
:
n
ti
t =
i =1
ti i- ; n .
17 . (
,
8 .); 30 . ( 6 .).
(W) :
W=
30 17
*100% = 43%.
30
, 43%.
. , , , . ,
, -. ,
-, .
, .
484
0
.. , .. ,
.. , ..
. , 85, , , 308015
.
: , , .
, . , . ,
10 79% ,
, [1].
. ,
. ,
. ,
[2, 3, 4, 5, 6].
. .
.
482 (
12 ). 199
283 60 74 ,
64, 5 2,3 . 22 ( ,
). - p.
. . 1 - .
486
.. . - ...
1
0
()
...
3
...
...
9
...
16
17
18
...
...
.
...
> 7,0 /
...
.
...
2 .
.
1 .
...
p
...
0,0002
...
0,0009
...
0,0012
...
0,0023
0,0029
0,0041
...
. ,
, , .
.
487
, , 2010, 4
.. , ..
. . ..
. , 26, , , 614000
..
. . ..
. , 26, , , 614000
..
. . ..
. , 26, , , 614000
189
20012003 . 20082009 . , . .
: , , .
- ,
[1], , [4], .
(). , , .
.
: 189 , 1 2 : 20012003 . (131 )
20082009 . (58 ). : 51,9% 48,1%
58,6% 41,4% .
1617 (73%).
- : ; ; ;
IgG () (); --
489
, , 2010, 4
, .
.
() (63,8%), (43,5%) ( = 0,016).
(63,8% ,
51,9%). 17,6% ( 10,3%). 9,2%
5,2% , . (20,7%), [2]. ,
- .
(60,3%)
(29,0%, < 0,05). (48,3%)
: , , , ,
, 17,3%
10,3%.
(24,1%). , , .
,
65,5% (38/58) 62,6% (82/131), , 44,7% 63,4%, ( > 0,05). (21% 25,2%). , .
22,4% (13/58) . () 38,5% (5/13).
(76,9%)
. 16,7% (2/12)
4,6 .
20012003 . 32,1%, 18,3%. , , , .
(78,8%, 43/56), (63,4%, 18/28) . 60,5% (26/43) 39% (7/18) .
490
.. .
1. , .
2.
.
3. .
4. ,
, -, , , .
491
, , 2010, 4
[3] .. : . ... - .
. , 2004. 250 .
[4] .. ,
: . ... - . . ., 2009. 294 .
PULMONARY TUBERCULOSIS
IN ADOLESCENTS IN MODERN CONDITIONS
J.A. Shabalina, A.A. Shurygin
Department of Phthisiopulmonology
Perm State Academy of Medicine n.a. cad. E.A.Wagner
Petropavlovskaya str., 26, Perm, Russia, 614990
I.I. Lvova
Department of Children Infectious Diseases
Perm State Academy of Medicine n.a. cad. E.A.Wagner
Petropavlovskaya str., 26, Perm, Russia, 614990
A.A. Varankina
Department of Phthisiopulmonology
Perm State Academy of Medicine n.a. cad. E.A.Wagner
Petropavlovskaya str., 26, Perm, Russia, 614990
Comparative analysis of pulmonary tuberculosis peculiarities in 189 adolescents of Perm region
was carried out in 20012002 and 20082009. It was established that fluorography is the most efficient method of tuberculosis reveal. The most frequent clinical form is infiltrative tuberculosis on the
background of opportunistic infections activation with bacterial emission and growth of multiple drug
tolerance of tuberculosis agent.
Key words: tuberculosis, adolescents, opportunistic infections.
0
.. , .. , .. ,
.. , ..
-
. , 95, , , 690022
- , .
- . , .
: , - .
- .
, , , , , .
(, ,
, , , .)
- . -
, ,
,
. , - , . .
, (, , ..).
160 . ,
.
(), , , , ..
( ) .
493
, , 2010, 4
, ( ) .
.
.
,
,
840 30 0,1 , 160 .
, (
) , 32 ( 32 ) (. 1).
(Fn)
. c 27,0 0,13 .
(),
[1].
. 1.
,
( ) .
[2] -
494
.. . - ...
, .
- .
1 ; F1-F7
. F1-F7;
32 , .
.
, , .
.
, , .
:
F1-3 (21,611,1 ) - ;
F1-4 (15,012,7 ) -2-
;
F1-5 (16,28,33 ) D2- ;
F2-1 (11,3510,12 ) -1-
;
F2-4 (9,454,86 ) - ;
F3-1 (6,753,47 ) D1- ;
F3-3 (5,42,77 ) - ;
F4-5 (2,021,04 ) ;
F6-1 (0,630,71 ) M2- ;
F6-4 (0.360,33 ) 3- ;
F7-1 (0,420,22 ) 3- .
-
, . ,
5 160 . . ,
495
, , 2010, 4
.
[3].
.
..
. , 3, , , 450000
() (). ,
(), ()
. 2013 . , , . 2013 50,0%.
: , , .
497
, , 2010, 4
(. 1). , . ,
2013 . 3515,0 ( 2008 . 11,6%), 3725,1 ( 7,0%), 3917,7
( 17,4%).
1
20012013 ., 100 .
2001
2158,4
2173,4
2087,5
4653,3
4909,8
4686,9
2002
2493,5
2488,9
2664,1
5125,7
5285,2
5535,9
2003
2569,8
2595,7
2697,1
5269,0
5508,5
5479,7
2004
2821,0
2881,9
2798,9
5548,5
5790,2
5603,7
2005
2961,7
3144,5
2982,9
5706,5
6139,1
6086,6
2006
3073,5
3313,6
3419,9
5842,1
6413,5
6282,8
2007
3128,7
3347,1
3598,4
5927,7
6512,7
6484,4
2008
3149,2
3479,5
3335,7
5914,0
6615,8
6124,6
2009
3277,8
3556,4
3586,7
6077,1
6722,8
6528,8
2010
3344,0
3613,7
3678,6
6153,8
6834,3
6625,8
2011
3405,2
3659,1
3763,7
6224,0
6936,6
6714,8
2012
3461,9
3695,5
3843,1
6288,8
7031,4
6797,1
2013
3515,0
3725,1
3917,7
6349,0
7119,8
6873,7
12 4 .
, 20012008 . , . ( 14,8%)
( 25,9%).
20012008 . ( 10,9%), ( 35,2%), (23,5%).
2008 . 12,3%, 28,3%.
(. 2).
.
,
. 20012008 . 4653,3
5914,0 100 . ( 27,0%), 4909,8 6615,8 ( 34,7%),
4686,9 6124,6 ( 30,7%).
,
, .
498
.. ...
2
(014 ) 2008 , %
100,0
100,0
100,0
100,0
100,0
100,0
15,8
35,1
12,3
33,9
16,4
23,6
0,1
0,1
0,1
0,1
0,1
0,2
0,4
0,2
0,4
0,2
0,4
4,6
4,1
28,3
3,7
5,4
26,2
79,3
60,3
59,2
61,9
77,9
49,7
, ( 3,5%).
2013 . 6349,0
( 2008 . 7,4%), 7119,8 ( 7,6%), 6873,7
( 12,2%) (. 1).
,
( 9,1%), ( 35,2%), ( 23,5%). ( 42,8%).
34,6%
23,6%. , 24,0% 26,2%, (20042005 .) 30,0%.
, 20012008 . .
. .
[1] .. // . .
2005. . 4. . 1014.
[2]
2004 . // . . 2006. 4. . 332.
[3] .. //
. 1994. 1. . 2628.
[4] .. - / .. , .. , .. [ .] // . 1997. 3. . 7075.
[5] .., .. - . .: , 2002. 266 .
499
, , 2010, 4
.. , .. ,
..
. . ..
., 26, , , 614000
140 121 , 19. ,
() 0,52, .
: , , , .
140 : 81 () 40 ,
(I II ), 19
(III ). -
39 (32,2%) . 82 (67,8%) (48 (59,3%)
I 34 (85%) II)
(44 (36,4%)), 23 (19%), () 19 (15,7%) () 42 (34,7%) .
46 (56,1%), 36 (43,9%) .
44 (36,4%) 23 (19%) ( 18 (11,6%); 5 (4,1%)).
()
41,22 4,94 /, III 13,77 4,09 / ( < 0,05).
,
35 / [1, 2], 83,3%, 100%,
89,7%.
42 (50,0%) 84 10
III . 23 (27,4%) , 19 (22,6%) .
I, II III : 2,18 0,73,
2,87 0,94 2,49 1,52 / , .
, I II (), ( < 0,05)
501
, , 2010, 4
.
I
II 1,20 0,54 / 1,18 1,10 / . 2,67 1,05 / 2,56 0,93 /
. ,
, :
(r = 0,655; = 0,01). ,
(), :
= / .
0,83 0,20 / ( < 0,05): I
0,66 0,15 / ( < 0,05), II 1,07 0,44 / ( < 0,05). III
0,20 0,06 / ( < 0,05). , 0,52, 64%, 100%,
94,1%.
, , 0,52 , ,
.
502
.. , .. ,
..
. , 48, , , 614990
, , , .
: , .
, , , . (medical
gas) ,
,
. , GMP, .
, , ,
. -
GMP III. 52249-2004
, .
,
52249-2004, Rules Governing Medicinal Products in European Union. Volume 4. EU
Guidelines to Good Manufacturing Practice Medicinal Products for Human and Veterinary Use (, . 4.
),
, . 1. , , .
503
, , 2010, 4
1
,
522492004
(cylinder)
150 ,
(gas) ,
1,013 (101,325 )
15
50
3 (300 ) 50
(ISO 10286: 1996 Gas cylinders Terminology.
Bilingual edition)
(area) ,
(container) ,
, , ,
,
(cryogenic gas) ,
1,013
150
(cryogenic vessel)
(maximum theoretical residual
impurity)
.
.
,
(bulk gas) ,
,
(blowing down)
(compressed gas) ,
50 (ISO
10286)
(liquified gas) ,
( )
50
504
(cylinder) ,
.
150 ( ).
( )
(gas) ,
1,013 (101,325 ) 15
3 (300
) 50 (ISO 10286).
(area) ,
(container) ,
, , ,
,
(cryogenic gas) ,
1,013 150
(cryogenic vessel)
1. ,
.
2.
,
.
(maximum theoretical residual impu
rity) ,
.
,
(bulk gas)
,
,
(blowing down)
(compressed gas) ,
50
(ISO 10286)
(liquified gas) ,
( )
50
.., .., ..
522492004
(air separa
tion plant)
, ,
, ,
. ,
(tanker) ,
(air
separation plant)
(,
)
, , ,
(tanker) ,
,
: (valve) (minimum pressure retention valve) , , ( 35 ).
(manifold), :
,
, ,
.
(purge),
, , , .
. ,
: ,
/ I2I. , , . .
,
. GMP
.
; . ,
. , , .
; -
505
, , 2010, 4
.
, , ..
. ,
, .
, ,
,
. : ,
,
.
() . , ,
, , .
.
. , , .
, .
.
. ,
. .
, ,
. , ,
. , . , . , ,
506
.., .., ..
, . ,
, , , , . ,
, .
500 ppm (/)
200 .
. ,
. , , , , ,
,
.
507
.. , .. ,
..
. , 48, , , 614990
, , ,
. ,
, .
: , , .
.
, , , ,
(, ), (, ), (), (), (); (), (, ).
(), , , ; ,
, ; ; , ,
.
.
, .
.
. . , , ,
,
. . , .
; -
508
;
[1]. , , , .
: 50%; 70%; 40
70%. 70%
, 40% 70% . 70%, 40% , 70%
, .
, , > 0,25 2 .
[2]. ,
8 ;
6 , 10 . .
.
, , , . . 1. ,
.
1
/
1
2
3
4
5
52,31
36,67
70,12
65,38
59,62
47,44
49,68
50,80
48,56
62,53
89,45
33,03
34,44
30,09
36,05
. , ,
.
,
, , .
509
, , 2010, 4
; .
. ,
.
.
EXPERIMENTAL SUBSTANTIATION
OF ALCOHOLIC EXTRACTS TECHNOLOGY
FROM THE SCROPHULARIACEAE FAMILY PLANTS
N.I. Shramm, L.K. Babiyan,
V.M. Petrichenko
Chair of botany
Perm state pharmaceutical academy
Lenin str., 48, Perm, Russia, 614990
The optimum preparation conditions of alcoholic extracts from Euphrasia, Melampyrum, Verbascum herbs providing the maximum yield of biologically active substances have been determined.
The technology of dry and liquid Euphrasia extracts, liquid Melampyrum extract, dry Verbascum
extract has been developed.
Key words: Euphrasia extract, Melampyrum extract, Verbascum extract.
..
..
. , 8, . 2, , , 119992
,
, .
,
, , [5]. : , , , ,
.
,
, .
: ,
, , .
,
, .. ,
, .
.. ( . .. )
()
- , .
. ( )
,
, .. .
,
, (-
511
, , 2010, 4
, )
, ,
.
, - .
- . , , , , - ,
.
,
, [3].
, . , .
,
43 , 5 10 ,
: , , ,
, , , , , ,
. (63%), (44%) (30%).
, , , ,
,
, . ,
, ,
.
. . 1 , ,
.
512
.. ...
. 1.
513
, , 2010, 4
(20%).
(17%),
(13%). 3% , , , .
. 2 , .
. 2.
. 2,
(63%), (60%), (43%) 1/3 (37%) ().
(80%) , .
,
(67%)
(63%); (50%) (47%);
, .
, , ,
, () [2].
, [1].
514
.. ...
, , [4].
- . , .
, .. , .
[1]
[2]
[3]
[4]
[5]
.. : . .: , 1991.
.. . .: ,
2003 20 .
.., .., .. :
. .:
- . -, 2008. 160 .
.., .., ..
/ . . .. .
.: , 2009. 186 .
. . ., 1986.
515
.. , ..
..
. , 1, . 17, , , 127018
Asarum europaeum L. ().
, .
: , Asarum europaeum, , , , , , .
516
.., .. ...
1
, /
, /
0,17
9,3
0,18
4,5
0,15
4,1
, /
, /
0,65
0,03
0,49
0,02
4,21
0,09
, . ,
(1,29%), (3,45%) (1,14%);
(103,7 /100 ), (102,9 /100 )
(48,5 /100 ); , . 14 (/, /): (0,07/5,3), (0,11/5,4),
(0,07/2,1), (0,03/3,6), (0,1/13,6), (0,42/69,9), (0,13/18,3), (0,41/12,5), (0,06/14,6), (0,15/14,9),
(0,08/12,8), (0,02/15,8), (0,06/7,5), (0,07/2,4).
, .
750
26,1 /, 0,52 /.
,
.
[1] .., .. . , //
. . 2009. 4. . 175180.
[2] / . .. . .: , 2006. . 140142.
[3] 42-2799-96. .
517
, , 2010, 4
..
. , 3, , , 450000
, -.
, ,
.
.
: , , .
. - ,
, [1]. ,
. [2, 3].
270 ,
-. . 4,1% 1019 , 12,2% 2029 , 30,7%
3039 , 21,5% 4049 , 31,5% 5059 .
, , - , ,
(. 1). , 29,8%
, , . 11,1% ,
. , , , .
, . , 20 18,2%
, 2029 22,6%, 3039 4049 34,2 34,5% .
, , , , ,
, . , 90,0% , 20 .
519
, , 2010, 4
1
( ), %
,
20
2029
3039
4049
5059
18,2
63,6
18,2
9,7
67,7
22,6
6,1
59,7
34,2
10,1
55,4
34,5
15,5
54,7
29,8
11,1
59,1
29,8
, %
100,0
90,6
96,0
94,0
92,0
93,8
10,9 100 , 60,9
, 28,8 - , 17,5 , 16,6 , 20 100
- , , .
20 10 100 , 18,2 , 9,1 ,
51,8 . , - , .
, , . ,
, 4,8% , 11,1%
, 19,2% , 32,1% ,
5,5% 27,3% .
, (40,5%), (26,9%) (25,3%).
( ).
, , - . . ,
, ,
.
,
2,6%, 52,1%. , (49,3%). 20 (81,8%), 2029
(54,5%).
, (35,4%),
520
..
(19,3%), (18,4%). , , . , , ,
, , .
(52,8%). (29,2%) (10,8%).
(, , ) . ,
( , ). , , ,
.
.
521
()
..
. , 2, , , 614990
4%
() .
: , , , , , .
, . .
4% . ( ) [1]. ,
.
. , , , [2, 3].
, , 4%
() .
, pH, 350 700
-3-01. ( pH 6,07,8).
400 2
568 2 , 455465 .
. , pH 7,2.
-. , .
30%.
522
.. ()
,
() .
1,0 8,0 /. ( 0,999). 0,191 /.
() 6
. () ,
0,958%.
, (80, 100, 120% ,
100% 0,05 ).
2,4, 3,0 3,6 /.
(.).
0,
.
.
. 1 4% 200 , ( ).
1,5 100 ,
4 7,2, 2 1%
95% 2 0,05% .
30 .; , .
568 1 . -
523
, , 2010, 4
: 100 1,5 , ; , .
() .
0,05 ( ) , ,
250 , 50 ,
( ). 1,5
100 , .
() 1 :
A a0 200 100 1,5 A a0 0,8
X =
,
=
A0 a 1,5 250 100
A0 a
; 0 ; , ; 0 , .
4% .
.
4%
()
, /
1,00
0,407
0,0500
0,410
0,0397
= 0,0401
0,410
0,0400
S = 0,000265
0,412
0,0402
Sx = 0,000120
0,412
0,0402
= 0,000737
0,414
0,0404
= 0,000329
= 1,84%
= 0,82%
, , , , ,
(4%
).
524
.. ()
..
, 3, , , 418003
.
: , .
,
, .
, -
[1, 2].
.
887
1520 . ,
, .
,
, ,
.
Microsoft Office Excel 2003.
( + ) , (. 1).
1
( )
,
,
0,23 0,06
0,39 0,05
15
16
0,13 0,02
0,45 0,03
17
0,08 0,01
0,33 0,02
18
0,08 0,01
0,35 0,01
19
0,12 0,02
0,49 0,02
20
0,11 0,03
0,13 0,03
0,41 0,03
3,5
0,40 0,03
: < 0,05: 17 , 18 , 19 , 20 .
526
( )
,
,
3,4,6
0,02 0,01
0,52 0,03
0,01 0,00
0,00 0,00
0,42 0,01
0,01 0,00
0,41 0,01
0,53 0,01
0,41 0,02
5
0,46 0,02
0,01 0,01
0,04 0,01
6
0,01 0,01
0,46 0,02
4,5
.. ...
. 1 ,
,
( < 0,05).
16 19 .
.. .. [3], 3 - : - ()
, ()
() (. 2).
2
1719
/
1
18
17
0,17 0,01
0,22 0,01
0,26 0,01
0,21 0,02
1,2,3
0,23 0,01
1
19
2
0,30 0,01
0,33 0,01
0,28 0,01
0,15 0,02
0,20 0,01
0,29 0,02
0,31 0,01
: ( < 0,05) : , , .
,
, .
1520 . 3.
3.
,
1
15
2
16
3
17
4
18
5
19
6
20
, %
14,29
56,52
47,37
51,52
47,50
33,33
41,76
,
%
14,22
4,35
17,54
8,54
10,00
16,67
11,88
1
, %
57,14
65,22
54,39
47,56
40,0
41,67
51,00
2
, %
42,86
17,39
26,32
29,27
40,0
25,00
30,14
3
, %
0,0
17,39
19,30
23,17
20,0
33,33
18,86
4
: < 0,05: 15 , 16 , 17 , 18
5
6
, 19 , 20 .
. 3 , ,
,
16- (56,52%). , (65,22%).
1719 47,37% 51,52%, 20-
33,33%,
527
, , 2010, 4
(16,67%).
19- 40,00% . (30,14%) 15 19 . , , , 20 33,33%,
18,86%.
,
, . 4.
4
,
1719
, %
, %
17
18
19
17
18
19
38,46
20,00
41,67
46,15
8,57
00,00
46,88
42,86
45,83
12,50
5,56
16,67
66,67
45,83
100,0
0,00
20,00
00,00
50,67
36,23
62,5
19,55
11,38
5,56
, %
, %
, %
17
18
19
17
18
19
17
18
19
23,08
40,00
50,00
46,15
37,17
33,33
30,77
22,86
16,67
59,38
58,33
37,50
21,88
19,44
41,67
18,75
22,22
20,83
66,67
40,00
33,33
16,67
40,00
33,33
16,67
20,00
33,33
49,71
46,11
40,28
28,23
32,20
36,11
22,06
21,69
23,61
, 100% 19 .
, 19 . 66,67% 33,33%, 16,67% 33,33%.
, ,
, .
, , , , ,
- , - .
528
.. ...
[3] .., ..
. .: , 1973. 320.
[4] .., .. //
. . .: , 1981. . 19. . 6585.
.. , ..
. -, 8, , , 117198
, , .
.
: , , , .
.
[1]. [2].
, , . :
(, , );
(, , ); .
. , . () (, , ).
- - 105 , ( 14) 2000
2010 .
, , 81 (1- ). 22 . 24 (2- ) (
20 ).
.
-
530
.., ..
. , 50%
, . 60 1-
, : ( 3 12 ), , (
), ,
. , , ,
. .
,
.
1-
. , , , , , 12 , ,
, ,
. (). 20 1-
, ,
. , , . , ,
, , . 1-
( , ,
, , , , ).
,
: ,
, , (
). 21 (17%) 1- 90% 2-
,
531
, , 2010, 4
(
). 60
1- , ,
, ,
, , , ,
, ,
, , , ..
.
.
1- ; 2-
.
0
..
,
. , 19, , , 355044
.. , ..
. , 19, , , 355044
.
: , .
.
() .
, ,
. , .
,
, , [1].
, , , , . - ().
- - .
:
1 , ,
;
533
, , 2010, 4
2 , ;
3 - , - .
, 1,55 ,
. , ,
, , , , , , , , , , . ,
,
[2].
45% .
- .
1992
. , 1,5
[3].
: -
.
.
,
. 10 447 ,
19982008 [4, 5].
. :
1. , - ( ) ,
, ..
2. ,
( ).
534
:
1. () .
/
.
2.
(
, ).
() .
-
. -
, ,
, , , , . .
442,8 . .
, ;
; ,
, ; ( ) , , .
,
, , , . 4 .
,
. , 48
. , , - .
20052009 . ( 100 . ), . 1.
1
20052009 . ( 100 . )
2005 .
2006 .
123 123,9
141,1
505,2
129 921,6
184,1
501,9
2007 .
141 527,0
222,9
651,2
2008 .
145 817,0
249,2
716,5
2009 .
150 265,8
233,5
655,9
2005 .
22,0
54,1
29,8
. 1, ,
2009
2005 .
535
, , 2010, 4
.
,
19982008 ,
10 447, 8766, ..
2 . , ,
. , , , .
- , - . .
-
22,7%, - 50,2%, 47,3% (. 1).
, , ,
. ,
, .
. 1.
. -
.
[1] .., .. : 4 . .,
1999.
536
[2] .. / . .. . .: , ,
2007. 192 .
[3] . ., 1992.
[4] - 2009 . , 2010. . 203.
[5]
2009 . , 2010.
. 719.
.. , .. ,
..
. -, 8, , , 117198
- ,
(), () (). , .
: - , , , .
- ( 59 ) [1].
.
, 2 .
1. 25 .
2. 25 .
. TM-2430, 93/42 EEC .
.
[24] III 30 , . BPLabWin STATISTICA 6.0.
. 38 , , , 7 ,
62 . 2100 , 798 ,
538
1302 . ,
: 210 , 252, 42
294 , : 441 , 315,
105, 441 .
. ,
, . ( 10.00 20.00),
(06.0010.00) (20.0000.00), (00.00
06.00), .
,
(p < 0,001).
(. 1, 2). , ,
, .
, , , . . .
-
. ,
, . :
,
.
, , , , . .
STATISTICA 6.0,
. 83% (. 1).
. . 2. , , . :
. ,
3 ,
.
539
, , 2010, 4
. 1. :
1 , 2 , 3
25
540
. 2. :
1 , 2 , 3
25
541
, , 2010, 4
1
t0 , ,
: 25
7,22
4,73
3,62
6,35
0,13
2,57
0,12
3,55
2,44
4,77
4,56
2,00
: 25
0,90
8,41
5,40
3,08
3,78
2,48
4,16
0,98
4,55
7,03
5,00
2,09
2
,
: 25
118,90 2,58
126,73 2,71
72,77 1,30
72,84 1,28
77,31 2,70
79,89 2,41
119,82 4,07
124,63 2,25
70,94 2,14
70,85 1,32
72,68 4,18
79,06 2,00
: 25
127,88 1,75
129,03 2,60
120,97 1,85
79,74 0,90
78,63 1,07
77,34 1,42
76,93 2,49
72,83 1,60
79,56 1,13
74,50 1,71
71,14 1,23
: p < 0,05, ,
125,53 2,17
. ,
. , , ,
.
[1] .. //
. 2009. 4. . 6064.
[2] .., .. : . ., 1999.
542
0
.. , ..
1
. , 6, , , 460000
..
. , 25, , , 460000
, : , , .
: , , .
. 1980 ,
, , , . ,
.
,
, .
,
. ,
(), ,
.
,
700 ,
. - , . 10 . 2001 ,
, ,
. 2003 -
544
. ,
, . , .
, . 2
( , , , , , , ,
, 10, ,
, .
, : , , , , , , : , .
,
, , .
: ( , ). , , ,
- ,
; , .
: ; ;
- ; .
, , .
, .
, , (. 1): , ,
, , , ; ; -
545
, , 2010, 4
, , , , ; , , , ; , , ;
, , -
, . , ..
, , ,
.
, (. 1) , :
; ; ,
5,6 063/ .
. 1. ,
, ,
.
, ,
. -
546
.
( ), , , .
: ; : , ,
; ; .
... : , , . ,
2010 .
2005 , 2.01.7
, . 2007
: - , , - , 1,
. .
, .
. 2008 ,
,
(www.antibiotic-plus.ru). ,
, . , IT
.
, , , , .. ,
.
( ).
, .. ,
.
. -
547
, , 2010, 4
, .. . 2 , .
: ( , ).
,
.
,
.
,
. ,
, Microsoft Framework.net3.5 #.
,
. , ,
, .
S.B. Choloyan
Municipal childrens hospital
Kobozeva str., 25a, Orenburg, Russia, 460000
Scientific materials about medical information system Antibiotic have shown in this article. There
is description of this medical computer software, results of implementation program, her improvement,
plans for the future in this text.
Key words: informatization of health service, medical information system.
548
Cornlissen G. , (Ph.D, ,
),
, Biokoc ()
.. -
(. :
nazaragaev@mail.ru, 8(926) 388-89-79)
-
, , -
(. : somvoz@live.ru, . 8(916) 927-37-37)
,
(. : somvoz@live.ru, . 8(916) 927-37-37)
... , -
, -
(. : somvoz@live.ru, . 8(916) 927-37-37)
..., -
549
, , 2010, 4
. , , (. :
somvoz@live.ru, . 8(916) 927-37-37)
-
,
(. : somvoz@live.ru, . 8(916) 927-37-37)
, -
69 . (. : somvoz@live.ru,
. 8(916) 927-37-37)
(. : somvoz@live.ru, . 8(916) 927-37-37)
-
,
(. : somvoz@live.ru, . 8(916) 927-37-37)
(. :
somvoz@live.ru, . 8(916) 927-37-37)
550
, ,
somvoz@live.ru, . 8(916) 927-37-37)
(.
. . .. -
, (. : somvoz@live.ru,
. 8(916) 927-37-37)
. . .. -
, (. : somvoz@live.ru,
. 8(916) 927-37-37)
-
.. (. : somvoz@live.ru, .
8(916) 927-37-37)
.. -
(. : somvoz@live.ru,
. 8(916) 927-37-37)
(. : somvoz@live.ru, . 8(916) 927-37-37)
-
(. : n_i_volkova@mail.ru, .
8(918) 555-30-69)
. .. (. : somvoz@live.ru,
. 8(916) 927-37-37)
- -
(. :
somvoz@live.ru, . 8(916) 927-37-37)
551
, , 2010, 4
. .. (. :
somvoz@live.ru, . 8(916) 927-37-37)
-
(. :
somvoz@live.ru, . 8(916) 927-37-37)
-
(. :
somvoz@live.ru, . 8(916) 927-37-37)
, -
(. : somvoz@live.ru, . 8(916) 927-37-37)
, -
(. : somvoz@live.ru, . 8(916) 927-37-37)
.. (. :
(. :
somvoz@live.ru, . 8(916) 927-37-37)
.. ,
, (. : somvoz@live.ru, .
8(916) 927-37-37)
. .. (. :
somvoz@live.ru, . 8(916) 927-37-37)
-
. (. : somvoz@live.ru,
. 8(916) 927-37-37)
552
,
(e-mail
zapirov@mail.ru, . 8(499) 120-81-90)
.. -
(. : somvoz@live.ru,
. 8(916) 927-37-37)
. .. (. :
somvoz@live.ru, . 8(916) 927-37-37)
.. . . ,
(. : somvoz@live.ru, .
8(916) 927-37-37)
, ,
. (email: trauma@sustav.ru,
. 8(495) 432-95-37)
-
(. : somvoz@live.ru, . 8(916) 927-37-37)
-
, - (. : somvoz@live.ru, .
8(916) 927-37-37)
..., ,
, (. : somvoz@live.ru, .
8(916) 927-37-37)
553
, , 2010, 4
(. :
somvoz@live.ru, . 8(916) 927-37-37)
-
4 (. ) (. :
loririna@yandex.ru, . 8(495) 955-65-64)
-
(. : somvoz@live.ru, .
8(916) 927-37-37)
. , -
, - (. : somvoz@live.ru,
. 8(916) 927-37-37)
..
, , (. :
somvoz@live.ru, . 8(916) 927-37-37)
-
(. : somvoz@live.ru, . 8(916) 927-37-37)
554
(. :
somvoz@live.ru, . 8(916) 927-37-37)
.. , -
, (. :
somvoz@live.ru, . 8(916) 927-37-37)
-
, , ,
(. : somvoz@live.ru, . 8(916) 927-37-37)
,
(. : somvoz@live.ru, .
8(916) 927-37-37)
.. , -
(. :
somvoz@live.ru, . 8(916) 927-37-37)
-
(. : somvoz@live.ru,
. 8(916) 927-37-37)
.. ...,
1 (. :
somvoz@live.ru, . 8(916) 927-37-37)
-
. . .. (. : somvoz@live.ru, .
8(916) 927-37-37)
555
, , 2010, 4
(. : somvoz@live.ru, . 8(916) 927-37-37)
. .. , -
. .. (. : somvoz@live.ru, .
8(916) 927-37-37)
.. -
(. :
somvoz@live.ru, . 8(916) 927-37-37)
. . ., -
.. (. : somvoz@live.ru, . 8(916) 927-37-37)
, -
, ,
(. : somvoz@live.ru, . 8(916) 927-37-37)
, -
, (. :
somvoz@live.ru, . 8(916) 927-37-37)
A , (. :
, (. :
somvoz@live.ru, . 8(916) 927-37-37)
, ,
(. : somvoz@live.ru, . 8(916) 927-37-37)
.. , ..., -
, , , ..., (. : somvoz@live.ru,
. 8(916) 927-37-37)
-
. .. , ,
-
,
,
.. , -
, (. : somvoz@live.ru,
. 8(916) 927-37-37)
21 . (. : somvoz@live.ru, .
8(916) 927-37-37)
E.. ,
, (.
: somvoz@live.ru, . 8(916) 927-37-37)
,
,
(. : somvoz@live.ru, . 8(916) 927-37-37)
5, -
2 , -
.. .
, (. : somvoz@live.ru, .
8(916) 927-37-37)
557
, , 2010, 4
.. .
, (. : somvoz@live.ru,
. 8(916) 927-37-37)
-
,
, ..., (. : somvoz@live.ru, .
8(916) 927-37-37)
-
, (. :
somvoz@live.ru, . 8(916) 927-37-37)
-
, , , (. : somvoz@live.ru,
. 8(916) 927-37-37)
, -
,
somvoz@live.ru, . 8(916) 927-37-37)
(.
, ,
(. : somvoz@live.ru, . 8(916) 927-37-37)
-
, ,
-
(. : ag_polyakova@.mail.ru, . 8(8314) 36-16-77)
..
, (. :
somvoz@live.ru, . 8(916) 927-37-37)
558
, , (. : somvoz@live.ru,
. 8(916) 927-37-37)
-
(. : somvoz@live.ru,
. 8(916) 927-37-37)
, , (. :
somvoz@live.ru, . 8(916) 927-37-37)
-
,
, (. : somvoz@live.ru, . 8(916) 927-37-37)
-
, , - (.
: somvoz@live.ru, . 8(916) 927-37-37)
-
(. 8(925) 079-19-12)
-
, ..., ,
(. : somvoz@live.ru, . 8(916)
927-37-37)
,
(. 8(495) 597-68-59)
559
, , 2010, 4
, ,
-
.. , -
(. :
somvoz@live.ru, . 8(916) 927-37-37)
-
(. 8(8182) 21-57-25)
. .. , -
, , (. :
somvoz@live.ru, . 8(916) 927-37-37)
(. : somvoz@live.ru, . 8(916) 927-37-37)
-
,
(. : somvoz@live.ru, . 8(916) 927-37-37)
-
, (.
: somvoz@live.ru, . 8(916) 927-37-37)
,
(. : syata@mail.ru)
- -
, ,
560
, , .
(. : somvoz@live.ru, . 8(916) 927-37-37)
, ,
(. : somvoz@live.ru, . 8(916) 927-37-37)
-
, , (. :
somvoz@live.ru, . 8(916) 927-37-37)
- -
, (. : somvoz@live.ru, .
8(916) 927-37-37)
. .. , (. :
somvoz@live.ru, . 8(916) 927-37-37)
,
(. : somvoz@live.ru, . 8(916) 927-37-37)
, , (. :
somvoz@live.ru, . 8(916) 927-37-37)
, , -
,
, ,
, ,
-
,
(. : somvoz@live.ru, . 8(916) 927-37-37)
561
, , 2010, 4
.. ,
,
(. : somvoz@live.ru, . 8(916) 927-37-37)
,
, (. : somvoz@live.ru, .
8(916) 927-37-37)
, -
, (. 8(863) 250-40-79)
-
,
, (. : somvoz@live.ru, .
8(916) 927-37-37)
, (. : somvoz@live.ru, .
8(916) 927-37-37)
.. , -
, (. : somvoz@live.ru,
. 8(916) 927-37-37)
.. , -
(. :
somvoz@live.ru, . 8(916) 927-37-37)
-
, (. : somvoz@live.ru,
. 8(916) 927-37-37)
562
, -
(. : 3664658@mail.ru,
8(495) 968-93-46)
.. , ,
.. (. : somvoz@live.ru, . 8(916) 927-37-37)
-
,
(. : somvoz@live.ru, . 8(916) 927-37-37)
,
, , .
. ( ) 2 .
.
.
13,5 21,4 .
: 4, 2,5 , 5,8 ,
3,75 .
Microsoft Word. Times New Roman.
. 10, , . ( ) (, , .),
, ( ). , ,
11,5.
10, . ( ) .
.
11,5 1 (45
). , , 10.
, 11,5, 0,5 ,
10 0,7 .
.
. 10. , , .
. et al., .
( 12, ). .
. (). //
. . . . . ,
( ).
564
. (). . : ( ), . ( ).
:
[1] .., .., .. . // . . 1997.
3. . 5558.
[2] Guzzetti S., Piccaluga E., Casati R. Sympathetic predominance in essential hypertension:
a study employing spectral analysis of heart rate variability // J Hypertens. 1988. V. 6.
9. P. 711717.
[3] .., .. . .: , 1988. 162 .
. , 10 .
, 5- .
: ,
(
(, , .), , ( ) , , ),
, .
.
, , .
. . .
, , Word ( ,
10 .
).
( ):
1) , ,
3 6 (900018 000 );
2) 3 (9000 );
3) 2 (6000 ) ,
, , , , ;
4) 8
(24 000 ).
.
565
, , 2010, 4
. 4 , .
: , 117198, . -, . 8. , , , .. .
. , , .
, ,
!
2010, 4
. ..
..
: ..
:
. , 3, , , 115419
.: (495) 955-07-16
:
. -, 8, , , 117198
.: (495) 434-73-03 E-mail: rudnvestnik@yandex.ru
23.11.2010. 6084/8.
. . Times New Roman.
. . . 66,50. 500 . 1307
. , 3, , , 115419, . (495) 952-04-41
BULLETIN
of Peoples Friendship
University of Russia
Scientific journal
Series
MEDICAL
2010, N 4